{
  "responseHeader":{
    "status":0,
    "QTime":13,
    "params":{
      "q":"(Background: leukemia OR \"acute lymphoblastic leukemia\" OR \"acute myeloid leukemia\" OR \"chronic lymphocytic leukemia\" OR \"chronic myeloid leukemia\" OR Doc_title: leukemia OR \"acute lymphoblastic leukemia\" OR \"acute myeloid leukemia\" OR \"chronic lymphocytic leukemia\" OR \"chronic myeloid leukemia\") AND (Background: ABL1 OR \"ABL\" OR \"JTK7\" OR \"p150\" OR \"c-ABL\" OR \"v-abl\" OR \"CHDSKM\" OR \"c-ABL1\" OR \"bcr/abl\" OR Doc_title: ABL1 OR \"ABL\" OR \"JTK7\" OR \"p150\" OR \"c-ABL\" OR \"v-abl\" OR \"CHDSKM\" OR \"c-ABL1\" OR \"bcr/abl\")"}},
  "response":{"numFound":353,"start":0,"docs":[
      {
        "Meeting_name":" Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients",
        "Background":"['Background', ' The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic myeloid leukemia (CML) and is present in a poor-risk subgroup of precursor B cell acute lymphoblastic leukemia (ALL), which represents 25% to 30% of adult ALL and 3% to 5% of childhood ALL. So far, the BCR-ABL aberration has been detected by cytogenetics, FISH or PCR, which are time consuming and require special facilities. We have used a simple flow cytometric bead assay (BD) for detection of the BCR-ABL fusion protein in cell lysates, The aim of our study was to see the effectiveness of Flowcytometric detection of BCR-ABL. Methods', ' Test Specimens', ' 100 patients, CML 74 and Adult ALL 20, Paediatric ALL 6. BD-BCR-ABL Protein Kit Protocol', \" Cell Lysate was prepared as per manufacturer's protocol using Ficoll-Paque medium and several washing with PBS and 5% FBS plus IX pretreatment A and IX pretreatment B. CBA Assay\", ' In BD Falcon 12 x 75 mm polystyrene tube 50 l each of lysate, BCR-ABL Capture Beads and BCR-ABL detection reagent were added. Tube contents were resuspended with 300l of BD CBA washed buffer. Samples were acquired with the BD FACS Canto II Flow Cytometer. FISH', ' Abbott Visys LSI BCR-ABL, Dual Fusion Translocation Probe. Results', ' Amongst 100 cases concordance was best obtained in CML cases where 65 cases were positive for BCR ABL by flow cytometric bead assay and 68 cases were positive with FISH. In case of adult and pediatric ALL 14 cases showed positivity with flowcytometric bead assay. In case of FISH, however, 16 cases were having BCR-ABL. Also bead assay is far quicker than FISH assay. Conclusions', ' We conclude that the flow cytometry immunobead assay is a fast and easy technique for specific detection of BCR ABL proteins in leukemic cells. The main advantaged of the immunobead assay are', ' 1) Not dependent on the breakpoint position in the BCR gene; 2) Can be run in parallel to routine immunophenotyping.']",
        "Doc_id":"ASCO_52497-74",
        "Doc_title":" Flow cytometric bead assay of BCR-ABL fusion proteins in leukemia patients",
        "_version_":1606189006646673408},
      {
        "Meeting_name":" ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.",
        "Background":"['The molecular etiology of human progenitor reprogramming into self-renewing leukemia stem cells (LSC) has remained elusive. While DNA sequencing has uncovered spliceosome gene mutations that promote alternative splicing and portend leukemic transformation, isoform diversity may also be generated by RNA editing mediated by adenosine deaminase acting on RNA (ADAR) enzymes that regulate stem cell maintenance. In this study, whole transcriptome sequencing of normal, chronic phase (CP) and serially transplantable blast crisis (BC) chronic myeloid leukemia (CML) progenitors revealed increased interferon- pathway gene expression in concert with BCR-ABL amplification, enhanced expression of the interferon responsive ADAR1 p150 isoform and a propensity for increased A-to-I RNA editing during CML progression. Lentiviral overexpression experiments demonstrate that ADAR1 p150 promoted expression of the myeloid transcription factor PU.1 and induced malignant reprogramming of myeloid progenitors. Moreover, enforced ADAR1 p150 expression was associated with production of a mis-spliced form of GSK3 implicated in LSC self-renewal. Finally, functional serial transplantation and shRNA studies demonstrate that ADAR1 knockdown impaired in vivo self-renewal capacity of BC CML progenitors. Together these data provide a compelling rationale for developing ADAR1-based LSC detection and eradication strategies.']",
        "Doc_id":"AACR_2013-247",
        "Doc_title":" ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.",
        "_version_":1606188988407742464},
      {
        "Meeting_name":" BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.",
        "Background":"['Background', ' The major mechanism underlying imatinib resistance in patients with chronic myeloid leukemia (CML) is clonal expansion of leukemic cells with point mutations in the BCR-ABL tyrosine kinase. We describe three novel ABL premature termination mutations leading to BCR-ABL truncation in leukemia patients with multidrug (imatinib/nilotinib/dasatinib) resistance. Methods', ' Peripheral blood or bone marrow samples from drug-resistant CML patients were collected. Total nucleic acids were purified and subjected to two rounds of PCR analysis, with the first PCR designed to eliminate amplification of the wild-type, non-translocated ABL gene. Bi-directional sequencing was then performed. HL60 cells (a Ph-negative myeloid leukemia cell line) and peripheral blood of healthy subjects were used as negative controls; a human CML cell line (K562) was used as a positive control. Results', ' We identified an exon 7 deletion in three CML patients, a 4-nt insertion (908insCAGG) near the exon 5/6 junction in one CML case, and an exon 6 point mutation (997C>T) in one patient with acute lymphoblastic leukemia (ALL). These mutations all create premature stop codons and cause termination at residues 381, 315, and 333, respectively, leading to truncated proteins with only the first quarter of the kinase domain (P-loop) or lacking the C-terminus of ABL including the A-loop. Conclusions', ' These novel mutations, and the previously documented 35-nt insertion in exon 8, may constitute a new class of mutations that 1) cause truncation of the BCR-ABL kinase; (2) abolish the regulatory element in the ABL kinase domain and the downstream C-terminal region; and (3) confer significant drug resistance.']",
        "Doc_id":"ASCO_33182-65",
        "Doc_title":" BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.",
        "_version_":1606189013505409024},
      {
        "Meeting_name":" Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain in Philadelphia-positive leukemias.",
        "Background":"['Background & Aims - In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL), tyrosine kinase inhibitor (TKI) therapy may select for drug-resistant BCR-ABL mutants, routinely assessed by Sanger sequencing (SS). We took advantage of ultra-deep sequencing (UDS) in order to', ' 1) resolve qualitatively and quantitatively the complexity of mutated populations surviving TKIs; 2) investigate their clonal structure and evolution in relation to time and treatment.Methods - We retrospectively performed a longitudinal analysis of 111 samples from 32 CML or Ph+ ALL patients who had received sequential treatment with multiple TKIs and had experienced sequential relapses accompanied by selection of TKI-resistant mutations. All samples had already been scored by SS. UDS of the BCR-ABL KD was done using Roche 454 technology (lower detection limit, 0.1%). Seqnext software was used for alignment and variant identification; Jalview and Figtree softwares were used for haplotype and phylogenetic reconstruction.Results - UDS showed that SS often misclassifies or underestimates BCR-ABL KD mutation status. In more than half of the cases, UDS revealed that up to five minor mutations with 1-20% abundance were present, either in samples scored as wild-type by SS or in samples already bearing one or more dominant mutations. The high degree of complexity was even more evident when the clonal relationships of multiple mutations were reconstructed and the relative abundance of all mutant subclones coexisting at each timepoint was assessed. This revealed that identical mutations may be acquired in parallel by independent subclones (e.g., one wild-type and one already harboring a mutation), via the same or different nucleotide changes leading to the same amino acid substitution (convergent evolution). Longitudinal quantitative follow-up showed that the landscape of all competing mutant subclones is highly dynamic, and that dominant subclones may be replaced as quickly as within one month in case of selective pressure change. Earlier identification of emerging TKI-resistant mutants was made possible by UDS.Conclusions - 1) sequential changes in the selective pressure exerted by TKIs may result in a heterogeneous mosaic of subclones harbouring different mutations or mutation combinations2) The ecosystem of mutant subclones is highly dynamic', ' acquisition of additional mutations dictates quick shrinkage or expansion of subclones over time3) Inherent sensitivity to a specific TKI is necessary but not sufficient to determine the fitness of a mutant subclone', ' competition with coexisting subclones also concurs to shape its fate4) Reasoning on the basis of mutations detectable by SS may not always be sufficient to predict responsiveness to a TKI.Supported by Fondazione CARISBO, PRIN, IGA MZCR NT11555.']",
        "Doc_id":"AACR_2013-4632",
        "Doc_title":" Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain in Philadelphia-positive leukemias.",
        "_version_":1606188985096339456},
      {
        "Meeting_name":" Dasatinib accelerates valproic acid-induced acute myeloid leukemia cells death by regulation of differentiation capacity",
        "Background":"['Dastinib (BMS-354825) is a FDA-approved small compound that was developed for chronic myeloid leukemia as a multi-targeted kinase inhibitor of wild-type BCR-ABL and SRC family kinases. Valproic acid (VPA; Orfiril) has been a well-known anti-epileptic drug worldwidely, and belong to the class I histone deacetylase inhibitor. The aim of this research is to determine the anti-leukemic effects of combination of dasatinib and VPA or their mechanism in acute myeloid leukemia (AML) cells. In this study, dasatinib showed potent inhibitory effects on VPA-treated AML cells that were associated with induced G1 phase cell cycle arrest and also apoptosis including the cleavage of PARP, caspase-3, -7 and -9. Moreover, inhibitors of caspase-3 and -9 (Z-DEVD-FMK and LEHD-CHO) efficiently inhibited dasatinib-induced apoptosis in VPA-treated AML cells. Therefore, dasatinib/VPA-induced cell death occurred via caspase-dependent apoptosis. Also, inhibitors of MEK/ERK (U0126 and PD98059) and p38 MAPK (SB203580) efficiently inhibited dasatinib/VPA-induced apoptosis. The combination of dasatinib and VPA differentiation capacity of AML cells is more powerful than each drug alone. So the combination is enough to push AML cells to death strongly by G1 cell cycle arrest and caspase-dependent apoptosis. In addition, MEK/ERK and p38 MAPK controls dasatinib/VPA-induced apoptosis as an upstream regulator. Finally, co-treatment of dasatinib and VPA is contributed to AML cell death by regulation of differentiation capacity. Taken together, these results indicate that dasatinib and VPA together have a potential for anti-leukemic therapy.']",
        "Doc_id":"AACR_2014-347",
        "Doc_title":" Dasatinib accelerates valproic acid-induced acute myeloid leukemia cells death by regulation of differentiation capacity",
        "_version_":1606189009569054720},
      {
        "Meeting_name":" Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.",
        "Background":"['Background', ' Coronary artery disease (CAD), peripheral arterial occlusive disease and cerebrovascular disease have been observed in pts treated with BCR-ABL tyrosine kinase inhibitors (TKIs). While uncommon, these events can be serious complications of BCR-ABL TKI therapy.  Methods', ' The cardiovascular (CV) profile of ponatinib (45 mg/day) was evaluated in 449 pts with chronic myeloid leukemia (CML) or Ph+ acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to prior TKIs in the phase 2 PACE trial. At analysis (23 July 2012), median follow-up was 12 (0.1-21) mos. Myocardial ischemic events including myocardial infarction (MI), CAD, and angina were analyzed.  Results', ' Myocardial ischemic serious adverse events (SAEs) (14 MI, 5 CAD, 2 angina) were reported in 21/449 pts (5%). 10 of these 21 pts had active cardiac disease at entry characterized by prior MI (4 pts), coronary revascularization (4 pts), or documented CAD; 5 had MI reported on study. 5/21 pts had other cardiac disease at entry (eg, valvular or pericardial disease); 5 had MI on study. Thus, 10/14 MIs occurred in 15 pts with known cardiac disease. 6/21 pts had no history of cardiac disease, but 5/6 had 1 CAD risk factor; 4 MIs occurred in these pts, all had risk factors. Of 21 pts with myocardial ischemic SAEs (13 CP-CML, 6 AP-CML, 2 BP-CML/Ph+ALL), mean age was 67 (42-87), and median duration since diagnosis was 12 (1-20) yrs. They were heavily pretreated (67% TKI use 5 yrs) with multiple CAD risk factors at entry (71% ischemia, 57% hypertension, 38% hypercholesterolemia, 33% diabetes [62% BMI >25]); 81% had 2 risk factors, 95% had 1. Median time to onset and duration of SAE was 160 (9E402) and 7 (1E98) days, respectively. At analysis, 18/21 pts had the SAE reported as resolved (managed by dose interruption [50%] or no dose change [33%]), and 13/21 pts remained on study. Response rates for the subset of 21 pts with cardiac SAEs were major cytogenetic response 77% in CP-CML; major hematologic response 67% in AP-CML.  Conclusions', '  In this uncontrolled study in heavily pretreated pts, these CV SAEs occurred mostly in pts with preexisting cardiac disease, and were primarily managed with satisfactory outcomes. Pts with preexisting CV co-morbidities should be monitored. Clinical trial information', ' NCT01207440.']",
        "Doc_id":"ASCO_109745-132",
        "Doc_title":" Analysis of the cardiovascular risk profile of Ph+ leukemia patients treated with ponatinib.",
        "_version_":1606189005223755777},
      {
        "Meeting_name":" Prognostic impact of Philadelphia chromosome in elderly acute lymphoblastic leukemia patients ineligible for hematopoietic stem cell transplantation.",
        "Background":"['Elderly acute lymphoblastic leukemia (ALL) patients are often unfit for neither dose-intensive chemotherapy nor stem cell transplantation, thus their clinical outcomes have been dismal. The increased incidence of BCR-ABL translocation with increasing age also contributed to poor prognosis but, it was our conjecture that the introduction of potent tyrosine kinase inhibitors (TKI) targeting ABL, BCR-ABL translocation might not deliver negative prognostic impact in elderly ALL. Considering that many elderly Ph- ALL patients do not tolerate cytotoxic chemotherapy required for effective tumor control, we supposed that efficacy of ABL TKIs and their combination strategy with low dose cytotoxic chemotherapy would result in better survival for elderly Ph+ ALL compared to their Ph- counterparts.']",
        "Doc_id":"AACR_2017-765",
        "Doc_title":" Prognostic impact of Philadelphia chromosome in elderly acute lymphoblastic leukemia patients ineligible for hematopoietic stem cell transplantation.",
        "_version_":1606188996541546496},
      {
        "Meeting_name":" Single cell assays of heterogeneity and clonality in leukemia",
        "Background":"['A range of hypotheses have emerged as to why imatinib (a targeted inhibitor of bcr-abl) seems unable to eliminate the most primitive chronic myeloid leukemia (CML) cells, such as bcr-abl amplification and clonal evolution. The biology of the CML imatinib-resistant cell is of critical importance to understanding why despite high percentages of initial clinical responses to imatinib (>80% of patients in chronic phase at some point obtaining complete cytogenetic remission), resistance, relapse and/or progression occurs in 20-30% of cases and most patients in remission still have residual disease detected by sensitive PCR monitoring of the CML specific bcr-abl transcripts. In acute myeloid leukemia (AML) as well, patients are typically treated with a chemotherapeutic regimen that leads to clinical responses in 80-95% of patients. However, over half of these patients will relapse and eventually die of disease suggesting that a subpopulation of leukemic cells are capable of both surviving treatment and causing regrowth of the tumor. In both diseases, it has not been definitively established what the identity of the cells responsible for resistance and relapse is, nor what combination of mutations, gene expression changes, and alternative splicing events are required for these cells resistant phenotype. Assessing changes in gene expression in the bulk samples provides a valuable overall picture of the phenotype of the predominant cell type is or if there are large changes in expression in less frequent cells, but will completely mask changes exhibited by rare cells. One limiting factor in our ability to study more levels of heterogeneity in leukemia subpopulations is the lack of appropriately powerful and sensitive techniques to assay more complex facets of cellular behavior in such small populations. We have developed several multiplexed, high sensitivity analysis techniques and applied them to study multiple facets of cell behavior and identity in rare cell samples, down to the single cell level. By analyzing expression and genotype in smaller samples, direct from cells, we can analyze heterogeneity in expression and alternative splicing, combined with both cell surface markers and the presence of multiple mutations. These innovative techniques have allowed us to study clonality in AML samples in detail via a robust assay that can identify multiple mutations occurring concurrently in single cells. We have also optimized a protocol to simultaneously assay gene expression of 24 in 100-500 cell samples from flow sorted leukemia cell populations. Finally multiplexed assays for alternative splice variant detection in single cells has enabled us to study whether alternative splice variant expression of several genes occurs concurrently in the same cells, or in different cells of the population. With these techniques in hand we have the unique opportunity to begin studying the biology of these diseases from a previously unrealistic angle.']",
        "Doc_id":"AACR_2012-3686",
        "Doc_title":" Single cell assays of heterogeneity and clonality in leukemia",
        "_version_":1606188993376944128},
      {
        "Meeting_name":" Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor.",
        "Background":"['Chronic Myeloid Leukemia (CML), a hematological malignancy, is largely caused by the Philadelphia (Ph) chromosome carrying the Break point Cluster Region-Abelson (BCR-ABL) oncogene. Imatinib is a BCR-ABL-targeted therapy and considered the standard of care in CML management. Resistance to imatinib therapy often develops because of mutations in the BCR-ABL kinase domain. In this study, we evaluated PBA2, a novel BCR-ABL inhibitor, for its anti-cancer activity against BCR-ABL expressing BaF3 cells. PBA2 shows potent activity against wild-type and T315I mutated BaF3 cells as compared with imatinib. PBA2 inhibited the phosphorylation of BCR-ABL and its downstream signaling in BaF3/WT and BaF3/T315I cells. PBA2 inhibited the mRNA expression of BCR-ABL in BaF3/WT and BaF3/T315I cells. Mechanistically, PBA2 increased the cell population in sub G1 phase of the cell cycle, induced apoptosis and elevated ROS production in both BaF3/WT and BaF3/T315I cells. Taken together, our results indicate that PBA2 exhibits anti-proliferative effects and inhibits the imatinib-resistant T315I BCR-ABL mutation. PBA2 may be a novel drug candidate for overcoming the resistance to imatinib in CML patients.']",
        "Doc_id":"AACR_2017-4158",
        "Doc_title":" Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor.",
        "_version_":1606188971003478016},
      {
        "Meeting_name":" BCR-Abl independent, Abl-TKI-therapy-resistant CML cells show enhanced sensitivity to GDC0941.",
        "Background":"['Introduction', \" Chronic Myeloid leukemia (CML) is driven by the BCR-ABL oncogene and is initially treated with ABL tyrosine-kinase inhibitors (ABL-TKI), such as Imatinib or Dasatinib. Despite strong initial responses to these drugs, many patients acquire resistance over time through acquisition of BCR-ABL mutations such as T315I, compound BCR-ABL mutations or through BCR-ABL-independent mechanisms. Even though the next generation pan-ABL inhibitor, Ponatinib, targets all know resistant ABL mutations, some patients don't benefit from Ponatinib and in these cases resistance to TKI therapy may be due to BCR-ABL-independent mechanisms. We analyzed the mechanism of ABL-TKI-dual-resistant CML cells independent of new BCR-ABL mutations and tested the sensitivity of these resistant cells to the PI3K inhibitor, GDC-0941 and/or the MEK inhibitor GDC-0973.Methods\", ' We created ABL-TKI-dual-resistant cells and clones through prolonged treatment of K562 and KCL22 cells with Imatinib and then Dasatinib. The cells and clones were tested for sensitivity to Imatinib, Dasatinib, Ponatinib, GDC-0941 and GDC-0973. Whole genome copy number scan (Oncoscan) and targeted deep sequencing using GAII were used to identify BCR-ABL mutations and newly acquired somatic gene alterations. Phosphoproteomic analysis of cell lysates by Reverse Phase Protein Arrays was used to profile cell signaling pathway status associated with resistance and sensitivity to these drugs.Results', ' The K562 ABL-TKI-dual-resistant cells were insensitive to all three ABL-TKIs including Ponatinib suggesting that resistance was mediated by a BCR-ABL-independent mechanism. Unexpectedly, the resistant cells and clones became more sensitive to GDC-0941 but not GDC-0973 compared to the parental cells. These resistant cells and clones had acquired new somatic mutations in p53, BRCA2, PTEN, RB, SMARCA4 and PBRM1, but not in BCR-ABL. Phosphoprotein profiling showed low phosphorylation of the BCR-ABL substrates c-ABL, SHC and FAK indicative of BCR-ABL-independent mechanisms of resistance. Activity of the PI3K/AKT and MEK/ERK pathways varied across the resistant clones. However, high levels of the AKT substrate, FOXO-1 directly correlated with Dasatinib resistance and with GDC-0941 sensitivity. Sensitivity to GDC-0941 also correlated with modulation of phospho-FOXO-1. Our data suggest that GDC-0941 may be a therapeutic candidate for CML patients who progress on TKI therapy through BCR-ABL-independent mechanisms of resistance.']",
        "Doc_id":"AACR_2013-3395",
        "Doc_title":" BCR-Abl independent, Abl-TKI-therapy-resistant CML cells show enhanced sensitivity to GDC0941.",
        "_version_":1606189034668818432},
      {
        "Meeting_name":" Bcr-Abl inhibition in leukemia cells creates metabolic addictions",
        "Background":"['Bcr-Abl kinase inhibitors are the standard therapy for chronic myelogenous leukemia (CML). While effective in controlling disease in chronic phase, these inhibitors often fail to completely eliminate Bcr-Abl+ CML cells and also fail to achieve durable remissions for advanced CML and Bcr-Abl+ acute lymphoblastic leukemias (ALL). Our lab employed a large-scale synthetic lethal shRNA screen to identify genes involved in CML survival upon treatment with the Bcr-Abl kinase inhibitor imatinib (IM) [Cancer Cell. 2010;18(1)', '74-87]. This screen identified several genes involved in energy utilization including a component of pyruvate dehydrogenase, dihydrolipoyllysine-residue acetyltransferase. CML proliferation depends on Bcr-Abl-driven glycolysis for energy production. Upon IM treatment, we hypothesized that these cells are forced to rely on other sources of energy including the TCA cycle and the electron transport chain, and that targeting alternative energy production pathways will enhance IM-mediated elimination of CML cells. Thus, we predicted that inhibition of mitochondrial respiration by knockdown or pharmacologic inhibition would cooperate with tyrosine kinase inhibitors (TKI) to eliminate Bcr-Abl+ leukemia. Indeed, our experiments have shown that knocking down pyruvate dehydrogenase in human blast crisis Bcr-Abl+ CML cells (K562) greatly sensitized cells to IM in vitro. Conversely, supplementing the cell culture media with increasing concentrations of methyl-pyruvate protected K562 cells from IM treatment. Moreover, we found that the mitochondrial ATP-synthase inhibitor Oligomycin A (OA) also synergized with IM to kill CML cells in vitro. Interestingly, the doses of OA are far below the IC50 and do not affect the oxygen consumption rates, indicating that mitochondrial respiration is not inhibited. These OA doses alter mitochondrial transmembrane potential and increasing superoxide levels. In addition, OA enhanced elimination of Bcr-Abl+ cells by a Bcr-Abl TKI in vivo and prolonged disease-free survival in a mouse model of Bcr-Abl+ B-ALL. Notably, drug doses of OA used had no apparent adverse effects on these mice. Targeting mitochondrial metabolism as an adjuvant drug therapy may prevent the survival of residual Bcr-Abl+ CML cells upon tyrosine kinase inhibitor treatment. This project is supported by pre-doctoral fellowship number F31CA157166 from the National Cancer Institute, and Leukemia and Lymphoma Society Grant']",
        "Doc_id":"AACR_2012-1127",
        "Doc_title":" Bcr-Abl inhibition in leukemia cells creates metabolic addictions",
        "_version_":1606188974182760448},
      {
        "Meeting_name":" Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia",
        "Background":"['Background', ' Chromosome abnormalities of leukemia cells have important prognostic significance in childhood acute lymphoblastic leukemia (ALL). B-cell precursor acute lymphoblastic leukemia (BCP-ALL) ETV6/RUNX1 (alias TEL/AML1) is most frequent i.e. 15 - 35% in the children with 2 - 18 age group. We report two new cases with Pre B- cell ALL without ETV6/RUNX1 rearrangement, showing amplification of AML1 gene detected by FISH analysis. Methods', ' Bone marrow samples were analyzed for chromosomal abnormalities with conventional G-banding techniques and interphase fluorescence in situ hybridization (FISH) using probes to detect BCR/ABL t(9;22)(q34-q11) fusion, cryptic TEL/AML1 t(12', '21)(p13-q22) and MLL rearrangement for del 11q23. Results', ' In first case a 3-year girl with four copies of AML (RUNX1) gene were observed in 95% of the cell with normal two copies of TEL (ETV6) gene in both interphase and metaphase FISH. We observed BCR-ABL negative translocation and no MLL gene rearrangement in all the interphase cells after doing FISH. We got a normal 46XX karyotype from bone marrow with conventional cytogenetics (CC) in the same patient. In second case, a 4-year male we observed four copies of AML and two copies of TEL gene in more than 80% of cells. In this patient, we got BCR-ABL negative translocation and three copies of MLL gene without any rearrangement through FISH. We got normal 46XY karyotype in the same patient through CC. Conclusions', ' In both the patients, we observed hyperdiploidy detected with four copies of RUNX1 gene showing tetrasomy of chromosome 21 detected with metaphase FISH analysis whereas G-banding shows normal diploidy. Bone marrow karyotype in combination with molecular cytogenetic techniques like FISH should be done for improvement in sensitivity and accurate cytogenetic analysis in childhood ALL patients for proper identification of prognostic group for optimum treatment. This is one of the few reported studies worldwide for amplification of RUNX1 gene from Indian subcontinent in childhood BCP-ALL.']",
        "Doc_id":"ASCO_34387-65",
        "Doc_title":" Amplification of RUNX1 gene in two new cases of childhood B-cell precursor acute lymphoblastic leukemia",
        "_version_":1606188991372066816},
      {
        "Meeting_name":" Novel kinase inhibitor for imatinib-resistant chronic myeloid leukemia with T315I mutation",
        "Background":"['Chronic myeloid leukemia (CML) is characterized by a constitutive activation of Bcr-Abl tyrosine kinase. Bcr-Abl/T315I is the predominant mutation that causes resistance to Imatinib. In the present study, we synthesized a novel Bcr-Abl inhibitor, HS-543, and investigated its effect on cell survival or apoptosis in CML cells bearing Bcr-Abl/T315I (BaF3/T315I) or wild-type Bcr-Abl (BaF3/WT). HS-543 showed anti-proliferative effects in the BaF3/WT cells as well as the BaF3/T315I cells with resistance to Imatinib and strongly inhibited the Bcr-Abl signaling pathways in a dose dependent manner. Furthermore, it significantly increased the sub G1 phase associated with early apoptosis, with increased levels of cleaved PARP and caspase-3, as well as the TUNEL-positive apoptotic cells. In addition, we found that HS-543 induced apoptosis with the loss of mitochondrial membrane potential by decreasing the expression of Mcl-1 and survivin, together with increasing the expression of Bax. In BaF3/T315I xenograft models, HS-543 significantly delayed tumor growth, unlike Imatinib. Our results demonstrate that HS-543 exhibits the induction of apoptosis and anti-proliferative effect by blocking the Bcr-Abl signaling pathways in the T315I-mutated Bcr-Abl cells with resistance to Imatinib. We suggest that HS-543 may be a novel promising agent to target Bcr-Abl and overcome Imatinib resistance in CML patients.']",
        "Doc_id":"AACR_2015-5389",
        "Doc_title":" Novel kinase inhibitor for imatinib-resistant chronic myeloid leukemia with T315I mutation",
        "_version_":1606188975477751808},
      {
        "Meeting_name":" Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia",
        "Background":"['Chronic myeloid leukemia (CML) is a myeloproliferative disorder by BCR-ABL, which can transform hematopoietic stem cells (HSCs) into leukemic stem cells (LSCs) with a limitless capacity for self-renewal. Despite substantial prognostic improvement of CML by a specific debulking of tumor burden with a tyrosine kinase inhibitor (TKI) targeting ABL kinase, imatinib-treated CML patients in chronic phase can relapse and progress to blast phase due to the remnant CML stem cells. Ecotropic viral integration site 1 (EVI1), a key transcription factor in HSC regulation, is known to predict poor outcomes in myeloid malignancies, however, incapability of prospective isolation of EVI1-high leukemic cells precludes the functional evaluation of intra-individual EVI1-high cells. In this study, we hypothesized that EVI1 is a valuable marker of CML stem cells as well as HSCs and aimed to cover in depth the regulation of CML stem cells by Evi1. Introduction of CML into Evi1-IRES-GFP knock-in mice, a versatile HSC-reporter strain, enabled us to separate Evi1-high CML cells from the individual and revealed that Evi1 was predominantly enriched in the stem cell fraction and associated with an enhanced proliferative as well as a leukemia-initiating capacity. Comparison of gene expression profiles between Evi1-high and -low CML cells revealed that Evi1-high CML cells had a more quiescent feature and a less differentiated feature than Evi1-low CML cells, suggesting that Evi1-high CML LSK cells could keep self-renewal capacity. Furthermore, Evi1-high CML cells exhibited apparent resistance to TKIs in vivo. Given that Evi1 heterozygosity ameliorated CML development in vivo and that the combination of Evi1 and BCR-ABL caused acute myeloid leukemia (AML) in mice resembling blastic transformation of CML, Evi1 could regulate CML development as a potent driver. In accordance to our data of Evi1-trafficking CML mouse, our single-cell analysis of primitive or differentiated subsets from primary CML-CP samples show that EVI1 was highly expressed in stem cell-enriched CD34+CD38-CD90+ cells, which implied that EVI1 could mark CML stem cells as well as normal HSCs. This point can be translated to human CML cases like that high EVI1 means the increasing number of CML stem cells. As opposed to Evi1-reporter CML models, in AML model by MLL-ENL oncogene, Evi1-high MLL-ENL leukemic cells showed no advantage in leukemia initiation compared to Evi1-low cells. Other Evi1-reporter AML models by MOZ-TIF2 and TEL-PDGFR+AML1-ETO never generated Evi1-high fraction, suggesting the high affinity of Evi1 for stem cell disease such as CML. In conclusion, high Evi1 can define the population of CML stem cells which are resistant to nilotinib. Combinatorial analyses of Evi1-IRES-GFP allele CML animals and single cells from primary CML-CP patients also covered in depth the critical regulation of CML stem cells by Evi1.']",
        "Doc_id":"AACR_2014-3901",
        "Doc_title":" Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia",
        "_version_":1606188989112385536},
      {
        "Meeting_name":" MicroRNA-150 expression induces differentiation of myeloid leukemias",
        "Background":"['Blocked myeloid differentiation is a major feature of chronic myeloid leukemia (CML) disease progression and acute myeloid leukemia (AML). Normal myeloid differentiation is a tightly controlled process involving the coordinated action of specific transcription factors, which are dysregulated by chromosomal translocations, DNA mutations, epigenetic changes, and aberrant gene and microRNA (miRNA) expression in leukemias. Previously, we identified decreased miR-150 expression in CML and AML cell lines and primary cells when compared to normal bone marrow, and determined miR-150 expression is decreased in CML by the Bcr-Abl fusion protein. Furthermore, lentiviral expression of miR-150 in AML cell lines and primary CML patient samples induced myeloid differentiation as detected by CD11b expression, morphologic differentiation, and colony forming ability in methylcellulose, both in the absence and presence of the differentiating agents. In this study, we elucidated the targets responsible for miR-150 induced differentiation. Expression of the validated miR-150 target MYB, a transcription factor involved in blocking differentiation in progenitor cells, was only decreased in miR-150 expressing cells in the presence of differentiating agent all-trans retinoic acid (ATRA). Furthermore, lentiviral overexpression of MYB lacking miR-150 binding sites in the 3-UTR partially decreased the CD11b expression in the presence and absence of ATRA in both control and miR-150 expressing HL60 cells. These results suggest additional miR-150 targets are involved in differentiation besides MYB. To identify additional miRNA-150 targets, we profiled changes in mRNAs associated with the RNA-induced silencing complex (RISC) using RNA-immunoprecipitation of Ago2 followed by microarray gene expression profiling in miR-150 versus control HL60 cells. Furthermore, although almost all functional investigations have focused on the mature strand, we have found that miR-150 and its partner star strand miR-150* are expressed at almost equal levels in normal myeloid hematopoietic cells, and are investigating the individual contributions of their separate targets in induction of differentiation. In conclusion, miR-150 expression promotes myeloid differentiation through targeting transcription factor MYB and additional targets, while downregulation of miR-150 in myeloid leukemias contributes to the block in differentiation.']",
        "Doc_id":"AACR_2012-146",
        "Doc_title":" MicroRNA-150 expression induces differentiation of myeloid leukemias",
        "_version_":1606188990962073600},
      {
        "Meeting_name":" Ponatinib demonstrates antitumor activity in RET- and FGFR-driven patient-derived xenografts",
        "Background":"['Background', ' Ponatinib is a potent pan-BCR-ABL tyrosine kinase inhibitor (TKI) approved for patients (pts) with refractory or T315I+ chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia. We have previously shown that ponatinib also inhibits oncogenic variants of KIT, RET, and FGFR in vitro. Moreover, ponatinib induced complete regression of KIT-mutant tumors in a gastrointestinal stromal tumor (GIST) patient-derived xenograft (PDX), a finding consistent with the preliminary evidence of efficacy observed in pts with refractory GIST (NCT01874665). In this study, we evaluated ponatinib in a panel of PDXs harboring oncogenic variants of RET and FGFR.Methods', ' The efficacy of ponatinib (20 mg/kg once-daily oral dosing) was compared to that of vehicle in 10 PDXs derived from a variety of tumor types containing oncogenic RET or FGFR fusions, high-level FGFR amplification (amp), or no known oncogenic drivers (WT; Table 1). Chemotherapeutic comparators (cisplatin or 5-fluorouracil) were included in 6 models. To confirm target modulation, levels of RET or FGFR phosphorylation in tumors were analyzed 6 hrs post dosing.Results', ' Ponatinib induced tumor regression or 80% tumor growth inhibition (TGI) in the 4 RET fusion PDXs, and 62-98% TGI in the 3 FGFR PDXs (Table 1). Complete abrogation of target phosphorylation due to ponatinib treatment was verified in the 3 models examined. The efficacy of ponatinib exceeded that of the chemotherapy comparator in RET-driven but not WT PDXs, further suggesting this efficacy was driven primarily through inhibition of the driver oncogene.Conclusion', ' Ponatinib demonstrates marked efficacy across several PDX models with either RET fusion-, FGFR2/3 fusion-, or FGFR2 amp-driven cancers, in a target dependent manner. These results provide additional support for evaluating ponatinib in pts with cancers positive for these aberrations; such trials are planned or ongoing (NCT01813734,  NCT02265341,  NCT01935336, and NCT02272998).Table 1', \" Ponatinib's efficacy in PDX tumor models\"]",
        "Doc_id":"AACR_2015-783",
        "Doc_title":" Ponatinib demonstrates antitumor activity in RET- and FGFR-driven patient-derived xenografts",
        "_version_":1606188980662960128},
      {
        "Meeting_name":" Inhibition of Bcr-Abl in human leukemic cells with a coiled coil protein delivered by a leukemia-specific cell penetrating peptide",
        "Background":"['The oncoprotein Bcr-Abl is the cause of chronic myeloid leukemia (CML). Current CML therapies target the tyrosine kinase domain of Bcr-Abl, but due to their non-curative nature, resistance to these drugs is common. Therefore, new treatments are needed for those patients refractive to available therapies. Bcr-Abl homo-oligomerization via its N-terminal coiled coil (CC) domain is required for tyrosine kinase activity. Our previous work has shown that it is possible to inhibit Bcr-Abl activity by targeting the CC domain with a altered version of the CC domain, known as CCmut3, delivered as a plasmid. In this study, CCmut3 is delivered to cells as a protein by utilizing a leukemia-specific cell-penetrating peptide (CPP). Here, recombinant CPP-CCmut3 was expressed, purified, and tested for its anti-oncogenic activity. CPP-CCmut3 was able to enter two leukemic cell lines (K562 and Ba/F3-P210) and inhibit Bcr-Abl activity as shown by induction of necrosis/apoptosis via 7-AAD/Annexin V staining, reduction of oncogenic potential in colony forming assays, reduction of cell proliferation, and inhibition of Bcr-Abl phosphorylation (kinase activity). Further, CPP-CCmut3 did not enter non-leukemic cell lines (HEK293 and MCF-7). While CPP-CCmut3 was able to enter the parental, non-leukemic Bcr-Abl- Ba/F3 pro-B cell line, it revealed no signs of activity in the assays performed, as expected. These results indicate the feasibility of using CPP-CCmut3 as a therapeutic against CML.']",
        "Doc_id":"AACR_2015-2641",
        "Doc_title":" Inhibition of Bcr-Abl in human leukemic cells with a coiled coil protein delivered by a leukemia-specific cell penetrating peptide",
        "_version_":1606189022923718656},
      {
        "Meeting_name":" PBA2, a dual BCR-ABL and GSK3kinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia",
        "Background":"['Despite the clinical efficacy of the BCR-ABL (Tyrosine Kinase Inhibitors) TKIs for the treatment of Chronic Myeloid Leukemia (CML), BCR-ABL-T315I mutation still confers higher-level resistance to imatinib and the second generation BCR-ABL TKIs. Ponatinib, as the third generation BCR-ABL TKIs, has the potential activity against CML with T315I mutant BCR-ABL whereas high frequency of serious adverse events limits its clinical use. Through a compound library screen, we identified a novel compound PBA2, a dual kinases inhibitor of GSK3 and BCR-ABL, as a promising agent for the treatment of imatinib-resistant CML. Not only can PBA2 inhibit cell growth but also induce terminal cell differentiation in a series of kinase mutant CML cell lines as well as T315I mutation. Remarkably, the mechanism of action of this compound involved the simultaneous inhibition effect of BCR-ABL and GSK3, which could be a fruitful approach to suppress the -catenin/CBP signal pathway that promoted the interaction of -catenin/p300, leading to growth inhibition and subsequent terminal differentiation. More importantly, we found a novel molecular link between CBP and BCR-ABL. We showed that CBP could regulate BCR-ABL expression through activating CREB which binds to the BCR-ABL promoter in CML cells to start transcription, and the BCR-ABL in turns affect the expression level of CBP. This positive feedback pathway between CBP and BCR-ABL represents a novel way for the treatment of CML, and the novel compound PBA2 targeting at this loop deserves further investigation in clinical trial.']",
        "Doc_id":"AACR_2016-3915",
        "Doc_title":" PBA2, a dual BCR-ABL and GSK3kinases inhibitor, represses a wide array of Imatinib resistant cell lines in chronic myeloid leukemia",
        "_version_":1606188975452585985},
      {
        "Meeting_name":" Identification of a novel lncRNA involved in Bcr-Abl mediated cellular transformation.",
        "Background":"['Aberrant expression of long noncoding RNAs (lncRNAs) is associated with various human cancers. However, little information is available about functional involvement of lncRNAs in tumorigenesis of chronic myeloid leukemia (CML) induced by Bcr-Abl oncogene. In this study, we performed a comprehensive analysis of lncRNAs in human CML cells using an lncRNA cDNA microarray combined with drug treatment. We identified an lncRNA termed lncRNA-up38 that was critically involved in Bcr-Abl-mediated cellular transformation. We found that expression of lncRNA-up38 was greatly upregulated by inhibiting Bcr-Abl kinase activity in K562 cells and leukemic cells derived from CML patients. Furthermore, our experiments demonstrated that lncRNA-up38 acted as a key regulator of 4EBP1 functioning during Bcr-Abl-mediated cellular transformation. Moreover, silencing lncRNA-up38 promoted leukemic cells survival and enhanced Bcr-Abl-mediated tumorigenesis, whereas forced expression of lncRNA-up38 sensitized leukemic cells to undergo apoptosis and inhibited Bcr-Abl-induced tumorigenesis. Additionally, our experiments have begun to address the mechanism of how lncRNA-up38 is regulated in the leukemic cells and showed that Bcr-Abl repressed lncRNA-up38 expression through c-Myc-dependent signaling. Taken together, these results reveal that Bcr-Abl-mediated cellular transformation is associated with downregulation of tumor-suppressor lncRNA-up38 and suggest a potential strategy for the treatment of Bcr-Abl-positive leukemia.']",
        "Doc_id":"AACR_2017-3450",
        "Doc_title":" Identification of a novel lncRNA involved in Bcr-Abl mediated cellular transformation.",
        "_version_":1606189015375020032},
      {
        "Meeting_name":" RNA editing enzyme ADAR1 drives leukemia stem cell differentiation and self-renewal in chronic myeloid leukemia",
        "Background":"['Chronic myeloid leukemia (CML) is the first cancer that was shown to originate from a genetic abnormality - the Philadelphia chromosome translocation, and production of its constitutively active protein tyrosine kinase product, BCR-ABL. The disease progresses slowly from chronic phase to accelerated phase, and later transforms to blast crisis (BC) stage. Cancer stem cells (CSCs) are a subset of tumor cells that have acquired certain treatment-resistant stem cell properties. High levels of RNA editing are associated with a primitive transcriptional program typical of human embryonic stem cells, and RNA editing plays an important role in both embryonic hematopoietic cell fate determination and in maintenance of normal hematopoiesis. Human RNA editing occurs primarily in secondary structures created by Alu retroelements and is carried out by enzymes such as the adenosine deaminase acting on RNA (ADAR) family. Among these, ADAR1 was also recently shown to be required for normal hematopoiesis by suppressing interferon-induced apoptosis. Our research focuses on dissecting the role of ADAR-mediated RNA editing in normal human hematopoietic progenitor cell development compared with malignant editing programs that may be activated in leukemia stem cells (LSC) during the progression of human CML. Our data demonstrates that BC LSC harbor increased levels of the interferon-responsive ADAR1 p150 isoform compared with chronic phase (CP) progenitors and normal cord blood progenitors. Expression of this isoform also exhibits a positive correlation with BCR-ABL expression levels - an effect which is specific to BC progenitors, suggesting that ADAR1 expression correlates with disease progression from CP to BC. In vitro hematopoietic progenitor assays with normal cord blood progenitors and CP samples transduced with lentiviral vectors overexpressing human ADAR1 reveals a significant shift in cell differentiation fate towards granulocyte-macrophage progenitor (GMP) colonies, which has been shown to be the initiating LSC population in CML Correspondingly, a progression towards erythroid lineage was observed in BC CML LSC transduced with lentiviral vectors expressing shRNA targeting ADAR1. Further qRT-PCR analyses revealed that the mechanism through which ADAR1 drives LSC and HSC differentiation towards myelopoiesis involves regulation of PU.1, which in turn inhibits GATA1 expression. Moreover, in vivo studies in a robust humanized CML mouse model showed a significant decrease in LSC serial transplantation potential of lentiviral shADAR1-transduced BC progenitors transplanted into neonatal RAG2-/-c-/- mice. Together, these data support a crucial role for ADAR1 in cell fate determination and self-renewal potential of hematopoietic stem cells in both normal human progenitors and in malignant LSC that drive disease progression and therapeutic resistance.']",
        "Doc_id":"AACR_2012-5217",
        "Doc_title":" RNA editing enzyme ADAR1 drives leukemia stem cell differentiation and self-renewal in chronic myeloid leukemia",
        "_version_":1606188990428348416},
      {
        "Meeting_name":" New approaches to overcome tyrosine kinase inhibitor resistances in chronic myeloid leukemia",
        "Background":"['Chronic myeloid leukemia (CML) is driven by the hyperactive fusion kinase Bcr-Abl, generated by a chromosomal translocation between chromosome 9 and 22. This oncogenic tyrosine kinase builds up its own signaling network with various proteins such as the docking protein Gab2 or the Src kinase Lyn. As a result, the cells become addicted to the constant signals derived from this fusion kinase. This is the reason why selective Bcr Abl tyrosine kinase inhibitors (TKIs), such as Imatinib mesylate or dasatinib, became so successful in the therapy of CML. Despite the great success of these TKIs in CML treatment, TKI resistance remains a serious clinical problem. These resistances can be caused by mutations in the Bcr-Abl oncogene, like the clinical relevant T315I mutation or by aberrant activity of components of the Bcr-Abl signaling network. In that regard, we could show that the overexpression of Gab2 or the expression of a hyperactive mutant of Lyn can confer TKI resistance.Using different CML cell lines and models we aimed to identify new approaches to overcome TKI resistances caused by Bcr-Abl mutations or aberrant downstream signaling. Therefore, we screened inhibitors for their ability to overcome Gab2 mediated resistance or to inhibit the activity of T315I mutated Bcr-Abl. We identified the multikinase inhibitors sorafenib and axitinib, both clinical approved as second line drugs in renal cell or hepatocellular carcinoma, as compounds reducing the viability of Bcr-AblT315I transformed cells. Interestingly, these inhibitors were highly active against TKI resistant Bcr-Abl positive cells in contrast to non-transformed cells. These results invite for the further evaluation of sorafenib and axitinib in the treatment of TKI-resistant CML.']",
        "Doc_id":"AACR_2015-2708",
        "Doc_title":" New approaches to overcome tyrosine kinase inhibitor resistances in chronic myeloid leukemia",
        "_version_":1606189014823469056},
      {
        "Meeting_name":" Liposomal bortezomib improves chemosensitivity and inhibits cell proliferation in part through BCR/ABL downregulation in CML",
        "Background":"['The t(9;22) Philadelphia chromosome translocation fuses the BCR gene to the c-ABL proto-oncogene resulting in a chimeric BCR/ABL protein. Although BCR/ABL inhibitor imatinib has shown unprecedented efficacy for treatment of chronic myeloid leukemia (CML), resistance to this agent due to BCR/ABL mutations or increased protein expression poses a significant clinical problem, thereby arguing for novel therapeutic approaches. BCR/ABL gene amplification frequently occurs in blast crisis and BCR/ABL expression is required for its mutation. BCR promoter contains Sp1 binding sites and proteasome inhibitor bortezomib (BORT) disrupts Sp1 transactivation, therefore, we hypothesized that BORT could abolish BCR/ABL expression leading to disrupted kinase activity. However, the fast clearance and the inability to reach target cells in vivo have limited its application. As such, we designed a liposomal BORT (L-BORT) and transferrin receptor (TfR)-targeted L-BORT (Tf-L-BORT) for the objective of enhancing BORT delivery efficiency. We observed that there were 3.6-fold and 10.4-fold increases in cellular uptake of L-BORT and Tf-L-BORT, respectively, compared to that of the free drug. We evidenced a 2.7-fold augmented chemosensitivity to doxorubicin (DOX) in cells exposed to subtoxic concentration of BORT, with a decrease in IC50 from 8 M to 300 nM. Tf-L-BORT further reduced IC50 of DOX to 90 nM. These data indicated the enhanced chemosensitizing efficacy of the L-BORT formulations. When single tumor cells from K562 tumor bearing mice were treated by subtoxic L-BORT combined with DOX, a synergy of toxicity was evidenced by 70-fold increased chemosensitivity (p<0.05). Tf-L-BORT was more effective in chemosensitizing tumor single cells than L-BORT, with decreased IC50 of DOX to 94 nM. Pharmacokinetic study in mice after i.v. bolus injection showed that L-BORT had slower tissue distribution (T1/2, 7.3 min vs. 2.9 min), increased elimination phase half-life (T1/2, 82.9 h vs. 68.3 h), decreased clearance (CL, 4.2 mL/h vs. 27.7 mL/h), and increased area under the plasma concentration-time curve (AUC, 4714.1 hng/mL vs. 721.4 hng/mL) compared to the free drug. This indicated a significant and potentially beneficial change in BORT pharmacokinetics in vivo. Mechanistically, when K562 cells were exposed to L-BORT (0, 10, 30 and 60nM) or DOX (0, 100, 200 and 500nM) for 48h, BCR/ABL protein was significantly decreased in a dose-dependent manner. Interestingly, the combination of L-BORT with DOX synergistically abrogated BCR/ABL and Sp1 protein expression. Altogether, these results highlight the therapeutic relevance of disrupting BCR/ABL protein expression and strongly support the utilization of L-BORT alone or in combination with DOX to treat CML patients harboring overexpressed BCR/ABL.']",
        "Doc_id":"AACR_2012-921",
        "Doc_title":" Liposomal bortezomib improves chemosensitivity and inhibits cell proliferation in part through BCR/ABL downregulation in CML",
        "_version_":1606189032012775424},
      {
        "Meeting_name":" Survival of BCR-ABL positive and negative chronic myeloid leukemia",
        "Background":"['Background', '  BCR-ABL negative chronic myeloid leukemia (CML) is uncommon without any previous largescale studies. Because of the genetic differences between BCR/ABL negative and positive CML, we compared their characteristics and outcomes in pre and post-imatinib era.   Methods', '  We used the Surveillance, Epidemiology, and End Results (SEER) 18 database and appropriate International Classification of Disease (ICD-O-3) histology codes to identify adult patients with BCR/ABL negative and positive CML diagnosed between 1973 and 2011. Propensity matching was performed using the MatchIt package of R v2.15.2 to create a matched dataset of BCR/ABL negative and positive CML in the pre-imatinib era (cases diagnosed before 2001) and the post-imatinib era (cases diagnosed after 2001).Kaplan Meier survival and multivariate analysis (Cox proportional hazard regression model) were done using SPSS v22.0.  Results', '  13,374 cases of BCR/ABL positive CML and 82 cases of BCR/ABL negative CML were identified. Patients with BCR/ABL negative CML, compared to BCR/ABL positive CML, were more likely to be older (69 vs. 60 years, p < 0.01) and diagnosed after 2001 (89% vs. 35.3%, p < 0.01). The median OS of BRC/ABL negative and positive CML was 15 months and 47 months respectively. OS was significantly lower among BRC/ABL negative CML (p < 0.01) but only during the post-imatinib era (p < 0.01). Multivariate analysis showed that OS was significantly lower among BRC/ABL negative (HR 2.15; 95% CI 1.57-2.92; p < 0.01) and with older age at diagnosis but better in more recent years. Gender and race did not influence OS.  Conclusions', '  Our study demonstrates that the difference in OS between BRC/ABL positive and negative CML may not be the result of their intrinsic biology behavior, rather due to the powerful impact of tyrosine kinase inhibitors. Preclinical studies have indicated a possible therapeutic role of JAK inhibitors (ruxolitinib) and SRC kinase inhibitors (dasatinib) in select BRC/ABL negative CML. Identification of actionable mutations, development of novel therapies and improvement in transplant techniques have the potential to improve the outcomes of  these patients.']",
        "Doc_id":"ASCO_147277-156",
        "Doc_title":" Survival of BCR-ABL positive and negative chronic myeloid leukemia",
        "_version_":1606188994715975680},
      {
        "Meeting_name":" Bcr/Abl induces expression of Aurora kinase A via Akt signaling",
        "Background":"['Aurora kinase A (AURKA) plays a pivotal role in the mitotic processes during cell division. We previously showed that AURKA was aberrantly expressed in hematological malignant cells including those from chronic myeloid leukemia (CML) compared to CD34+ hematopoietic stem/progenitor cells isolated from healthy volunteers. This study explored molecular mechanisms by which bcr-abl induced expression of AURKA; Lentiviral transduction of p210 bcr-abl into murine lymphoid Ba/F3 as well as human CD34+ hematopoietic stem/progenitor cells potently increased levels of AURKA in association with phosphorylation of AURKA and Akt, as assessed by real time RT-PCR and Western blot analysis. On the other hand, exposure of CML K562 cells which constitutively expressed phosphorylated forms of Akt and AURKA to imatinib, an inhibitor of bcr-abl kinase, de-phosphorylated both Akt and AURKA. In addition, the capability of bcr-abl to induce expression of AURKA in human CD34+ hematopoietic stem/progenitor cells was blunted when Akt was inactivated by a short hairpin RNA. These observations suggested that p210 bcr-abl activated AURKA at least in part via Akt signaling. Moreover, we found that lentiviral transduction of imatinib-resistant T315I mutant of bcr-abl into Ba/F3 cells also activated both Akt and AURKA. Importantly, exposure of p210 T315I bcr-abl-expressing Ba/F3 cells to a specific inhibitor of AURKA effectively inhibited their proliferation in vitro. Taken together, AURKA may be a promising molecular target in bcr-abl driven hematological malignancies and inhibition of AURKA could be useful to overcome imatinib-resistance mediated by bcr-abl mutants.']",
        "Doc_id":"AACR_2012-12",
        "Doc_title":" Bcr/Abl induces expression of Aurora kinase A via Akt signaling",
        "_version_":1606189032227733504},
      {
        "Meeting_name":" Downregulation of miR-217 correlates with resistance of ph+ leukemia cells to ABL tyrosine kinase inhibitors",
        "Background":"['This study found that long-term exposure of chronic myelogenous leukemia (CML) K562 cells to BCR/ABL thyrosine kinase inhibirors (TKIs) caused drug-resistance in association with an increase in levels of DNA methyltransferases (DNMTs) and a decrease in levels of microRNAs (miRNAs) miR-217. These observations are clinically relevant; an increase in levels of DNMT3A in association with downregulation of miR-217 were noted in leukemia cells isolated from individuals with BCR/ABL TKI-resistant philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) and CML. Further studies with TKI-resistant K562 cells found that forced expression of miR-217 inhibited expression of DNMT3A through a miR-217-binding site within the 3-untranslated region of DNMT3A and sensitized these cells to growth inhibition mediated by the TKI. Of note, long-term exposure of K562 cells to dasatinib (10 nM) together with 5-Aza-2-deoxycytidine (5-AzadC) (0.1 M) potently inhibited proliferation of these cells in association with upregulation of miR-217 and downregulation of DNMT3A in vitro. In addition, a decrease in levels of DNMT3A and an increase in levels of miR-217 were noted in K562 tumors growing in immune deficient mice that were treated by the combination of 5-AzadC and dasatinib. Taken together, Ph+ leukemia cells acquire TKI-resistance via downregulation of miR-217 and upregulation of DNMT3A. Inhibition of DNMT3A by forced expression of miR-217 or 5-AzadC may be useful to prevent drug resistance in individuals who receive TKIs.']",
        "Doc_id":"AACR_2014-1717",
        "Doc_title":" Downregulation of miR-217 correlates with resistance of ph+ leukemia cells to ABL tyrosine kinase inhibitors",
        "_version_":1606189024761872384},
      {
        "Meeting_name":" 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.",
        "Background":"['Background', ' The approved tyrosine kinase inhibitor (TKI)ponatinib is potently active against native and resistant BCR-ABL, including T315I. Methods', ' The pivotal PACE trial (NCT01207440) evaluated ponatinib (starting dose 45 mg/d) in pts with chronic myeloid leukemia (CML) or Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) refractory to dasatinib or nilotinib, or with T315I. Dose reductions were recommended in Oct 13 due to observed arterial occlusive events (AOEs). Efficacy and safety at 4 yrs, as well as by yr for chronic phase (CP) CML pts, are reported (data as of 3 Aug 15). Exposure-adjusted incidence rates of new AOEs are reported as the no. of events/100 pt-yrs. Results', ' Of 449 pts, 59% received  3 prior TKIs. At analysis, 30% of pts (median follow-up 37.3, range 0.158.5 mo) and 41% (110/270) of CP-CML pts (48.2, 0.158.5 mo) remained on study. Responses continued to deepen over time (Table) despite dose reductions. Estimated 4-yr rates for PFS, OS, and maintenance of MCyR and MMR were 56%, 77%, 82% and 61%, respectively. For advanced phase pts, the estimated 4-yr OS was 51%; median OS for blast phase/Ph+ALL pts', ' 6.9 mo (95% CI, 5.0-9.2). Common (in  30% of pts) TEAEs were thrombocytopenia 44%, abdominal pain 43%, rash 42%, constipation 37%, headache 37%, dry skin 36%, fatigue and hypertension 30%. AOE rate/serious AOE rate was 23%/19%, including cardio- 13%/9%, cerebro- 9%/7%, and peripheral-vascular 9%/7%. Of pts with AOEs (n = 104), 38% remained on study. Exposure-adjusted incidence rates of new AOEs fell after the first 2 yrs', ' 15.5 yr 1, 15.7 yr 2, 10.4 yr 3, and 9.6 yr 4. Nearly 2-yrs after recommended dose reductions, 87% (114/131) and 74% (70/95) of CP-CML pts were estimated to maintain MCyR and MMR, respectively, and 8% (6/75) of all dose-reduced pts without a prior AOE on trial had an AOE. Conclusions', ' After 4 yrs,heavilypretreated pts continue to show deep and lasting responses on ponatinib, and ~2 yrs post recommended dose reductions, maintenance of response is high, and the incidence of newly occurring AOEs has decreased. Clinical trial information', ' NCT01207440Cumulative response rates (%) with ponatinib in CP-CML pts (n = 267, efficacy evaluable).MCyRCCyRMMR / MR4.5Yr 1555130 / 9Yr 2585336 / 16Yr 3595339 / 22Yr 4595439 / 23']",
        "Doc_id":"ASCO_163683-176",
        "Doc_title":" 4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.",
        "_version_":1606188972606750720},
      {
        "Meeting_name":" A critical role of LincRNA-Up6 in Bcr-Abl-induced tumorigenesis.",
        "Background":"['Long noncoding RNAs (lncRNAs) have been implicated in numerous human malignancies, including leukemia. Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) is a stem cell disease induced by Bcr-Abl hybrid gene. In an attempt to provide better understanding of the mechanisms by which Bcr-Abl mediates cellular transformation, lncRNA microarray was used to determine the differentially expressed non protein-coding genes in K562 human leukemic cells in response to disruption of Bcr-Abl expression. All the lncRNA genes whose expressions were altered by at least 2-fold were clustered and displayed. We further investigated the functional involvement of selected lncRNA genes in regulating cell proliferation, cell survival and tumor formation. Interestingly, expression of a long intergenic noncoding RNA which we named as lincRNA-Up6 was found to be greatly up-regulated by silencing the Bcr-Abl expression in K562 cells. We showed that forced over-expression of lincRNA-Up6 sensitized imatinib-induced apoptosis in Bcr-Abl transformed cells. In addition, we observed that over-expression of lincRNA-Up6 significantly inhibited K562 xenograft growth in nude mice. Furthermore, we found that lincRNA-Up6 was involved in negative regulation of STAT5-dependent expression of anti-apoptotic Bcl-XL protein. Importantly, our experiments showed that expression of lincRNA-Up6 had profound effects on signaling pathways associated with development of leukemia stem cells of CML, resulting in inhibition of Bcr-Abl-mediated tumor formation. Together, these results suggest that lincRNA-Up6 suppresses Bcr-Abl-induced tumorigenesis, and the tumor suppressor function of lincRNA-Up6 may be of significance for the development of novel therapeutic strategies for treating CML.Citation Format', ' Jilong Chen, Guijie Guo, Qingzheng Kang. A critical role of LincRNA-Up6 in Bcr-Abl-induced tumorigenesis. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 1826. doi', '10.1158/1538-7445.AM2013-1826']",
        "Doc_id":"AACR_2013-1826",
        "Doc_title":" A critical role of LincRNA-Up6 in Bcr-Abl-induced tumorigenesis.",
        "_version_":1606188990138941441},
      {
        "Meeting_name":" Evaluating the chromatin state as a predictive biomarker for BET inhibitor sensitivity in hematological malignancies",
        "Background":"['The BET (bromodomain extra-terminal) family of proteins are a group of epigenetic regulators that control gene transcription by reading acetylated lysines on histone tails and recruiting transcription complexes. The various BET inhibitors developed show strong anti-tumor effects against a broad range of hematologic malignancies. The BET inhibitor JQ1 shows strong anti-proliferative activity in sub-sets of multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and lymphoma cell line models. At present, however, predictive biomarkers of BET inhibitor sensitivity have not been identified. We hypothesize that the chromatin state characterized by various histone post-translational modifications (acetylation, methylation, etc.), can drive sensitivity to BET inhibition. By examining basal expression of epigenetic marks in panels of sensitive and resistant heme cell line models and further validating these histone modification trends in primary AML and multiple myeloma cultures, we may be able to identify predictive biomarkers of BET inhibitor sensitivity in hematological malignancies.']",
        "Doc_id":"AACR_2016-4516",
        "Doc_title":" Evaluating the chromatin state as a predictive biomarker for BET inhibitor sensitivity in hematological malignancies",
        "_version_":1606188982473850880},
      {
        "Meeting_name":" BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells",
        "Background":"['In this study, we showed that the levels of enhancer of zeste homolog 2 (EZH2) in bone marrow mononuclear cells (BMMNCs) isolated from individuals with chronic myeloid leukemia (CML) (n = 12) were greater than those in BMMNCs isolated from healthy volunteers (n = 6). Lentiviral transduction of the BCR/ABL gene in Ba/F3 cells increased EZH2 levels in parallel with phosphorylation of STAT5. Notably, chromatin immunoprecipitation assays showed that STAT5A bound to a promoter region of the EZH2 gene, resulting in an increase in the transcriptional activity of EZH2 in leukemia cells. Importantly, downregulation of EZH2 by short hairpin RNAs (shRNAs) inhibited the expression of the antiapoptotic protein XIAP and increased the miR-219 levels associated with a decrease in hypermethylation of miR-219-1 CpG islands. Moreover, overexpression of miR-219 decreased the levels of XIAP in CML cells. Since the 3-untranslated region (3-UTR) of XIAP contains miR219-5p-complementary binding site, miR-219 might modulate the expression of XIAP through binding of miR-219 on the 3-UTR of XIAP.Taken together, BCR/ABL positively regulates the expression of EZH2 via STAT5 signaling. EZH2 modulates epigenetic changes at DNA methylated regions encoding miR-219 and downregulates the level of miR-219, resulting in upregulation of XIAP.']",
        "Doc_id":"AACR_2016-3562",
        "Doc_title":" BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells",
        "_version_":1606189032364048384},
      {
        "Meeting_name":" Recombinant stapled proteins for the treatment of chronic myeloid leukemia",
        "Background":"['The oncoprotein Bcr-Abl is the cause of chronic myeloid leukemia (CML). Current therapies target the tyrosine kinase domain of Bcr-Abl, but due to their non-curative nature, resistance to these drugs is common. Therefore, new treatments are needed for those patients refractive to available therapies. Bcr-Abl homo-oligomerization via its N-terminal coiled coil (CC) domain is required for tyrosine kinase activity. Our previous work has shown that it is possible to inhibit Bcr-Abl activity by targeting the CC domain with a peptidomemetic known as CCmut, delivered as a protein using a cell-penetrating peptide (CPP-CCmut). CPP-CCmut selectively enters leukemic cells and inhibits Bcr-Abl, as seen by Western blot, 7AAD, Annexin V, cell proliferation, and colony forming assays.This leukemia cell-permeable CPP-CCmut protein domain is our lead compound for CML therapy, but to be translatable to the clinic it must be modified to improve proteolytic stability. For this reason, we created stapled versions of this CPP-CCmut. Stapled peptides are resistant to proteolysis, and are emerging as a viable strategy for disrupting protein-protein interactions in diseases including HIV and cancer. Until recently, peptide stapling required incorporation of unnatural amino acids; therefore these peptides were created via solid-state synthesis. However, the synthesis of the 81 amino acid CPP-CCmut is no trivial matter. The ability to staple a longer sequence such as our protein domain is now possible using thiol-ene coupling. This exciting new chemistry allows for the stapling of recombinant proteins at substituted cysteine residues (instead of stapling substituted unnatural amino acids incorporated into synthetically made peptides). Thiol-ene coupling is used here to staple recombinant CPP-CCmut, and provides a path for translation of our lead compound to the clinic.Molecular modeling has identified optimal locations for staples on CPP-CCmut, which include 29/36, 36/43, 50/57, 57/64, as well as double staples 29/36-50/57 and 36/43-50/57. These staple locations still allow for dimerization of CPP-CCmut with Bcr-Abl, as indicated by free energy calculations and helicity. The staple locations have also been optimized for maximal coverage from proteolytic degradation.This work acts as a proof-of-concept that proteins (not just peptides) can be stapled, thus greatly expanding the variety and complexity of stapled proteins for use in the exciting field of targeting protein-protein interfaces to treat disease.']",
        "Doc_id":"AACR_2016-3817",
        "Doc_title":" Recombinant stapled proteins for the treatment of chronic myeloid leukemia",
        "_version_":1606189005787889664},
      {
        "Meeting_name":" Rational design of selective MNK 1 and 2 kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia patients",
        "Background":"['The marketed BCR-ABL tyrosine kinase inhibitor (TKI), imatinib (Gleevec) is a very successful targeted anti-cancer therapy. It has revolutionized the treatment of early stage or chronic phase (CP) chronic myeloid leukemia (CML). Unfortunately, a proportion of CP patients experience suboptimal responses to BCR-ABL TKIs, and progress to blast crisis (BC) stage of CML with poor survival rate. A potential cause of the resistance to TKI is the elevated level of phosphorylated eukaryotic initiation factor 4E (eIF4E), which has been found to be a consistent feature in patient-derived BC-CML samples. Importantly, both in vivo and in vitro studies have demonstrated that the MAP kinase-interacting serine/threonine-protein kinases 1 and 2 (MNK1/2) phosphorylate eIF4E on Ser209, and that the overexpression of eIF4E drives oncogenesis in a variety of cancers including BC-CML. Furthermore, several reports have indicated that eIF4E phosphorylation at Ser209, as well as eIF4E overexpression, is critical to tumor progression.We found that a BC-CML cell line, K562, that expresses a serine to alanine phospho-mutant at position 209 of eIF4E, shows reduced ability to form tumors in mice compared to wildtype eIF4E. In addition, our recent work has demonstrated the importance of the MNK-eIF4E axis in activating BC leukemia stem cell (LSC) function (Lim et al., PNAS18; 110(25)', 'E2298-307, 2013). These data highlight the critical importance of MNK1/2-dependent eIF4E phosphorylation in cancer progression and maintenance, and suggests that inhibition of MNK1/2 is an attractive therapeutic approach to treat BC-CML. Consequently, we set out to identify selective inhibitors of the MNK1/2 kinases to treat BC-CML patients.Here, we report our hit finding strategy, as well as our hit to lead optimization process. Results describing structure activity relationships, pharmacokinetics properties, and biochemical characteristics of a highly specific MNK1/2 inhibitor, are presented. Our data demonstrate that drug-like molecules can be developed to potently and specifically inhibit the MNK kinases. We also show that simultaneous inhibition of MNK and BCR-ABL is effective at inhibiting BCR-ABL-driven growth and proliferation, as well as inhibiting the MNK-eIF4E-dependent self-renewal function of BC-LSCs. A combination of selective MNK and BCR-ABL inhibitors may provide clinical benefit to BC-CML patients.']",
        "Doc_id":"AACR_2016-2134",
        "Doc_title":" Rational design of selective MNK 1 and 2 kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia patients",
        "_version_":1606189026600026112},
      {
        "Meeting_name":" MicroRNA expression in white blood cells of CML patients",
        "Background":"['Introduction', ' Treatment of chronic myeloid leukemia (CML) with the BCR/ABL-inhibitor imatinib led to a tremendous progress of over-all survival. However therapy resistance in a significant proportion of patients remains a severe clinical problem. Aside mutations of the BCR/ABL gene, regulation of cellular transporters or downstream factors may contribute to non-response. We aimed to investigate micro-RNA expression profiles in peripheral leukocytes of 21 newly diagnosed CML patients without BCR/ABL-mutations in order to identify biomarkers to treatment-response of imatinib. Methods', ' Ten responders (molecular remission) and 11 non-responders were included. Expression of 667 microRNAs was analyzed using a TaqMan Low-Density Array system. Relative fold change of microRNAs between groups was calculated according to the 2^-Ct method. MicroRNAs with a fold change>2 and a P-value<0.01 were considered significant. MicroRNAs with minor expression (Ct-value>20) were not included. Putative targets of dysregulated microRNAs were considered, if predicted by at least three databases, and further analyzed using the DAVID-bioinformatic database. Results', ' Four microRNAs were significantly deregulated (miR-7, miR-744*, miR-616, miR-212) between responders and non-responders, when being treatment-nave, predicted to have 97 potential targets. In depth target analysis showed that transcription regulators (21% of the predicted targets) are highly enriched compared to normal gene expression background of humans. Pathway analysis revealed six genes involved in cancer pathways, whereas four of them are directly involved in the chronic myeloid leukemia pathway (SMAD4, NRAS, RB1, RAF1). In responders seven microRNAs were deregulated before and after therapy, whereas five other microRNAs were deregulated within the group of non-responders. Three deregulated microRNAs were identified in both groups. Most predicted target genes are involved in MAPK signaling and exocytosis, 13% of the targets were predicted to be transcription regulators, and 18% cellular (especially uptake) transporters. Conclusion', ' We identified distinct microRNA pattern comparing blood samples of responders and non-responders prior to imatinib therapy. Predicted target genes were primarily transcription factors and oncogenes. In contrast, transporters and exocytotic pathways are in addition frequent targets of microRNAs deregulated after imatinib therapy. The suitability as biomarkers for prediction of imatinib-response requires further confirmation.']",
        "Doc_id":"AACR_2012-1097",
        "Doc_title":" MicroRNA expression in white blood cells of CML patients",
        "_version_":1606189000817639424},
      {
        "Meeting_name":" Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines",
        "Background":"['The hallmark of chronic myeloid leukemia (CML) is the presence of Bcr-Abl oncoprotein that is essential for leukemogenesis and accumulation of neoplastic cells. The Abl tyrosine kinase inhibitor imatinib mesylate (Gleevec) represents the standard treatment for CML. However, a number of CML patients develop imatinib resistance and several mechanisms of resistance have been described. While most mutant forms are sensitive to second-generation tyrosine kinase inhibitors, the T315I mutation remains completely refractory to imatinib, as well as to these agents. Treatment of CML patients harboring T315I mutation is still an unmet medical need in the imatinib and post-imatinib era. We have identified P2745, a novel orally bioavailable small molecule that is effective in imatinib resistant mutations and particularly T315I mutation form to address this unmet medical need. In vitro P2745 showed potent cytotoxicity (IC50 0.8-5 M) in twelve Bcr-Abl mutated imatinib resistant cell lines including T315I compared to wild type Bcr-Abl cell lines. P2745 did not show cytotoxicity upto 30 M in normal fibroblasts (MRC-5 and WI-38) and normal human peripheral blood mononuclear cells thus indicating specificity towards cancerous cells. P2745 inhibited pCrkLTyr207 in imatinib-resistant CML cell lines accompanied with down regulation of Bcr-Abl protein levels. Additionally, it up regulated tumor suppressor protein SMAR-1 which resulted in negative regulation TGF-/SMAD-dependent pathway as demonstrated by low phosphorylated levels of SMAD2 and SMAD3, two key players implicated in the preservation of the malignant progenitor population, and partly responsible for the resistance to treatments targeting Bcr-Abl. P2745 also induced significant apoptosis in imatinib resistant cell lines (Y253F, T315I and E255V) but not in normal MRC-5 cell line. In addition, like imatinib it induced 80-90 % apoptosis in cells derived from CML patients. In vivo studies demonstrated significant (p<0.001), dose dependent efficacy in imatinib resistant T315I cells xenograft in SCID mice. It also demonstrated significant in vivo efficacy in Bcr-Abl wild type imatinib sensitive K-562 (p<0.05) and Ba/F3 (p<0.001) xenografts in SCID mice. PK-PD evaluation in imatinib resistant xenograft experiments indicated that at the efficacious dose, P2745 modulated proteins responsible for CML pathogenesis (60-80 %), which correlates with the levels of P2745 in the tumors. This unique mechanism of action makes P2745 a promising clinical candidate for CML patients harboring T315I mutation.']",
        "Doc_id":"AACR_2012-1822",
        "Doc_title":" Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines",
        "_version_":1606189013136310272},
      {
        "Meeting_name":" Quantification of BCR-ABL by digital PCR in samples with high copy numbers and rates of molecular responses (as defined by EUTOS) compared to those detected with standard quantitative real-time PCR.",
        "Background":"['Background', ' The Digital PCR (dPCR) technique has the potential to monitor minimal residual disease in patients with BCR-ABL positive leukemias, since it allows absolute quantification of the target sequence. A concern re dPCR is possible non-linearity at high copy numbers (CN). We assessed linearity for BCR-ABL and ABL quantitation by dPCR and compared the rates of molecular responses (MR), on the EUTOS scale, in patients (pts) with chronic myeloid leukemia (CML) who had received 18 months of nilotinib treatment in the ENEST1st trial (NCT01061177) as determined by dPCR or qPCR. Methods', ' 230 cDNA samples with e13 or e14/a2 BCR-ABL fusion genes were analysed in Leipzig (L, n = 75) or Mannheim (M, n = 155) by qPCR between 2012 and 2013. The cDNA samples were re-analysed in L by dPCR using a Droplet Digital PCR System (BIO-RAD). To assess the linearity of the assay, the ERM standard was diluted to BCR-ABL and ABL CN from 150000 to 1 and measured in replicate. Results by dPCR were about 20% lower than the calculated dilution. Linearity could be shown for CN as high as 120000 for ABL and BCR-ABL with a fraction of 81-165 negative droplets at the highest concentration. Results', ' The median CN of BCR-ABL and ABL was 12 (range 0-2050) and 59350 (range 7690-176000) by dPCR and 10 (range 0- 1529) and 53537 (range 4013  250800) by qPCR, respectively. Both methods detected similar numbers of BCR-ABL+ samples (dPCR 186, qPCR 189) with a median % BCR-ABL of 0.022 by dPCR compared to 0.019 by qPCR before, and 0.014 after, conversion to IS.he cumulative rates of MMR, MR4 and MR4.5 or better at 18 months of treatment were 83, 43 and 29% with qPCR. The distribution in MR classes was significantly different between the methods (p < 0.001), with dPCR indicating decreased cumulative rates of MR3, MR4 and  MR4.5. Significantly fewer pts achieved  MR4 when analyzed by dPCR (n = 77 vs. 100, p < 0.05). Of the 191 samples scored  MMR by qPCR, 71 (37%) were one or more MR classes higher by dPCR. In contrast, only 13% were scored into a deeper MR class. Conclusions', ' dPCR is linear, even at high CN, and compared to qPCR, generates differing rates of MR in patients with CML .']",
        "Doc_id":"ASCO_167101-176",
        "Doc_title":" Quantification of BCR-ABL by digital PCR in samples with high copy numbers and rates of molecular responses (as defined by EUTOS) compared to those detected with standard quantitative real-time PCR.",
        "_version_":1606189029994266624},
      {
        "Meeting_name":" Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multi-agent chemotherapy.",
        "Background":"['Background', '   Imatinib mesylate (IM) and other tyrosine kinase inhibitors that inhibit BCR-ABL have revolutionized the treatment of chronic myelogenous leukemia and also improved Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) outcomes. BCR-ABL inhibitors are generally well tolerated, but both IM and dasatinib induce platelet dysfunction, which is of particular concern in the setting of thrombocytopenia in ALL patients. Three Ph+ ALL patients receiving IM in conjunction with systemic and intrathecal (IT) chemotherapy at the University of Maryland Greenebaum Cancer Center (UMGCC) developed subdural hematomas (SDH). We sought to define risk factors for SDH.  Methods', '  Charts were reviewed for SDH risk factors, including thrombocytopenia, coagulopathy, lumbar punctures and meningeal leukemia, and SDH incidence was compared in Ph+ and Ph- ALL patients receiving multi-agent systemic and IT chemotherapy with and without IM, respectively, at UMGCC from 2007 through 2010.  Results', '  Three Ph+ ALL patients developed SDH during treatment courses 1, 3, and 3, respectively. SDH was unilateral in two patients and bilateral in one. All were thrombocytopenic and had undergone repeated lumbar punctures, but none was coagulopathic nor had meningeal leukemia. SDH was treated with burr hole surgery in two patients, and conservatively in one. One patient died of resistant leukemia and one of post-transplant complications, while the third is alive and in remission 26 months after diagnosis and 22 months after SDH. SDH incidence was significantly higher in Ph+ compared to Ph- ALL patients receiving treatment with and without IM, respectively (3 of 10 vs. 0 of 22; p<0.05).  Conclusions', '  Our data suggest that IM is a risk factor for SDH, likely due to IM-induced platelet dysfunction, and that patients with Ph+ ALL receiving IM, and likely dasatinib, in conjunction with systemic and IT chemotherapy may be at increased risk of SDH and should be closely monitored for subtle manifestations of this serious complication.']",
        "Doc_id":"ASCO_81024-102",
        "Doc_title":" Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multi-agent chemotherapy.",
        "_version_":1606188975067758592},
      {
        "Meeting_name":" BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.",
        "Background":"['Background', '  Advent of 2nd-generation TKIs has brought additional treatment options for Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients (pts). To analyze the changes they have determined in mutation frequency and type, we have reviewed the database recording the results of BCR-ABL mutation analyses done in our laboratory from 2004 through 2011.  Methods', '  781 tests on 258 pts were performed by direct sequencing.  Results', '  143 pts were analyzed because of imatinib resistance; 101 (71%) had one or more mutations (a single mutation in 91 pts; two mutations in 10 pts). Three mutation types were by far the most frequent', ' T315I (38 pts, 37%), E255K (19 pts, 18%) and Y253H (19 pts, 18%). Of 84 pts who had developed resistance to 2nd- or 3rd-line therapy with dasatinib, nilotinib or bosutinib after imatinib failure, 65 (77%) were positive for Bcr-Abl mutations; 30 (46%) carried multiple mutations (up to four) and in 19 of them (63%) this was consequence of multiple lines of therapy. The most frequent newly acquired mutation in this setting was the T315I, detected in 35/57 (61%) cases acquiring mutations on dasatinib. Mutation analysis was also performed in 15 resistant pts enrolled in a study of dasatinib as 1st-line treatment of Ph+ ALL; 12 pts were positive, 11 of them had a T315I.  Taking advantage of a next-generation sequencer (Roche 454), allowing a high sensitive and quantitative mutation scanning of Bcr-Abl, serially collected samples from 24 selected cases who developed mutations and resistance to one or more TKIs were retrospectively analyzed to study the kinetics of expansion of mutant clones. Results will be presented.  Conclusions', '  Although 2nd generation TKIs are more potent and have much fewer insensitive mutations, long-term disease control remains a problem and the T315I becomes an even tougher enemy. The high genetic instability fosters mutational events anytime during TKI treatment and some mutation types (T315I, Y253H) have been observed to emerge and take over very quickly (from <0.01% to 90% in one-two months).  Supported by PRIN, AIL, AIRC, Fondazione CARISBO.']",
        "Doc_id":"ASCO_95211-114",
        "Doc_title":" BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.",
        "_version_":1606188982515793921},
      {
        "Meeting_name":" A model of oncogene addiction",
        "Background":"['Background', ' Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome and the fusion gene BCR-ABL, which has been shown to activate key signaling pathways, including PI-3 kinase, RAS/ERK and STAT5. ABL tyrosine kinase inhibitors (TKIs) are highly effective clinical agents that inhibit downstream signaling, trigger CML cell apoptosis, and provide clinical evidence for the phenomenon of oncogene addiction,\" whereby cell survival becomes critically dependent upon the activity of a particular oncogene product. TKI therapy has largely failed to achieve the same degree of clinical success in other activated kinase-driven malignancies, suggesting that BCR-ABL is relatively unique in its ability to establish a state of oncogene addiction.Results', ' To dissect the mechanism by which BCR-ABL coordinates STAT5 and RAS/ERK signaling to establish a state of oncogene addiction, JAK2 kinase activity and RAS-GTP levels were assessed in the CML patient-derived cell line K562. Surprisingly, basal levels of RAS-GTP were low and JAK2 kinase activity was not detectable. Treatment of K562 cells with erythropoietin (EPO) only very modestly activated JAK2. Similarly, EPO treatment after one hour of BCR-ABL inhibition also failed to rescue STAT5 or RAS/ERK activation. However, with more prolonged BCR-ABL kinase inhibition, we observed a time-dependent increase in the ability of EPO to rescue STAT5 and ERK phosphorylation. After 24hrs of BCR-ABL inhibition, EPO treatment led to a significant increase in both JAK2 activation and the GTP loading of RAS relative to vehicle treated cells. These data suggest that BCR-ABL kinase activity hampers the ability of JAK2 to activate STAT5 and RAS/MAPK . Further, 24hr treatment with the MEK inhibitor PD0325901 allowed for a comparable degree of EPO-mediated JAK2 activation, suggesting that the negative regulation of JAK2 is mediated at least in part by a MEK/ERK-dependent mechanism. These observations were subsequently validated in an isogenic system utilizing TF-1 cells. Similar to the EPO/JAK2 axis in K562 cells, TF1-BCR-ABL cells exhibit attenuated GM-CSF signaling relative to control TF1-puro cells, which was restored only after prolonged BCR-ABL inhibition. Significantly, we have observed that BCR/ABL-expressing cells irreversibly commit to apoptosis before growth factor signaling is fully restored.Conclusions', ' Our data suggest that BCR-ABL-mediated oncogene addiction is a consequence of a high level of physiologic negative feedback mechanisms that dampen growth factor receptor signaling. Our findings also help reconcile recent evidence that JAK2 inhibition restores the sensitivity of CML stem/progenitor cells to ABL TKI treatment in vitro with the observation that JAK2 is completely dispensable for BCR-ABL-induced myeloid disease in mice.']",
        "Doc_id":"AACR_2013-4308",
        "Doc_title":" A model of oncogene addiction",
        "_version_":1606188973731872768},
      {
        "Meeting_name":" Alternatively spliced truncated BCR-ABL1 protein in CML patients with resistance to kinase inhibitors.",
        "Background":"['Background', ' We have reported that some patients with imatinib-resistant chronic myeloid leukemia (CML) express an alternatively spliced BCR-ABL mRNA with a 35-bp insertion (BCR-ABL135INS), resulting in the addition of 10 residues and truncation of 653 residues. Molecular dynamic simulation suggested that this truncation and insertion of new 10 AA results in structural changes similar to those seen in BCR-ABL with T315I mutation. Here we evaluate the prevalence of BCR-ABL135INS in imatinib-resistant CML, examine the effect of this mutation on resistance to compared the efficiency of various kinase inhibitors in vitro, and suggest a model for persistent CML and a possible strategy to eradicate residual disease. Methods', ' Using a sensitive PCR method, we determined the prevalence of the alternatively spliced BCR-ABL135INS mRNA in 288 patients with chronic-phase CML resistant to imatinib. Expression of truncated protein was confirmed by Western blot. We then tested the effectiveness of various kinase inhibitors on human K562 CML cells expressing different levels of BCR-ABL135INS along with wild-type BCR-ABL1. Results', ' BCR-ABL135INS mRNA was detected in 210 (73%) of the 288 patients. Only 25% of BCR-ABL135INS positive cases showed coexistance of ABL1 kinase point mutation. Immunoprecipitation studies demonstrated that expression of the predicted 143-kD BCR-ABL135INS protein at levels proportional to those predicted by mRNA. Expression of BCR-ABL135INS in K562 cells was sufficient to conferred resistance to imatinib, dasatinib, and nilotinib in a dose-dependant fashion. However, no resistance was detected using aurora kinase inhibitor (MK 0457) or homoharringtonine (HHT). BCR-ABL135INS suppressed imatinib, nilotinib, and dasatinib-mediated dephosphorylation of CRKL, LYN, SRC, and STAT5, but had no effect on MK 0457-mediated dephosphorylation. The combination of imatinib with nilotinib or HHT showed strong synergy, overcoming BCR-ABL135INS-induced resistance in vitro. Conclusions', ' These findings emphasize the importance of the overlooked alternatively spliced BCR-ABL135INS protein and may provide a strategy to treat resistant disease and eradicate residual CML.']",
        "Doc_id":"ASCO_33284-65",
        "Doc_title":" Alternatively spliced truncated BCR-ABL1 protein in CML patients with resistance to kinase inhibitors.",
        "_version_":1606189027824762880},
      {
        "Meeting_name":" Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.",
        "Background":"['Background', ' Essential to cancer cell signaling, the Growth factor Receptor Bound protein-2 (Grb2) is utilized by oncogenic tyrosine kinases to activate Ras and ERK. BP1001is a liposome-incorporated antisense which inhibits Grb2 expression. The study aimed to define safety, maximum tolerated dose (MTD), pharmacokinetics, and anti-leukemic activity of BP1001 in patients (pts) with hematologic malignancies. Methods', ' This is a standard 3+3 phase I dose-finding study in pts with relapsed/refractory acute myeloid leukemia (AML), chronic myeloid leukemia in blast phase (CML-BP), and myelodysplastic syndrome (MDS). BP1001 was given twice weekly, IV over 2-3 hours for 28 days. Dose escalation proceeded through 5, 10, 20, 40, 60, and 90 mg/m2. Upon completion of single agent phase I cohorts 1-6, the combination of cytarabine 20 mg SubQ BID x 10 days + 60 mg/m2 BP1001 (cohort 7) or 90 mg/m2 BP1001 (cohort 8) was studied. Results', ' A total of 38 pts were treated', ' AML (n = 29), CML-BP (n = 5) and MDS (n = 4). Cytogenetic / molecular abnormalities included', ' t(9;22) (n = 2), diploid (n = 11), complex (n = 7), BCR-ABL (n = 5; including T315I in 2), FLT3D835 (n = 1), FLT3ITD (n = 1), CEBPA (n = 1), NPM1 (n = 2), TP53 (n = 3), IDH1 (n = 1), IDH2 (n = 3), NRAS (n = 1), JAK2 (n = 2), GATA2 (n = 1), TET2 (n = 1), DNMT3A (n = 1). Of 38 pts, 26 were evaluable; 12 failed completion of a full cycle due to disease progression and were replaced per protocol. Only one pt on 5 mg/m2 experienced a dose limiting toxicity (DLT), grade 3 mucositis and hand-foot syndrome, while on high-dose hydroxyurea for proliferative CML-BP. Among 26 evaluable pts, a median of 1 cycle was administered (1-5)', ' 6 received 2 cycles, 4 received 5 cycles, and all others received 1 cycle. Among the 21 evaluable pts on single agent cohorts, 11 experienced  50% reduction in peripheral or bone marrow blasts; 2 had improvement of leukemia cutis; 6 had transient decline in blasts (n = 3) and/or stable disease (n = 3). Among the 5 evaluable pts on combination therapy, 2 achieved CR and 2 achieved PR. Conclusions', ' BP1001 at 5-90 mg/m2 is well tolerated with no MTD identified. Results demonstrate the novel BP1001 + cytarabine combination is well tolerated with early evidence of anti-leukemic activity including CR in 2 relapsed AML pts. Clinical trial information', ' NCT01159028']",
        "Doc_id":"ASCO_162879-176",
        "Doc_title":" Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.",
        "_version_":1606189018607779840},
      {
        "Meeting_name":" Inhibition of Bcr-Abl tyrosine kinase sensitizes cells to sapacitabine",
        "Background":"['CNDAC, the active form of sapacitabine, is a nucleoside analog which kills cells by a unique mechanism of action. Incorporation of CNDAC triphosphate into DNA results in a single-strand break, which is converted to a one-ended double-strand break (DSB) upon subsequent collapse of the DNA replication fork. CNDAC-induced DSBs are repaired predominantly through the homologous recombination pathway which consists the key recombinase Rad51 and its associated proteins. Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm; its central pathogenesis is a reciprocal chromosomal translocation between chromosomes 9 and 22. This abnormal chromosomal fusion results in the formation of a chimeric gene that encodes a constitutively active tyrosine kinase, Bcr-Abl, which promotes CML through stimulating downstream signaling cascades for cell survival and deregulated cell growth. Bcr-Abl tyrosine kinase modulates DNA repair mechanisms to protect leukemic cells from DNA damage induced cell death. In response to DSBs, it phosphorylates Rad51 at Tyr315 which enhance the damage repair process. Based on this evidence, we hypothesized that inhibition of Bcr-Abl will further sensitize cells to CNDAC. To test this postulate, we used the CML cell line K562 as well as murine Ba/F3 cells transfected with wild-type Bcr-Abl (Ba/F3p210wt) or the Bcr-Abl mutant (Ba/F3p210T315I) as model systems. Two tyrosine kinase inhibitors (TKI) were utilized to inhibit Bcr-Abl. Imatinib, the first generation TKI, is only effective inhibiting wild type Bcr-Abl. Ponatinib, a subsequent TKI, is potent in inhibiting both wild type and mutant Bcr-Abl tyrosine kinases. First, these cells were treated with CNDAC, imatinib or ponatinib alone to determine the IC50 values for each drug using PrestoBlue cell viability assay. Based on the single drug IC50s, combinations of CNDAC with imatinib or ponatinib were applied to these cell lines and their combination indexes were calculated by CalcuSyn software. We found that CNDAC and imatinib were synergistic in K562 and Ba/F3 wild type Bcr-Abl cells while they were additive in the Bcr-Abl T315I mutant cells. In contrast, ponatinib sensitized CNDAC treatment as their combination was synergistic in all these cell lines. Finally, to investigate the mechanism underlying the observed synergism, K562 cells were treated with either equitoxic concentrations of CNDAC, imatinib or ponatinib alone or in combinations for 48 hours when lysates were collected for immunoblot analysis. It was found that when Bcr-Abl was inhibited, the phosphoryation of Rad51 at Tyr315 was reduced, phospho H2AX and cleaved caspase 3 were increased in response to CNDAC. Thus further sensitization of CNDAC was a result of deficient damage repair due to Bcr-Abl inhibition. Together, our results link the Bcr-Abl tyrosine kinase to CNDAC-induced DNA damage repair process and provide rationale for CNDAC/sapacitabine combination therapy in diseases such as CML.']",
        "Doc_id":"AACR_2014-5454",
        "Doc_title":" Inhibition of Bcr-Abl tyrosine kinase sensitizes cells to sapacitabine",
        "_version_":1606189000157036544},
      {
        "Meeting_name":" Shp2 is required for CML initiation and maintenance",
        "Background":"[\"Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm (MPN) caused by the constitutively activated BCR-ABL tyrosine kinase. CML progresses from an initial chronic phase, through an accelerated phase, to a final and fatal blast crisis. Current first-line therapy for CML involves tyrosine kinase inhibitors (TKIs) such as imatinib, dasatinib, or nilotinibs. However, TKIs don't completely cure CML, as revealed by low complete molecular response rate and frequent disease relapse upon drug withdrawal. Studies of patient samples and mouse models indicate that this most likely results from lack of dependence of CML stem cells (CML-SCs) on BCR-ABL for survival. It is important to further identify potential targets of CML-SC. Shp2 is a non-receptor protein tyrosine phosphatase involed in RTK, cytokine, and integrine signaling pathways, and is a target of Abl kinase during cell proliferation. It is required for survival and maintenance of normal hematopoietic stem cells (HSCs). In the context of CML, BCR-ABL constitutively phosphorylates Gab2, which then binds to Shp2, resulting in its inappropriate activation of downstream pathways, including the Ras-Erk cascade. Gab2 is required for CML initiation in vivo. We hypothesized that Shp2 is required for CML development from the stem cell level and might be an effective target for treatment of CML. Using our induced Shp2 deletion tools, we found that Shp2 is required for CML initiation and maintenance in a bone marrow transplant model of CML. Moreover, primitive CML cells undergo elevated cell death upon Shp2 knockout. This implicates Shp2 as a potential target for CML therapy in future.\"]",
        "Doc_id":"AACR_2012-1352",
        "Doc_title":" Shp2 is required for CML initiation and maintenance",
        "_version_":1606189032603123712},
      {
        "Meeting_name":" Development of a \"dual-hit\" combination therapy for CML.",
        "Background":"['Functioning as a constitutively active tyrosine kinase, the oncoprotein Bcr-Abl, the causative agent of chronic myeloid leukemia (CML), requires homo-oligomerization via a coiled-coil domain present on the N-terminus of the Bcr portion of the protein. Currently, small molecule therapeutics that target the tyrosine kinase domain (tyrosine kinase inhibitors, or TKIs) are administered as the gold standard treatment for CML. However, evidence shows that the acquisition of mutations in the tyrosine kinase domain against these small molecules is inevitable, rendering many of the therapeutics useless against mutated forms of Bcr-Abl. The most recently discovered TKI, ponatinib (AP24534), has shown to combat nearly all of the commonly seen mutations, including the previously uncontrollable T315I mutation. But, ponatinib is not without limitations, as it has been shown to cause dose-dependent pancreatitis and thrombocytopenia as adverse side effects. While many small molecules have been created to target the tyrosine kinase domain, our recent work has shown that disruption of Bcr-Abl oligomerization can also induce apoptosis and decrease the oncogenic potential of the disease. This work was done using a modified coiled-coil domain, termed CCmut3, which was rationally designed and mutated to bind to the endogenous Bcr-Abl coiled-coil domain, inhibiting oligomerization and thus preventing Bcr-Abl signaling. The purpose of this work is to exploit a dual-hit approach to inhibit Bcr-Abl using two therapeutics with different mechanisms of action. Here, we show that combining CCmut3 with ponatinib not only increases the potency of the therapy but also lowers the required therapeutic dose of ponatinib in vitro using K562 cells (Bcr-Abl-positive, human CML cells). Western blot analysis shows that both Bcr-Abl phosphorylation and phosphorylation of downstream signaling targets STAT5 and CrkL can be decreased using the combination at a ponatinib dose of 100 pM. In addition, transformative ability (via colony forming assay) very significantly declines when using a 1 nM dose in combination as opposed to simply administering 1 nM ponatinib only. Finally, caspase 3/7, 7AAD, and DNA segmentation assays were performed to show enhanced apoptosis induction upon combination treatment when compared with either CCmut3 or ponatinib treatment alone. Currently, this combination is being tested in a Bcr-Abl-positive Ba/F3 cell line containing the T315I mutation in the Abl tyrosine kinase domain. Lastly, attempts to truncate and cap the CCmut3 helix to provide stability and more simple therapeutic delivery are underway, in addition to elucidating the individual intracellular mechanisms of action of both CCmut3 and ponatinib.']",
        "Doc_id":"AACR_2013-2170",
        "Doc_title":" Development of a \"dual-hit\" combination therapy for CML.",
        "_version_":1606189035020091392},
      {
        "Meeting_name":" Efficacy and safety of bosutinib (BOS) for Philadelphia chromosomepositive (Ph+) leukemia in older versus younger patients (pts).",
        "Background":"['Background', ' BOS is an oral dual Src/Abl kinase inhibitor with potent activity in Ph+ leukemia. Methods', ' Efficacy and safety of BOS 500 mg/d was evaluated in older (65 y; n = 119) and younger (<65 y; n = 451) pts in 3 cohorts', ' chronic phase chronic myeloid leukemia (CP CML) after imatinib (IM; CP2L cohort; n = 287); CP CML after IM + dasatinib (DAS) and/or nilotinib (NIL; CP3L cohort; n = 119); and accelerated/blast phase (AP/BP) CML or acute lymphoblastic leukemia after IM  DAS and/or NIL (ADV cohort; n = 164). Results', ' Baseline events (65 y vs <65 y) included respiratory disorders (35% vs 13%), cardiac disorders (29% vs 9%), and diabetes (4% vs 4%).  Median baseline medications were 3 (65 y) and 5 (<65 y).  Median BOS duration was 11 mo and median follow-up was 31 mo for all pts.  80% of 65 y and 67% of <65 y pts discontinued BOS, including 32% and 18% due to an adverse event (AE; most commonly thrombocytopenia [6% vs 3%]).  Rates of response were similar or lower in older versus younger pts (Table).  On-treatment transformation to AP/BP CML was similar between groups.  Incidences of nonhematologic treatment-emergent AEs were generally similar between older and younger pts, notably (all grades/grade 3 for 65 y vs <65 y)', ' diarrhea (85%/9% vs 81%/8%), infection (56%/15% vs 49%/10%), and edema (8%/0% vs 4%/<1%).  Common grade 3 lab abnormalities (65 y vs <65 y) were thrombocytopenia (35% vs 35%), neutropenia (21% vs 25%), and anemia (19% vs 19%). Conclusions', ' BOS demonstrated similar efficacy and acceptable safety in both older and younger pts across Ph+ leukemia cohorts.']",
        "Doc_id":"ASCO_100244-114",
        "Doc_title":" Efficacy and safety of bosutinib (BOS) for Philadelphia chromosomepositive (Ph+) leukemia in older versus younger patients (pts).",
        "_version_":1606188994173861888},
      {
        "Meeting_name":" Combination therapy for chronic myelogenous leukemia",
        "Background":"['Single-agent tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukemia (CML) has been largely effective in keeping the disease at bay. However, resistance to therapy and persistence of a subset of leukemic cells demonstrate the necessity for multiple-agent therapy. We have developed a unique interfering peptide, CCmut2 (Dixon et al., JBC 2011) able to disrupt BCR-ABL dimers. This disruption of trans-auto phosphorylation exacts its activity via the coiled-coil domain in BCR, but leads to an overall similar effect as TKIs - induction of apoptosis and reduction in proliferation. Here we detail the results of this peptide (delivered as a gene and transcribed in vitro) in combination with small molecule or biologic agents. The secondary agents include', ' chloroquine which is used to inhibit lysosomal acidification and block cellular macroautophagy; zileuton, a specific inhibitor of arachidonate 5-lipoxygenase (Alox5) known to enhance the proliferative capacity of CML cells; and GO-201, an interfering peptide targeting MUC-1, a known oncogene expressed in CML cells. These agents in combination with CCmut2 were hypothesized to improve therapeutic potency and enhance leukemia-specific cytotoxicity. All assays were performed in BCR-ABL expressing K562 cells in vitro. Western blots confirming knockdown of the autophagy gene ATG7, Alox5, and MUC-1 using shRNA were carried out. The autophagy pathway was further validated by blotting for autophagic microtubule-associated protein light chain 3 (LC3) conversion from LC3-I to LC3-II following combination therapy with CCmut2 and chloroquine. Transformative ability of K562 cells was evaluated using a methylcellulose colony forming assay following co-transfection with CCmut2 and a shRNA. Next, the specific drugs targeting these pathways were also used in combination with the CCmut2 and assessed for apoptotic potential using caspase 3/7 activity and DNA segmentation. Proliferation was investigated using trypan blue exclusion and transformative ability was further assessed with multi-drug combinations. MUC-1 inhibition in combination with CCmut2 resulted in a potent combination in K562 cells. Other combinations hinted at an additive or synergistic enhancement of apoptosis and reduction in proliferation.']",
        "Doc_id":"AACR_2012-5615",
        "Doc_title":" Combination therapy for chronic myelogenous leukemia",
        "_version_":1606188994574417920},
      {
        "Meeting_name":" New diagnostic and therapeutic target KU-MEL9 for chronic myeloid leukemia (CML)",
        "Background":"[\"Overall survival of patients with chronic myeloid leukemia (CML) has dramatically changed over past ten years by the introduction of targeted therapy with tyrosine kinase inhibitors (TKIs). However, it has been reported that more than half of patients eventually relapse after the cessation of TKIs, suggesting that CML cells including leukemic stem cell (LSC) cannot be completely eradicated by TKIs. To this end, the identification of targets expressed in LSC is crucial for developing highly effective therapies for CML. In this study, we evaluated the gene expression of cancer testis antigen KU-MEL9, which was found in melanoma research, in a variety of human cell lines. This gene was highly expressed in several cell lines of hematological malignancies including CML and multiple myeloma (MM). We then investigated the gene expression of KU-MEL9 in bone marrow samples from 20 CML patients by standard RT-PCR method. Gene expression of KU-MEL9 were found in 17 patients (85%), and correlated with the expression of BCR-ABL fusion gene in most of the cases. On the other hand, 6 samples from normal donors didn't express this gene. In 2 CML patients who achieved a molecular remission with imatinib, the expression of KU-MEL9 gene was still observed, although BCR-ABL gene was not detected. It suggested that KU-MEL9 was expressed in residual CML cells including LSC and could be a more sensitive biomarker for CML patients. We also examined the possibility of KU-MEL9 being as a target of cytotoxic T cells (CTL) for immunotherapy to eradicate remaining LSCs after TKI treatment. Although this study had limited number of patient sample, KU-MEL9 may be a useful target for diagnosis and treatment for CML patients.\"]",
        "Doc_id":"AACR_2012-2682",
        "Doc_title":" New diagnostic and therapeutic target KU-MEL9 for chronic myeloid leukemia (CML)",
        "_version_":1606189026830712832},
      {
        "Meeting_name":" Decoding the role of myocyte enhancer factor 2C in chronic myeloid leukemia disease progression.",
        "Background":"['Chronic myeloid leukemia (CML) is a myeloproliferative disorder of hematopoietic stem cell and is marked by the presence of the Philadelphia chromosome, a reciprocal translocation occurring between the long arm of chromosome 9 and 22 resulting in the formation of a fusion BCR-ABL1+ oncogene which encodes a constitutively active non-receptor tyrosine kinase. Clinically, the disease progresses through three phases', \" an initial chronic phase, accelerated phase and terminal blast phase, which is marked by increased production of immature myeloid precursor cells. Earlier we have shown that BCR-ABL mediated repression of miR-223 results in the activation of mef2C and ptbp2 in chronic myeloid leukemia. Transcription factor MEF2C, required for cell survival and proliferation, is important for lymphopoiesis, and its ectopic expression in myeloid progenitors antagonizes myelopoiesis. We reported that MEF2C expression increases as the disease progresses from chronic phase to blast phase and by knocking down MEF2C in a CML cell line we showed that it negatively correlates with the CEBPA expression, a granulocytic transcription factor. Imatinib, the drug of choice for CML, abrogates MEF2C expression and reverses CEBPA repression both in the cell line and the primary cells. In the present study we observed that when the cells were treated with anisomycin it degraded MEF2C expression in 16hrs which imatinib can achieve after 24hrs. Investigators have demonstrated that anisomycin acts as a potent signaling agonist, synergizing with growth factors and phorbol esters to superinduce immediate-early genes such as c-fos, fosB, c-jun, JunB, and JunD. However here blocking the MAPK kinases with inhibitors didn't reverse the inhibition suggesting that these pathways may not be involved in the anisomycin mediated MEF2C degradation in CML. Mef2c gene consists of three alternative exons, 1/2, skipping exon  and 3'splice site . In order to characterize the role of mef2c gene in CML, first we investigated the different isoforms of mef2c in CML cell line (KCL22) by amplification of the whole mef2c gene and cloning the same in a TOPO vector. Several clones were checked and sequenced. Two different types of isoforms (1+ - + and 1+ - -) were found to coexist in KCL22 cells along with an exclusion of 9 bases (AACACAGGT) from the splice junction of exon 4 and 5, which was not reported earlier. However, K562 cells along with KYO-1 and LAMA-84 showed the presence of 9 bases. Nine base pair deletion was also observed in CML patient samples (both CP and BC). Interestingly sequencing of the mef2C genomic region from the cell lines and the same patient samples showed the presence of 9 bases. The different isoforms were transduced in mouse lineage negative bone marrow cells and also transplanted in mice either alone or in combination with BCR-ABL to study the effect of the isoforms in disease progression, the results of which will be discussed.\"]",
        "Doc_id":"AACR_2017-3513",
        "Doc_title":" Decoding the role of myocyte enhancer factor 2C in chronic myeloid leukemia disease progression.",
        "_version_":1606188977205805056},
      {
        "Meeting_name":" A requirement for SOCS-1 and SOCS-3 phosphorylation in BCR-ABL-mediated transformation",
        "Background":"['Previous studies have demonstrated that constitutive activation of JAK/STAT signaling is required for efficient transformation by the Abelson murine leukemia virus (A-MuLV), which expresses v-Abl oncoprotein. Importantly, there is increasing evidence that deregulation of the JAK or STAT activity plays a critical role in BCR-ABL-induced malignant transformation. SOCS-1 and SOCS-3 are inhibitors of JAK-STAT pathway and as such are involved in a negative feedback loop of cytokine signaling. However, the mechanism by which Abl oncogene bypasses SOCS inhibitory regulation remains poorly defined. Here, we found that co-expression of BCR-ABL with SOCS-1 or SOCS-3 resulted in tyrosine phosphorylation of these SOCS proteins. Interestingly, tyrosine-phosphorylated SOCS-1 was detected in three of five primary CML samples which express BCR-ABL. BCR-ABL-dependent phosphorylation of SOCS-1 and SOCS-3 occurred mainly on Tyr 155 and Tyr 204 residues of SOCS-1, and Tyr 221 residue of SOCS-3. Phosphorylation of these SOCS proteins was associated with its binding to BCR-ABL, and this interaction was disrupted by mutation of the sites of SOCS phosphorylation. We demonstrated that BCR-ABL-dependent phosphorylation of SOCS-1 and SOCS-3 alters their inhibitory effects on the activation of JAK1 and JAK2 and thereby enhances JAK-STAT signaling. Moreover, disrupting the tyrosine phosphorylation of SOCS-1 or SOCS-3 promotes K562 leukemic cells to undergo apoptosis and blocks tumor formation in mouse model. Together, these results reveal a requirement for tyrosine phosphorylation of SOCS-1 and SCOCS-3 in BCR-ABL-mediated transformation in the presence of these SOCS proteins.']",
        "Doc_id":"AACR_2012-11",
        "Doc_title":" A requirement for SOCS-1 and SOCS-3 phosphorylation in BCR-ABL-mediated transformation",
        "_version_":1606188990681055232},
      {
        "Meeting_name":" Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.",
        "Background":"['Background', ' BCR-ABL kinase domain mutations frequently cause tyrosine kinase inhibitor (TKI) failure in chronic myeloid leukemia (CML). Ponatinib, a potent oral pan-BCR-ABL TKI, has shown preclinical activity against all single mutants tested, including T315I. The impact of baseline (BL) mutations on response to ponatinib (45 mg once daily) and end of treatment (EOT) mutations in pts discontinuing treatment were evaluated in the phase II PACE trial.  Methods', ' Heavily pretreated chronic phase (CP) CML pts (93% received 2 prior TKIs, 60% 3) resistant or intolerant to dasatinib or nilotinib (N=203) or with T315I confirmed at BL (N=64) were enrolled. The primary endpt was major cytogenetic response (MCyR).  Min follow up at analysis (9 Nov 2012) was 12 mos (median 15 [0.1-25]). Sanger sequencing was done at one central laboratory.  Results', ' At BL, no mutations were detected in 51% of pts, 1 mutation in 39%, and 2 mutations in 10%; 26 unique mutations were observed. Responses were observed regardless of BL mutation status. MCyR rates were', ' 56% overall, 49% in pts with no mutations, 64% 1 mutation, 62% 2 mutations; 57% in pts with mutation(s) other than T315I, 74% T315I only, 57% T315I + other mutation(s). Responses were seen against each of the 15 mutations present in >1 pt at BL, including T315I, E255V, F359V, Y253H. 99 pts discontinued, 56 had EOT mutations assessed. 5 pts lost a mutation, 46 had no change, 5 gained mutations (Table). 11 pts lost MCyR (none with T315I); of the 6 discontinuing, 4 had EOT mutations assessed and no changes from BL were seen.  Conclusions', ' Responses to ponatinib were observed regardless of BL mutation status. No single mutation conferring resistance to ponatinib in CP-CML has been observed to date.  Data with a minimum follow up of 18 mos, including pts with advanced disease, will be presented.  Clinical trial information', ' NCT01207440.']",
        "Doc_id":"ASCO_112559-132",
        "Doc_title":" Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.",
        "_version_":1606189012290109440},
      {
        "Meeting_name":" KLF4 promotes self-renewal by repressing DYRK2-mediated degradation of c-Myc in leukemic stem cells",
        "Background":"['Chronic myeloid leukemia (CML) is the first blood cancer known to originate from a single hematopoietic stem cell (HSC) by expression of BCR-ABL, a product of the chromosomal translocation t(9;22), that slowly progress to a lethal fast-growing leukemia caused by malignant reprogramming of progenitor cells (blast crisis). Although CML can be successfully managed with targeted therapy by suppressing BCR-ABL kinase activity with tyrosine kinase inhibitors (TKI), patients remain in remission as long as they adhere to a lifelong treatment. The leukemic stem cell (LSC) population emerges as a key CML reservoir that escapes TKI therapy by developing BCR-ABL-independent mechanisms of self-renewal and survival. LSC still remains an elusive target because of our poor understanding of specific self-renewal mechanisms and inability to selectively eliminate LSC without damaging normal hematopoiesis. Thus, there is a need for alternative drugs for relapse patients to prevent reactivation of BCR-ABL-positive LSC after stopping chemotherapy or emergence of chemoresistance and as frontline therapy to achieve treatment-free remission. We found that somatic deletion of the transcriptional factor Krppel-like factor 4 (KLF4) in BCR-ABL(p210)-induced CML severely impaired disease maintenance. This inability to sustain CML in the absence of KLF4 was caused by attrition of LSCs in bone marrow and the spleen and impaired ability of LSCs to recapitulate leukemia in secondary recipients. This data suggest that KLF4 promotes self-renewal of LSCs whereas serial transplantation indicates that KLF4 restricts stress self-renewal of normal HSCs and thus inhibition of KLF4 function would impair LSC self-renewal without altering blood production. Analyses of global gene expression in purified LSCs and genome-wide binding of KLF4 in a murine CML cell line revealed that KLF4 represses the gene encoding for the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2). Immunoblots revealed elevated levels of DYRK2 protein in KLF4-deficient LSCs purified from the bone marrow of CML mice. Because phosphorylation of c-Myc and p53 by DYRK2 induces proteosomal degradation and cell death, respectively, we found that DYRK2 upregulation in KLF4-deficient LSCs was associated with a reduction of c-Myc protein and increased cleavage of PARP. As a proof-of-principle of the therapeutic potential of this finding, we explored the efficacy of vitamin K3 to eradicate LSCs by inhibiting the ubiquitin E3 ligase SIAH2 in charge of DYRK2 degradation. Vitamin K3 efficiently reduced cell viability in a panel of human-derived CML cell lines by inducing Dyrk2 expression and apoptosis. The identification of Dyrk2 as a critical mediator of LSC downfall is an innovative paradigm poised to support the development of LSC-specific therapy to induce treatment-free remission in CML patients.']",
        "Doc_id":"AACR_2016-3334",
        "Doc_title":" KLF4 promotes self-renewal by repressing DYRK2-mediated degradation of c-Myc in leukemic stem cells",
        "_version_":1606189030968393728},
      {
        "Meeting_name":" Absolute quantification of BCR-ABL RNA using multiplexed digital RT-PCR",
        "Background":"[\"Reciprocal translocation and fusion of the genes encoding BCR (chromosome 22) and ABL1 (chromosome 9) are typical and causative for approximately 95% of chronic myeloid leukemias (CMLs). Specific and effective drugs targeting the protein products of these gene fusions have been developed and are used in current clinical practice. Molecular diagnostic methods are used for patient identification, for tracking drug effectiveness, and monitoring minimal residual disease (MRD). However, the use of quantitative PCR (qPCR) for this purpose has been problematic, particularly for determination of low limits of detection (LOD) and for comparing results between labs. International standards have been developed to ameliorate these issues, but there are significant ongoing challenges with these efforts. Here we address these challenges through the development of a multiplexed reverse transcription digital PCR (RT-dPCR) assay, and provide a direct comparison between samples run using the International Standardized qPCR and the new multiplexed RT-dPCR method.Digital PCR isolates individual single target molecules into compartments for endpoint PCR, with absolute quantification provided by simply counting the number of PCR-positive compartments. Using the RainDrop dPCR system, we partitioned each sample's target RNA molecules into a single-molecule droplet format, together with a one-step reverse transcription master mix (SuperScript III Platinum Taq, LifeTech) and standard qPCR hydrolysis probes/primers (IDT), for endpoint PCR and absolute quantification. We used a 4-plex multiplexed assay that counts 1) the e13\", 'a2 isoform of BCR', 'ABL; 2) the e14', \"a2 isoform of BCR-ABL; 3) GUSB RNA as an endogenous counting control, and; 4) a synthetic RNA as an exogenous control.Initial characterization of the multiplexed assay's specificity and sensitivity were performed using RNA from cell lines (K562 for e14\", 'a2; Invivoscribe clonal cell line for e13', 'a2 and e1', \"a2; U937 for a negative control). Samples derived from blood were split and quantified using either qPCR together with International Standard Protocols and reagents, or using the 4-plex RT-dPCR assay. Concordance and comparison of the two assay's LODs will be presented. Sensitivity assessment based on control generated data provides evidence of detection as low 1 in 200,000 without hitting a detection limit.The use of dPCR provides significant advantages over standard qPCR methods including absolute quantification which eliminates the need for standard curves, the ability to use RNA directly, the use of an exogenous control (non-ABL) and easy isoform analysis.\"]",
        "Doc_id":"AACR_2015-4736",
        "Doc_title":" Absolute quantification of BCR-ABL RNA using multiplexed digital RT-PCR",
        "_version_":1606189036514312192},
      {
        "Meeting_name":" The tyrosine kinase inhibitor axitinib targets T315I gatekeeper-mutant Philadelphia chromosome-positive leukemias in vitro and in vivo",
        "Background":"['The use of ABL1 kinase inhibitors has dramatically improved the outcome for chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) patients. However, resistance after treatment still poses a major clinical challenge. The most common resistance mechanism following treatment with first or second line therapy is the occurrence of a T315I mutation in the kinase domain of BCR-ABL1. Only one clinically available ABL1 inhibitor, ponatinib, has been shown to target this gatekeeper mutation, but has recently been associated with significant adverse effects. Hence, there is an unmet need for new and improved therapies for patients with T315I BCR-ABL1 leukemias.In this study we set out to functionally and molecularly profile BCR-ABL1 T315I-driven CML/Ph+ALL patient samples to understand the disease pathogenesis and identify novel therapies with a drug sensitivity and resistance testing (DSRT) platform covering 306 approved and investigational oncology compounds. Mononuclear cells isolated from patient bone marrow were plated with drugs on 384-well plates. Each compound was tested for its effect on cell growth and survival in a 10,000-fold concentration range enabling the generation of dose response curves and by comparing to healthy donor mononuclear cells, selective drug sensitivity scores (sDSS).Ex vivo DSRT results of one CML and two Ph+ALL patient samples with the T315I mutation revealed a marked and specific sensitivity (IC50 30-40nM) to the tyrosine kinase inhibitor axitinib, originally developed as a VEGFR inhibitor. Strikingly, sensitivity to axitinib was higher in these T315I positive patient samples than in T315I negative CML or ALL patient samples or any other leukemic samples. Supporting the notion that axitinib is a direct T315I BCR-ABL1 inhibitor we observed that Ba/F3 cells transformed with T315I BCR-ABL1 were sensitive to axitinib while the same cells transformed with wild type BCR-ABL1 were not. Finally, we discovered that axitinib has been described to have selective binding towards T315I ABL1 compared to the wild type kinase (Kd 1.5 nM vs. 36 nM, respectively, Davis et al. 2011, Nat. Biotechnol. 29', '1046-1051). Based on this information, the T315I CML patient mentioned above was compassionately treated with axitinib for 2 weeks resulting in a rapid 4-fold reduction of the mutated transcript levels in blood suggesting targeted in vivo activity of the drug.In summary, we demonstrated that axitinib is a potent BCR-ABL1 T315I inhibitor both in vitro and in vivo. In light to the fact that axitinib is currently approved as a second line therapy for renal cell carcinoma and is well tolerated in patients, there is an opportunity to repurpose axitinib for Ph+ leukemia patients with T315I mutations with significantly shorter clinical development time.']",
        "Doc_id":"AACR_2014-4763",
        "Doc_title":" The tyrosine kinase inhibitor axitinib targets T315I gatekeeper-mutant Philadelphia chromosome-positive leukemias in vitro and in vivo",
        "_version_":1606189001396453376},
      {
        "Meeting_name":" Enhanced SH3",
        "Background":"['Bcr-Abl is the oncogenic protein-tyrosine kinase responsible for the pathogenesis of chronic myelogenous leukemia (CML). Clinical management of CML has been revolutionized by imatinib, a selective ATP-competitive inhibitor of Bcr-Abl kinase activity. Imatinib selectivity is due in part to its ability to recognize and stabilize the inactive conformation of the kinase domain. This conformation is stabilized by intramolecular binding of the SH3 domain to theSH2-kinase linker, which in turn packs against the back of the kinase domain. Imatinib resistance can be caused by point mutations that either affect drug binding directly (e.g., through mutation of the gatekeeper position, Thr315) or that allosterically disturb the downregulated kinase domain conformation (e.g., through mutation or phosphorylation of the SH3 domain). These observations suggest that strengthening the regulatory SH3', 'linker interaction present inBcr-Abl may stabilize a downregulated kinase domain conformation, thus sensitizing the kinase domain to inhibitor action. To explore this possibility, we created a series of modified c-Abl and Bcr-Abl proteins with enhancedSH3-linker interactions. By systematically increasing the proline content of the linker, we identified high-affinity linkers that stabilized intramolecularSH3 binding without disturbing the overall regulation of the kinase core.Enhanced SH3', 'linker interaction completely reversed c-Abl core activation by aC-lobe myristate binding pocket mutation, and substantially reduced activation by mutations in the ATP binding site (T315I) as well as the SH2', 'C-lobe interface (Y158D). Remarkably, enhanced SH3', 'linker interaction dramatically sensitized Bcr-Abl not only to imatinib but also to the myristic acid binding pocket inhibitor, GNF-2. These effects were observed in the context of both wild-type and imatinib-resistant forms of Bcr-Abl. Hydrogen exchange mass spectrometry of recombinant Abl core proteins with high-affinity linkers revealed dynamic coupling between the SH3', 'linker interface, the GNF-2 binding site in the C-lobe myristate binding pocket, and the active site.Taken together, these studies provide strong evidence that regulatorySH3', 'linker interaction is retained in the context of Bcr-Abl, and supports the idea that small molecules enhancing natural regulatory interaction at theSH3', 'linker interface may have utility as chemical sensitizers of Bcr-Abl drug action in the kinase domain.']",
        "Doc_id":"AACR_2013-2221",
        "Doc_title":" Enhanced SH3",
        "_version_":1606189005994459136},
      {
        "Meeting_name":" FGF2 promotes resistance to ABL kinase inhibitors in CML.",
        "Background":"['Despite the clinical success of imatinib in treating chronic myeloid leukemia (CML), patients who develop resistance to available ABL inhibitors remain a clinical challenge. There is compelling evidence to suggest that the bone marrow microenvironment hinders the efficacy of kinase inhibitors, and may eventually lead to overt resistance. We developed a screen of nearly 300 molecules from the microenvironment to evaluate molecules that protect CML cells from imatinib. This screen identified Fibroblast Growth Factor 2 (FGF2) as a factor that mediates kinase inhibitor resistance in the CML cell line K562. Inhibition of FGFR with the selective inhibitor PD173014 attenuated the protective effects of FGF2, and siRNA revealed that FGF2 promotes survival through activation of FGFR3. FGFR3 was found to subsequently activate Ras and the MAPK pathway to promote K562 survival - despite effective inhibition of BCR-ABL by imatinib. More impressively, addition of FGF2 to K562 cells in long-term cultures with imatinib revealed that FGF2 was reproducibly capable of promoting growth and eventual imatinib-resistance in K562 cells (N=5). In contrast, K562 cells cultured in media alone or with other myeloid growth factors, did not develop resistance to imatinib. Sequencing of the kinase domain in resistant cells did not reveal mutations of the ABL kinase domain as a mechanism of resistance. Inhibition of both FGFR and BCR-ABL in the FGF2 imatinib-resistant outgrowths was synergistic in promoting cell death.To evaluate whether FGF2 may be involved in resistance in CML patients, immunohistochemistry of bone marrow samples from imatinib, dasatinib and nilotinib resistant patients revealed increased FGF2 staining compared to normal controls and CML patients at diagnosis, suggesting that FGF2 levels increase over time and promote resistance in vivo. Further evidence that FGFR may be important in kinase resistance is emerging from clinical trials of the novel ABL inhibitor, ponatinib. Although ponatinib was specifically developed to bind BCR-ABL with the T315I mutation, it is also a multi-kinase inhibitor, including inhibition of FGFR in the low nanomolar range. To wit, ponatinib was able to suppress FGF2 imatinib-resistant outgrowths in the low nanomolar range whereas imatinib, dasatinib and nilotinib were ineffective, even at high doses. In clinical trials, ponatinib has proven effective not only against T315I mutated BCR-ABL, but also in patients with minor or even no mutations of the ABL kinase domain (in press). This suggests that stimulation of growth pathways by the microenvironment, such as FGF2, may be an important mechanism of resistance in some CML patients. Moreover, our approach provides a method to predict pathways of resistance in leukemia cell lines and primary patient samples. This strategy has the potential to define rational combinations of kinase inhibitors that can circumvent resistance before it is even clinically apparent.']",
        "Doc_id":"AACR_2013-4971",
        "Doc_title":" FGF2 promotes resistance to ABL kinase inhibitors in CML.",
        "_version_":1606189017808764928},
      {
        "Meeting_name":" Molecular cytogenetic study in pediatric b-lineage acute lymphoblastic leukemia (BCP-ALL)",
        "Background":"['Background', ' Chromosome abnormalities of leukemia cells have important prognostic significance in childhood acute lymphoblastic leukemia (ALL). The prevalence of various chromosomal abnormalities shows geographical and racial variation. There is limited data from the Indian sub- continent. Methods', ' Bone marrow samples of 89 children between age group of 1-18 diagnosed with ALL were analyzed for chromosomal abnormalities with conventional G-banding techniques and interphase fluorescence in situ hybridization (FISH) using locus specific probes to detect cryptic TEL/AML1 t(12', '21)(p13-q22),BCR/ABL t(9;22)(q34;q11) and MLL rearrangement for 11q23 by dual color fluorescence in situ hybridization (FISH). Results', ' The median age at diagnosis was 7 years. The male to female (sex ratio) in our group was 2.7', '1. Bone marrow cytogenetics results were available for 77 (86.5%) patients and out of these 37 (48%) had normal karyotype, 40 (51%) patients had structural and numeric chromosomal abnormality, 21(27%) patients had hyperdiploidy (>50 chromosomes), 4 (5%) case were hypodipoidy (<46 chromosomes) and 15 (19%) had structural abnormalities. FISH analysis for ETV6/RUNX1 t(12', '21)(p13-q22) was available for 21 B lineage-ALL patients with normal karyotypes and it showed fusion signals in 9 (42%) cases and amplification of AML(RUNX1) with four and more copies was observed in 4 (19%) patients. Conclusions', ' Bone marrow karyotype in combination with molecular cytogenetic techniques like FISH has improved the sensitivity and accurate identification of prognostic markers in childhood ALL patients. Though the numbers are small, we report increased prevalence of ETV6/RUNX1 (alias TEL/AML1) involving t(12', '21)(p13- q22) in B lineage ALL than previously reported in studies from this region.']",
        "Doc_id":"ASCO_49633-74",
        "Doc_title":" Molecular cytogenetic study in pediatric b-lineage acute lymphoblastic leukemia (BCP-ALL)",
        "_version_":1606189011777355776},
      {
        "Meeting_name":" Allosteric regulation of Abl and Bcr-Abl kinases by enhanced SH3",
        "Background":"['Bcr-Abl is the oncogenic protein-tyrosine kinase responsible for the pathogenesis of chronic myelogenous leukemia (CML). Clinical management of CML has been revolutionized by imatinib, a selective ATP-competitive inhibitor of Bcr-Abl kinase activity. Despite the clinical success of imatinib in the chronic stage of CML, it is less effective in advanced disease due to the emergence of drug resistance often caused by point mutations in the Bcr-Abl kinase domain. Recently, we demonstrated that introduction of the gatekeeper resistance mutation T315I into a recombinant c-Abl core protein enhanced basal kinase activity. Imatinib selectivity is achieved in part by binding and stabilizing the unique inactive conformation of the Abl kinase domain. This conformation is stabilized allosterically by intramolecular binding of the SH3 domain to the SH2-kinase linker, which in turn docks against the back of the kinase domain. The goal of this project, therefore, was to determine whether kinase activation induced by T315I, as well as a mutation in a recently described allosteric inhibitor binding site in the kinase domain C-lobe (A356N mutant), could be overcome by enhancing the SH3', 'linker interaction. For these experiments, we engineered nine High Affinity Linker (HAL) variants of Abl in which SH3', 'linker interaction was tightened through sequential addition of proline residues to the linker. Enhanced SH3', 'linker interaction was confirmed by analysis of SH3 dynamics using hydrogen-deuterium exchange mass spectrometry. Using cell based assays, we identified Abl-HAL core proteins that remain locked in an inactive conformation. To determine the impact of the HAL sequences on activating mutations in the kinase domain, the strongest HAL sequence was combined with the T315I and A356N mutations. Remarkably, the HAL substitution completely reversed Abl core activation by the A356N mutation, and partially reversed the effect of T315I. We next introduced the HAL sequence into p210 Bcr-Abl coding region (wild-type and T315I), and expressed these forms of Bcr-Abl along with matched controls in the human myeloid cell line, TF-1. The Bcr-Abl HAL mutants transformed TF-1 cells to a cytokine-independent phenotype as effectively as wild-type Bcr-Abl but were much more sensitive to induction of apoptosis by the allosteric inhibitor, GNF-2. Furthermore, TF-1 cells transformed with Bcr-Abl-HAL bearing a wild-type kinase domain also showed greater sensitivity to imatinib and the related inhibitor nilotinib, suggesting that enhanced SH3', 'linker interaction structures the kinase domain in a favorable conformation for drug action. Our results provide new evidence that SH3', 'linker interaction not only has a strong allosteric effect on the regulation of the c-Abl kinase core, but also on Bcr-Abl sensitivity to both ATP-competitive and allosteric inhibitors as well.']",
        "Doc_id":"AACR_2012-5599",
        "Doc_title":" Allosteric regulation of Abl and Bcr-Abl kinases by enhanced SH3",
        "_version_":1606188994044887040},
      {
        "Meeting_name":" Let-7 brings new insights into chronic myeloid leukemia therapy.",
        "Background":"['Human chronic myelogenous leukemia (CML) is a malignancy of pluripotent hematopoietic cells that is caused by the deregulated activity of the tyrosine kinase that is encoded by the chimeric bcr-abl oncogene. Given that CML cells are usually highly resistant to chemotherapy, novel and more efficacious strategies against this disease are urgently needed. MicroRNA (miRNA) is a set of newly discovered 20-22 nucleotides RNA molecules, and they broadly repress their cognate target genes at post-transcriptional/translational level. Up to date, there are approximately 2,000 human miRNA transcripts have been characterized, which are estimated to modulate more than 30% human genes and are widely involved in many essential biological processes including differentiation, proliferation, apoptosis, and also tumorigenesis. In this study, we studied let-7, a miRNA with tumor suppressive signature, for its therapeutic potential in CML. When treating CML K562 and KU812 cell by imatinib, let-7 can be significantly induced. Overexpression of let-7 can sensitize K562 and KU812 cells to imatinib, while knock-down of let-7 can increase the drug resistance of these cells. The mechanistic studies found that let-7 was able to promote apoptosis of CML cells, inhibit the tumor cell proliferation, and lead to a cell cycle arrest in the G0/G1 phase. These results demonstrate that let-7 is a potential target for treating CML by imatinib and/or other anti-cancer druges. The pro-apoptosis and anti-proliferation roles of let-7 in CML cells may provide novel insights into discovery and development novel drugs for conquering this malignant disease.Citation Format', ' Bin Yi, Xiaobo Li, Wenjun Du, Gary A. Piazza, Yaguang Xi. Let-7 brings new insights into chronic myeloid leukemia therapy. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 1848. doi', '10.1158/1538-7445.AM2013-1848']",
        "Doc_id":"AACR_2013-1848",
        "Doc_title":" Let-7 brings new insights into chronic myeloid leukemia therapy.",
        "_version_":1606188980602142720},
      {
        "Meeting_name":" Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia",
        "Background":"[\"We have developed AGS67E, an antibody drug conjugate that targets CD37, a tetraspanin highly expressed on malignant B cells, for the potential treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). AGS67E is a fully human anti-CD37 monoclonal IgG2 antibody conjugated to the potent microtubule-disrupting agent, MMAE, via reduced cysteines and the protease cleavable linker, maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl.AGS67E exhibits potent in vitro binding, internalization and cytotoxicity on a variety of NHL, CLL and AML models and patient-derived samples, including CD34+CD38- leukemic stem cells. AGS67E also demonstrates potent anti-tumor responses, including complete tumor regressions in a variety of NHL, CLL and AML xenografts, including Rituxan refractory models and patient-derived samples. In general, CD37 was highly expressed across all models and a strong correlation was observed between the in vitro and in vivo efficacy of AGS67E.To confirm binding of AGS67E in a variety of normal and patient-derived NHL, CLL and AML samples, we developed flow cytometry and immunohistochemistry (IHC) assays which have confirmed reported CD37 expression data in NHL & CLL. In normal hematopoietic cells, AGS67E bound strongly to B cells and to a much lesser extent to monocytes, T cells, neutrophils and NK cells. AGS67E also bound with high and similar affinity to cynomolgus monkey B cells and was equally cytotoxic to these and human B cells. In other normal tissues, AGS67E binding was only evident where lymphoid structures were apparent such as in the spleen and lymph node. With respect to CD37 expression in NHL, CLL and AML, AGS67E was found to bind to >80% of NHL and 100% of CLL and AML samples.Taken together, our findings suggest that AGS67E may serve as a potential therapeutic for NHL, CLL and AML. To our knowledge, this body of work is also the first demonstration that CD37 is well expressed and potentially drug-able in AML.\"]",
        "Doc_id":"AACR_2014-2650",
        "Doc_title":" Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia",
        "_version_":1606189041050451969},
      {
        "Meeting_name":" A novel CD33/CD3-bispecific BiTE antibody can effectively recruit autologous T cells from AML-patients for in vitro cell lysis of CD33+ blasts",
        "Background":"[\"Bispecific T cell-engaging (BiTE) antibodies are single-chain antibody constructs which combine dual specifity against CD3 on T cells and against a tumor-associated antigen. Phase 1 and 2 clinical trials with the CD19/CD3-bispecific BiTE antibody blinatumomab have shown very high response rates in patients suffering from non-Hodgkin's lymphoma and acute lymphoblastic leukemia. Here, we report on the potential of a novel BiTE antibody targeting CD33 in redirecting autologous T cells for in vitro lysis of blasts from acute myeloid leukemia (AML) patients. Initial antibody titration experiments showed that CD33 BiTE concentrations at low picomolar ranges mediate effective lysis of leukemic cell lines. We next analysed primary samples from AML patients, which were co-cultured with mononuclear cells (MNC) from healthy donors in presence or absence of specific BiTE antibodies at an E\", 'T ratio of 1', '1. After 48h of incubation in the presence of 1ng/ml CD33 BiTE we observed a decrease of both CD33+ AML blasts as well as CD33+ monocytes when compared to samples with control BiTE or without BiTE. 1ng/ml CD33 BiTE specifically induced strong upregulation of activation markers CD25 and CD69 on the vast majority of all CD4+ and CD8+ T cells. We furthermore investigated whether T cells from AML patients were able to mediate lysis of CD33+ leukemia cells by CD33 BiTE. T cells purified from peripheral blood or bone marrow of newly diagnosed AML patients were tested for BiTE mediated lysis of U-937 target cells. Redirected T cells from AML patients were capable of eliminating leukemic cells in the presence of CD33 BiTE as effectively as T cells from healthy controls. In consequence of this we studied blast lysis and T cell behaviour in a completely autologous setting using cryo-conserved samples from AML patients. Despite strong activation of T cells only moderate lysis of myeloid cells was observed after 48h, possibly due to low E', 'T ratios in these samples. Therefore, to allow autologous T cell expansion, cells were cultured for up to 144h. After this prolonged incubation, CD33 BiTE-mediated redirected lysis of AML blasts and myeloid cells was observed in most but those patient samples that had a very low initial effector-to-target (E', 'T) cell ratio. To adress this problem, we stimulated autologous T cells in a first step by incubating AML samples in presence of 1ng/ml CD33 BiTE for 7 days. After purification of the expanded T cells we performed autologous cultures with high initial E', 'T ratio (1', '1). This led to fast, effective and almost complete lysis of CD33+ target cells. Taken together, autologous T cells from AML patients are effectively engaged and activated by the novel CD33 BiTE and redirected for the elimination of myeloblasts at low picomolar concentrations in vitro and may thereby constitute a promising novel therapeutic option for the treatment of patients with CD33+ acute myeloid leukemia.']",
        "Doc_id":"AACR_2012-4622",
        "Doc_title":" A novel CD33/CD3-bispecific BiTE antibody can effectively recruit autologous T cells from AML-patients for in vitro cell lysis of CD33+ blasts",
        "_version_":1606189024380190721},
      {
        "Meeting_name":" Leukemia-specific immunity in healthy individuals and patients post-transplant targets phosphorylated tumor antigens",
        "Background":"['The major antigenic targets of endogenous tumor immunity remain unknown although many minor targets have been identified. At a proteomic level, cancer is considered a disease of deregulated cell signal pathway activation; therefore we investigated whether endogenous anti-tumor immunity targeted phosphorylated protein antigens generated through the transformation process. In previous work we identified phosphorylated peptides differentially expressed on primary leukemia samples', ' 58 for acute myeloid leukemia (AML) samples and 31 for chronic lymphocytic leukemia (CLL). Many of the identified phosphopeptides were derived from established leukemogenic oncoproteins such as MLL, RUNX1, c-Myc, EP300, CXCR4, SKI, GRK, CD19, CD20, NCOA1, and TLK1 among others and differentially expressed between malignant and healthy counterpart tissue (splenic B cells, bone marrow). Using ELISpot and HLA-phosphopeptide multimers, we screened 10 healthy donors, 17 patients in complete remission with underlying AML and 14 patients with CLL. Healthy donors (HD) exhibited a highly heterogeneous reactivity against this panel of phosphoantigens but all responded to at least 10/57 phosphoantigens tested. Further investigation revealed this immunity resided within the central memory CD8 T cell compartment at the same magnitude of responses as those against influenza and adenovirus. By contrast only 2/12 AML and 5/14 CLL patients demonstrated anti-phosphopeptide immunity compared to 10/10 HDs (2< 0.01 for both). In contrast immunity against viral and mitogenic stimuli was similar between patients and HDs. Following allogeneic stem cell transplantation the majority (10/12) AML patients reconstituted anti-phosphopeptide immunity. In some cases dramatic expansions, of similar magnitude to cytomegalovirus responses, were observed approaching 1% of CD8 T cells for a single phosphopeptide epitope. In CLL, none of whom were transplanted, we found that over the study period of 12 months that among the patients with anti-phosphopeptide immunity only 1 of 5 patients required treatment compared to 4 of 9 patients requiring treatment where no anti phosphopeptide responses were seen (2=NS). Importantly, ex vivo expanded phosphopeptide specific T cells isolated from both healthy individuals and patients post-transplant were able to kill both HLA-matched primary leukemia samples and AML cell lines in a phosphopeptide-specific manner. These data suggest a prominent role for tumor-associated phosphopeptide antigens in the prevention and control of haematolymphoid disease in man.']",
        "Doc_id":"AACR_2012-512",
        "Doc_title":" Leukemia-specific immunity in healthy individuals and patients post-transplant targets phosphorylated tumor antigens",
        "_version_":1606189029127094273},
      {
        "Meeting_name":" Imatinib-induced downregulation of Skp2 inhibits cell growth in human squamous cell carcinoma.",
        "Background":"['It is apparent that Skp2(S-phase kinase associated protein) plays a crucial role in tumorigenesis of various human cancers. Imatinib, inhibitor of BCR-ABL tyrosine kinase, KIT and PDGF receptor, has been approved for the treatment and investigation of chronic myeloid leukemia, gastrointestinal stromal tumors and additional various solid tumors. But An area of skin cancer has not been yet investigated. The aim of this study was to explore the role of the Skp2 in Imatinib antitumor effect on human skin cancer. To explore Imatinib effect on growth of A431 cells (squamous cell carcinoma / skin cancer) we conducted CCK8 assay and Flow cytometry. Western blot assay was performed for determining the functions and molecular mechanism of Imatinib in A431 cells. we found that Imatinib significantly inhibited cell growth and induced cell cycle arrest at G0/G1 phase. Furthermore, we observed that depletion of Skp2 triggered cell cycle arrest and colony formation inhibition by Imatinib. Mechanistically we identified that Imatinib markedly downregulated Skp2 protein expression and subsequently upregulated p21 expression via increased protein stability. In conclusion, Imatinib exerts its antitumor activity via inhibition of Skp2 - p21 axis and these findings suggest that targeting Skp2 by Imatinib could be promising therapeutic approach for Squamous cell carcinoma therapy.']",
        "Doc_id":"AACR_2017-2108",
        "Doc_title":" Imatinib-induced downregulation of Skp2 inhibits cell growth in human squamous cell carcinoma.",
        "_version_":1606189041226612736},
      {
        "Meeting_name":" Sub-clonal heterogeneity and risk of treatment failure in Philadelphia-positive leukemias.",
        "Background":"['Molecularly targeted therapies have been exceptionally successful in the treatment of some malignancies, most notably chronic myeloid leukemia (CML). However in other cancers, e.g. Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL), drug resistance is a frequent occurrence. Resistance mutations may pre-exist as a consequence of intra-tumor heterogeneity; thus the extent of heterogeneity may determine the likelihood of treatment failure. Intra-tumor heterogeneity is challenging to quantitate, as heterogeneous mutations are likely to occur below the background error rate of conventional approaches for mutation detection. To overcome this limitation and explore the relationship between intra-tumor heterogeneity and drug resistance in Ph+ leukemias, we utilized single-molecule Duplex Sequencing (DS) of the ABL1 gene. DS eliminates sequencing errors by independently tagging the two strands of individual DNA molecules; true mutations are present at the same position in both strands, while PCR and sequencing errors are only present in one strand. DS has an error rate below 0.00001%, and thus enables quantitation of heterogeneous mutations with unprecedented resolution. We find that CP-CML, a disease that is often well controlled with targeted therapy, has an extremely low burden of intra-tumor heterogeneity at the time of diagnosis, with a sub-clonal mutation burden similar to that of normal individuals. Simulations which take into account the low cancer stem cell fraction of CP-CML and the sub-clonal mutation burden we measured reveal that only a minority of CP-CML patients will harbor pre-existing drug resistance, which may explain the unusual success of targeted therapy in this setting. Next, we studied patients with advanced Ph+ leukemias (refractory BP-CML and Ph+ ALL), which have a high rate of treatment failure and poor outcomes. We find that patients with BP-CML and Ph+ALL have a significant elevation in sub-clonal heterogeneity relative to those with CP-CML. We demonstrate that the higher extent of intra-tumor heterogeneity correlates with a significantly higher rate of drug resistance mutations and compound resistance (i.e. two concurrent resistance mutations) in patients. Unlike CP-CML, pre-existing mutations conferring resistance to targeted therapy are nearly certain in refractory BP-CML and Ph+ ALL as a consequence of the load of intra-tumor heterogeneity and high cancer stem cell fraction. We support this concept by three distinct approaches', ' (i) detection of pre-existing sub-clones that drive treatment failure; (ii) modeling the growth kinetics of resistant clones; and (iii) extrapolation of the mutation burden measured by DS. Our results suggest that intra-tumor heterogeneity influences the likelihood of resistance to molecularly targeted therapy. Quantitation of sub-clonal mutation load may be broadly applicable in other malignancies for predicting the likelihood of response to targeted therapy and monitoring disease progression.']",
        "Doc_id":"AACR_2017-2071",
        "Doc_title":" Sub-clonal heterogeneity and risk of treatment failure in Philadelphia-positive leukemias.",
        "_version_":1606189014859120640},
      {
        "Meeting_name":" Dasatinib induces apoptosis in head and neck squamous cell carcinoma cells through down-regulation of epidermal growth factor receptor (EGFR) in vitro and in vivo",
        "Background":"['Background', ' Head and neck squamous cell carcinoma (HNSCC) is a worldwide disease with aggressive course and dismal outcome. Dasatinib, a bcr-abl inhibitor, has been approved clinically for the treatment of chronic myeloid leukemia and demonstrated to be effective against solid tumors in vitro through Src inhibition. Here, we disclose that dasatinib induced apoptosis of HNSCC cells in vitro and in vivo through down-regulation of EGFR. Methods', ' HNSCC cells, including Ca9-22, FaDu, HSC3, SAS, SCC-25, and UMSCC1 were treated with dasatinib. Cell viability, apoptosis, and underlying signal transduction were evaluated. Results', ' Dasatinib exhibited differential sensitivities against HNSCC cells. The growth inhibition and apoptosis were correlated with its inhibition on Akt, Erk, and bcl-2, but irrespective of Src inhibition. Accordingly, we found that down-regulation of epidermal growth factor receptor (EGFR) was a determinant of dasatinib sensitivity. Dasatinib inhibited EGFR through lysosome degradation. Increased EGFR activation by ligand administration rescued cells from dasatinib-induced apoptosis, whereas inhibition of EGFR enhanced its apoptotic effect. Estrogen receptor (ER) was demonstrated to play a role in bcl-2 expression, and dasatinib inhibited ER at pre-translational level. ER worked in concert with EGFR to regulate dasatinib-induced apoptosis. Furthermore, xenograft model showed that dasatinib inhibited HSC3 tumor growth through in vivo down-regulation of EGFR and ER. Conclusion', ' Down-regulation of EGFR is a novel mechanism responsible for dasatinib-induced apoptosis in HNSCC.']",
        "Doc_id":"AACR_2012-2880",
        "Doc_title":" Dasatinib induces apoptosis in head and neck squamous cell carcinoma cells through down-regulation of epidermal growth factor receptor (EGFR) in vitro and in vivo",
        "_version_":1606188975274328065},
      {
        "Meeting_name":" A genome-wide RNA interference screen identifies autophagy mediators with therapeutic implications in chronic myeloid leukemia.",
        "Background":"['Autophagy plays a critical role in cancer formation and therapeutic resistance. However, little is known about how autophagy is regulated in cancer and how it mediates therapeutic resistance. Here we elect to use chronic myeloid leukemia (CML) as a cancer model to study autophagy in that it is driven by a single onco-protein BCR-ABL, whose activity can be selectively blocked by imatinib a front-line treatment for CML. Moreover, imatinib resistance frequently occurs in CML patients. Thus, unraveling autophagy regulation in CML and its role in overcoming imatinib resistance has substantial therapeutic benefits not only for CML but also for other cancers that can be treated by imatinib. In this report, we performed a genome-wide RNA interference screen in K562 human CML cells using monodansylcadaverine (MDC) that marks autolysosomes followed by fluorescence-activated cell sorting to label and isolate autophagic cells. We have identified 336 candidate genes, knockdown of which significantly increased MDC fluorescence. Our further validation utilized Cyto-IDTM Green dye that selectively stains autophagy vacuoles and quantitative RT-PCR that measures knockdown efficiency of shRNAs. We have uncovered a set of genes acting as autophagy mediators in K562 cells. To study their role in imatinib resistance, we measured the effect of imatinib in combination with the knocking down of autophagy mediators. Our results showed that the shRNA of VAMP7, a pivotal factor in vesicle transportation, substantially sensitized K562 cells to imatinib. Intriguingly, our further work revealed that depletion of VAMP7 blocked the activity of key autophagy suppressors AKT and mTOR, suggesting that VAMP7 and perhaps other autophagy mediators regulate imatinib sensitivity through signaling pathways that inhibit autophagy. In conclusion, a set of genes revealed by a genome-wide RNA interference screen mediates autophagy in CML cells and, more importantly, some of these genes render CML cells resistant to imatinib thereby becoming appealing drug targets.']",
        "Doc_id":"AACR_2013-1671",
        "Doc_title":" A genome-wide RNA interference screen identifies autophagy mediators with therapeutic implications in chronic myeloid leukemia.",
        "_version_":1606188985880674304},
      {
        "Meeting_name":" Exploring the contribution of ubiquitin binding domain of Bcr-Abl in chronic myelogenous leukemia",
        "Background":"['Chronic myelogenous leukemia (CML) is invariably associated with the expression of the p210 Bcr-Abl fusion protein. Although the Abl-encoded tyrosine kinase activity is important for leukemogenesis, the emerging problems of acquired resistance and minimal residual disease highlight the need for new complementary targets for pharmacological intervention. In our previous studies, we had identified a non-classical ubiquitin binding domain (UBD) within the NH2-terminal of p210 Bcr-Abl. Deletion of the UBD (p210 Bcr-Abl(UBD)) impairs the interaction between p210 Bcr-Abl and p--catenin (ser33). Over-expression of p210 Bcr-Abl, but not p210 Bcr-Abl(UBD), leads to an accumulation of phosphorylated -catenin, and at least two of its known transcriptional targets, cyclin D1 and c-Myc. The interaction between p210 Bcr-Abl and -catenin is ubiquitination dependent. -catenin is a central component of the Wnt pathway which plays a critical role in the regulation of hematopoiesis. In a murine bone marrow transplantation model for CML, mice transplanted with hematopoietic cells that express p210 Bcr-Abl(UBD) have significantly increased life spans compared to mice transplanted with p210 Bcr-Abl expressing cells. Delayed disease progression is associated with decreased levels of -catenin, and reduced numbers of granulocyte macrophage progenitors (GMPs), in the bone marrow. Deletion of UBD also impairs the transplantability of CML cells. Based on these observations we propose a model in which p210 Bcr-Abl may influence the Wnt signaling pathway, and leukemic expansion, by binding ubiquitinated -catenin, and stabilizing it against degradation. Stabilized -catenin leads to increased self-renewal of CML stem cells and progenitors. Importantly, this activity is contained within Bcr sequences, and is independent of tyrosine kinase activity.']",
        "Doc_id":"AACR_2012-2557",
        "Doc_title":" Exploring the contribution of ubiquitin binding domain of Bcr-Abl in chronic myelogenous leukemia",
        "_version_":1606189033126363136},
      {
        "Meeting_name":" Impact of poly-A and ribo-depletion RNA-seq library construction protocols on transcriptomic analysis of samples from patients with haematological malignancies",
        "Background":"['RNA sequencing (RNA-seq) is a versatile tool for characterization and quantification of transcriptomes. It has become the main approach to elucidate the transcriptomic landscape in leukemia. However, the knowledge about the advantages and disadvantages of RNA-seq in clinical decision-making and the suitability of mainstream RNA-seq library preparation methods for leukemia research are still in their infancy. Here, we have generated and sequenced polyadenylation selection (PA) and ribo-depletion (RD) RNA-seq libraries from acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) patient samples and compared their fusion-gene, differential expression and related pathways and variant discovery abilities.Our analysis demonstrated that the RD protocol provided, on average, 5% more uniquely mapped reads than the PA protocol (81.5% of reads). Overall, 60%, 35%, and 3% of the reads in the RD libraries mapped to exonic, intronic, and intergenic regions, respectively. The corresponding numbers in the PA libraries were 76%, 21%, 3%, suggesting that PA captures more mature RNAs than the RD preparation and provides a higher read coverage for exon regions. The RD preparation was also marginally better in removing ribosomal RNAs (rRNAs) than the PA protocol. Regarding transcript quantification, both RD and PA produced fairly equivalent measures of RNA abundance. The patient-matched PA and RD libraries showed a high correlation (r = 0.96) that was slightly less than that seen between technical replicates (r = 0.98) but slightly more than that seen between library-matched sample from patients with the same disease (r = 0.93), indicating that inter-patient variance is the main source of variance in RNA-seq studies. Interestingly, based on a receiver operating characteristic (ROC) analysis using known leukemia gene signatures or gene targets of 17 clinically used drugs in AML and ALL treatment, the PA is more optimal than the RD method for disease classification (area under curve 0.69 vs. 0.65) and personalized cancer therapy guidance (AUC of 0.73 vs, 0.71). Finally, both methods equally detected known fusion genes, which were supported with high number of reads on fusionjunctions. However, in the case of lowly expressed fusion transcripts, only the RD method was able to detect fusions.In conclusion, both protocols produced consistence measures and were of similar usability. However, RD preparation captured more transcriptomic features and was more suitable for fusion-gene discovery, which may be of clinical relevance for sub-typing leukemia patients. The PA method on the other hand had higher overall sensitivity and specificity in gene expression analyses and was, based on our results, more suitable than RD for clinical classification and drug treatment guidance.']",
        "Doc_id":"AACR_2016-1517",
        "Doc_title":" Impact of poly-A and ribo-depletion RNA-seq library construction protocols on transcriptomic analysis of samples from patients with haematological malignancies",
        "_version_":1606189002448175104},
      {
        "Meeting_name":" MYC antagonizes imatinib-induced differentiation in chronic myeloid leukemia cells through downregulation of p27KIP1",
        "Background":"['Imatinib is a BCR-ABL kinase inhibitor and the most used drug in chronic myeloid leukemia (CML). MYC (c-Myc) is a transcription factor frequently deregulated in human cancer that exerts multiple biological activities, including differentiation inhibition. We found that MYC expression is higher in bone marrow cells form CML patients at diagnosis, as compared with healthy controls. Moreover, high MYC levels at diagnosis correlated with a poorer response to imatinib treatment. One of the major characteristics of CML progression is the loss of cell differentiation. We showed that low concentrations of imatinib induce erythroid differentiation in the CML-derived K562 cell line. We have studied the effect of MYC on the differentiation induced by imatinib using K562 sublines carrying inducible (by zinc cation) or activable (by 4-hydoxy-tamoxifen) MYC alleles. In both cell lines, MYC largely prevented the erythroid differentiation induced by imatinib. The differentiation inhibition mediated by MYC is not due to increased proliferation of MYC-expressing cells or enhanced apoptosis of differentiated cells in the presence of MYC. We previously reported that p27/Kip1 (p27) overexpression induces erythroid differentiation in K562. Thus, we explored the effect of imatinib on p27 levels and we found that imatinib up-regulated p27 in a time- and concentration-dependent manner. siRNA-mediated silencing of p27 antagonized the erythroid differentiation induced by imatinib, indicating that p27 up-regulation is at least in part responsible for differentiation. MYC abrogated the imatinib-induced up-regulation of p27KIP1 concomitantly with the differentiation inhibition, suggesting that MYC inhibits imatinib-mediated differentiation of K562 cells by antagonizing p27 up-regulation. We previously reported that MYC induced SKP2, a component of the ubiquitin ligase complex that targets p27 for degradation. MYC was able to induce SKP2 in the presence of imatinib. Thus, MYC-mediated inhibition of the differentiating effect of imatinib in CML cells is in part a consequence of the SKP2 induction of MYC, which in turn would down-regulate p27. The results suggest that, although MYC deregulation does not directly confer resistance to imatinib, it might be a factor that contributes to progression of CML through the inhibition of differentiation.']",
        "Doc_id":"AACR_2012-3080",
        "Doc_title":" MYC antagonizes imatinib-induced differentiation in chronic myeloid leukemia cells through downregulation of p27KIP1",
        "_version_":1606188983390306304},
      {
        "Meeting_name":" Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation",
        "Background":"['Background', ' Imatinib (IM) has greatly improved survival in chronic myeloid leukemia (CML). However, IM must be continued for an indefinite period of time. A multicenter trial \"Stop Imatinib\" (STIM) was initiated in July 2007, in order to evaluate the persistence of complete molecular remission (CMR) after stopping IM and determine factors associated with CMR persistence. Methods', ' Inclusion criteria were IM treatment duration 3 years and sustained CMR, defined as BCR-ABL transcripts below a detection threshold of a 5-log reduction (undetectable by RQ-PCR) for 2 years. Molecular relapse was defined as RQ-PCR positivity confirmed on 2 successive occasions. In case of relapse, pts were rechallenged with IM at 400 mg daily. Molecular monitoring was performed according to international recommendations. Results', ' Sixty-nine pts were recruited among which 60 with a follow-up >1 month, including 22 males and 38 females. Median age was 62 (29-80), 31 pts had been treated with IFN prior to IM and 29 with IM frontline (de novo). Median follow-up was 5 months (1-16). Relapse occurred in 37 pts within 6 months of IM discontinuation. Only 1 pt relapsed after 6 months (M7). All patients in molecular relapse were sensitive to IM reintroduction. At last follow-up in December 2008, CMR was sustained in 8 pts at M14 and 3 pts at M16. No differences in terms of demography, duration of IM treatment and CMR duration were found between pts who relapsed and those who did not. At M9, the probability of persistent CMR was 46% (95% CI', ' 32-59%), 53% (95% CI', ' 33-69%) for previously IFN-treated pts and 39% (95% CI', ' 20-58%) for de novo pts (p = 0.54). A trend for a lower probability of relapse in low Sokal score pts was observed. Conclusions', ' Our data confirm that CMR can be long-lasting after discontinuation of IM. Using stringent criteria, it is possible to stop IM in patients with sustained CMR, even in those treated with IM as a single agent. Updated follow-up will be presented.']",
        "Doc_id":"ASCO_32299-65",
        "Doc_title":" Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation",
        "_version_":1606189019921645568},
      {
        "Meeting_name":" TRAIL induces apoptosis preferentially in cell cycle arrested tumor cells, e.g., in tumor cells from children with acute lymphoblastic leukemia upon knockdown of cyclinE.",
        "Background":"['Resting tumor cells represent a huge challenge during anti-cancer therapy due to their increased treatment resistance. Example given, during minimal residual disease remaining tumor cells might be non-cycling. TNF-related apoptosis-inducing ligand (TRAIL) is a putative future anti-cancer drug currently in phase I and II clinical studies. We recently showed that TRAIL is able to target leukemia stem cell surrogates (Blood 2012,119,4224). Here we tested the ability of TRAIL to target cell cycle arrested tumor cells.Primary tumor cells from children with acute lymphoblastic leukemia were amplified in immuno-compromised mice and used for in vitro knockdown studies, besides tumor cell lines. Cell cycle arrest was induced in G0, G1 or G2 using cytotoxic drugs, phase-specific inhibitors or RNA interference against cyclinB and E. Cell cycle was visualized by flowcytometry analysis including phosphorylation of Serine 10 in Histone H3 to discriminate G2 from M phase.Biochemical or molecular arrest at any point of the cell cycle increased TRAIL-induced apoptosis, independently from the tumor cell type, the cell cycle inhibitor used or the check point addressed. In contrast, when cell cycle arrest was disabled by addition of caffeine, the anti-tumor activity of TRAIL was reduced. Most importantly for clinical translation, tumor cells from three children with B-precursor or T-cell acute lymphoblastic leukemia showed increased TRAIL-induced apoptosis upon knockdown of either cyclinB or cyclinE arresting the cell cycle in G2 or G1, respectively.Taken together and in contrast to most conventional cytotoxic drugs, TRAIL exerts enhanced anti-tumor activity against cell cycle arrested tumor cells. Therefore, TRAIL might represent an interesting drug to treat static tumor disease, e.g., during minimal residual disease.Citation Format', ' Harald Ehrhardt, Franziska Wachter, Michaela Grunert, Irmela Jeremias. TRAIL induces apoptosis preferentially in cell cycle arrested tumor cells, e.g., in tumor cells from children with acute lymphoblastic leukemia upon knockdown of cyclinE. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 3326. doi', '10.1158/1538-7445.AM2013-3326']",
        "Doc_id":"AACR_2013-3326",
        "Doc_title":" TRAIL induces apoptosis preferentially in cell cycle arrested tumor cells, e.g., in tumor cells from children with acute lymphoblastic leukemia upon knockdown of cyclinE.",
        "_version_":1606188987374895104},
      {
        "Meeting_name":" Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.",
        "Background":"['Background', ' Dasatinib, a potent tyrosine kinase inhibitor, is indicated for treating imatinib-resistant or -intolerant patients with CML (all phases) or Ph+ acute lymphoblastic leukemia. Based upon results of a phase III dose-optimization study (CA180-034), the approved dosing regimen for patients with CP-CML with resistance, intolerance, or suboptimal response to imatinib was changed to 100 mg once daily from the initially approved 70 mg twice daily. This study assesses the efficacy and safety of dasatinib 100 mg once daily with a minimum follow-up of 48 months. Methods', ' Study design and endpoints have been described previously. Patients were randomized using a 2x2 factorial design to 1 of 4 treatment arms', ' 100 mg once daily (n=167), 50 mg twice daily (n=168), 140 mg once daily (n=167), and 70 mg twice daily (n=168). Results', ' Similar response rates were achieved in all arms and similar rates of progression-free survival (PFS; defined as no loss of complete hematologic response or major cytogenetic response, development of advanced disease, elevated white blood cells, or death as recorded by site investigators) were observed in resistant patients with or without baseline BCR-ABL mutations. At the 36-month follow-up, the PFS rate with 100 mg once daily was highest (Table). PFS data from a minimum follow-up of 48 months will be presented. The long-term safety profile of dasatinib 100 mg once daily will also be described. The likelihood of eventually achieving long-term endpoints based on cytogenetic status at 6 and 12 months will be determined. Conclusions', ' With a minimum follow-up of 48 months, dasatinib 100 mg once daily offers an acceptable benefit-risk profile for patients with CP-CML who are resistant, intolerant, or suboptimally responsive to imatinib. The landmark analyses and the long-term data to be shown will provide useful outcome information to clinicians treating patients with dasatinib according to achieved responses at key intervals, particularly among those with an allogeneic stem cell transplantation option. 100 mg once daily70 mg twice daily140 mg once daily50 mg twice daily 24-month CCyR (last assessment)50% 53% 50% 49% 36-month PFS73%67%60%72% 36-month OS87%80%84%84%']",
        "Doc_id":"ASCO_51147-74",
        "Doc_title":" Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily.",
        "_version_":1606188980920909824},
      {
        "Meeting_name":" Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model",
        "Background":"['Dasatinib, a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia, has been shown to exert immunomodulatory effects in addition to direct oncokinase inhibition. Recently, we observed that dasatinib induces a rapid (within one hour after oral administration) and marked mobilization of lymphocytes (up to 8-fold increase in lymphocyte count), which closely follows the drug plasma concentration. In addition, in a subgroup of patients a clonal expansion of large granular lymphocytes occurs, which is correlated with good therapy response.As dasatinib-induced immunomodulatory effects are not leukemia specific, we aimed to exploit this activity to slow down or inhibit the growth of a syngeneic murine melanoma model and to characterize in detail the anti-tumor immune responses.Ovalbumin expressing murine melanoma cell line B16.OVA was grown under the skin of immunocompetent mice. The mice (n=6/group) were treated daily i.g. either with 30 mg/kg dasatinib or vehicle only. Blood was collected before tumor transplantation, before treatment, and on treatment days 4, 7 and 10. Tumor volumes were measured manually and specific growth rate was calculated based on the first and the last day of the treatment. In addition to white blood cell differential counts, immunophenotyping of blood and tumor homogenate was done by flow cytometry using antibodies against CD45.1, CD3, CD4, CD8b and NK1.1, and SIINFEKL-pentamer to detect B16.OVA-specific cells. To assess the functional properties of lymphocytes, we used antibodies against immune checkpoint inhibitors CTLA-4 and PD-1, and a degranulation marker CD107.On the 10th day of treatment, the tumor volumes were smaller in dasatinib group compared to control group, and there was a significant decrease in the tumor growth rate (0.06 vs. 0.18, p=0.01). Furthermore, dasatinib treated mice had increased proportion of CD8+ cells in the circulation (21% vs. 14%, p=0.04) and the CD4/CD8 ratio was significantly decreased (1.39 vs. 1.52, p= 0.04). During the tumor growth the mean CTLA-4 expression on CD8+ cells increased from 1.2% to 9% in the control group, whereas, in dasatinib group the increase was more modest (1.2% to 5.7%). Interestingly, 80% of tumor infiltrating CD8+ cells expressed PD1 antigen compared to <5% of PD1 positive CD8+ cells in the peripheral blood suggesting lymphocyte anergy or exhaustion induced by tumor cells.To conclude, dasatinib treatment slowed down the tumor growth in B16.OVA mouse model, which could be associated with the immunomodulatory effects of dasatinib. However, combinatorial treatment regimens may be needed as dasatinib is not able to fully break the immune cell anergy induced by tumor cells.']",
        "Doc_id":"AACR_2014-2587",
        "Doc_title":" Dasatinib-induced reduction of tumor growth is accompanied by the changes in the immune profile in melanoma B16.OVA mouse model",
        "_version_":1606189027078176768},
      {
        "Meeting_name":" Reduction of oxidative stress promotes daunorubicin resistance in acute lymphoblastic leukemia cells",
        "Background":"['The regulation of oxidative stress is fundamental to cell survival and function. Oxidative stress is a result of accumulation of reactive oxygen species (ROS), which are produced by cell metabolism and in response to certain stressors. Cancer cells have higher than normal ROS levels and elevated antioxidant defense mechanisms. Daunorubicin (DNR), a widely used chemotherapy, is a topoisomerase II inhibitor that induces cell death through DNA double strand breaks and increased ROS. We have previously shown that adipocytes protect acute lymphoblastic leukemia (ALL) cells against DNR in vitro and that media cultured by both adipocytes and ALL cells together (ALCM) can protect ALL cells from DNR. We hypothesize that this protection is in part mediated by adipocytes alleviating oxidative stress in ALL cells.Murine pre-B ALL cells isolated from a BCR/ABL transgenic mouse (8093) and human leukemia cell lines (BV173, Nalm6, REH, SEM, RS4;11, HL60, and Molt4) were used. The ALL cells were co-cultured with 3T3-L1 adipocytes using a transwell system. Cells were collected for gene expression analysis using qPCR. Intracellular ROS was measured by flow cytometry with 2-7-dichlorodihydrofluorescein (DCFH-DA). Four of the six human leukemia cell lines tested were protected by adipocytes against DNR treatment. Western blots showed that DNR induced a significant increase in the cleaved to procaspase-3 ratio, which was reversed by ALCM (No drug', ' 0.240.2, DNR', ' 0.830.14, ALCM+DNR', ' 0.240.19; p = 0.004 for DNR vs. ALCM+DNR, n = 4). Expression of the oxidative stress response genes gclc, gclm and p21 was upregulated in 8093 cells upon DNR treatment (fold change over baseline', ' 1.820.37, 2.350.73, 5.551.50; p<0.05, n = 3), while the presence of adipocytes prevented this upregulation (fold change over baseline', ' 0.830.11, 0.880.02, 1.750.57; p<0.05, n = 3). To investigate the oxidative stress induced by DNR, Nalm6 cells were treated with five doses of DNR for 6 hours alone or in the presence of pre-adipocytes or adipocytes. There was a dose-dependent increase in%ROShigh cells regardless of feeder type. At 200nM DNR, there were significantly fewer%ROShigh cells when co-cultured with adipocytes compared to no feeder or pre-adipocytes (p<0.05, n = 3). To test whether alleviating oxidative stress alone would cause DNR resistance, BV173, Nalm6 and REH cells were treated with DNR (100, 200 and 300nM, respectively) or a combination of DNR and the anti-oxidant, N-acetyl cysteine (NAC; 20mM). The addition of NAC significantly protected the cells from DNR (p<0.05, n = 3).These findings demonstrate that adipocytes contribute to drug resistance by alleviating oxidative stress in ALL cells. Further research is required to identify the soluble factors responsible for these protective effects.']",
        "Doc_id":"AACR_2015-1247",
        "Doc_title":" Reduction of oxidative stress promotes daunorubicin resistance in acute lymphoblastic leukemia cells",
        "_version_":1606188992262307841},
      {
        "Meeting_name":" Inadequate BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.",
        "Background":"['Background', ' Recommendations for baseline and quarterly measurement of the BCR-ABL fusion transcript to monitor imatinib response in patients with chronic myelogenous leukemia (CML) were formally introduced in October 2006, and have been incorporated into nationally recognized treatment guidelines. Methods', ' To assess BCR-ABL testing rates, we conducted a retrospective cohort analysis using a >10 million-member health plan database comprised of integrated pharmacy and medical claims. The study cohort was defined as patients with an index imatinib pharmacy claim from July 1, 2006, to December 31, 2006, who had a CML diagnosis (ICD-9 205.1X; N = 504), and a minimum of 3 months continuous follow-up by claims history (N = 465). Over a period of up to four quarters from the index imatinib prescription date, BCR-ABL testing in each quarter was assessed by the presence of any of a set of 19 CPT-4 codes. BCR-ABL testing rates in each individual quarter and in consecutive quarters were measured. Results', ' The overall study cohort was 57% male; mean (SD) age was 5214 y/o, with 26% 19-44 y/o, 57% 45-64 y/o, and 15% 65 y/o. Median duration of f/u was 559 days (interquartile range 302-628 days), and a cohort of 359 patients had 4 quarters of f/u. At least one BCR-ABL test was recorded in 60% of patients. The rate of first quarter BCR-ABL testing was 40%, and remained at 42%-43% in quarters 2 thru 4. Consecutive quarterly testing rates were 24% through the second quarter, 18% through the third quarter, and 14% through the fourth quarter. Conclusions', ' In this retrospective claims database analysis, only 14% of a large cohort of CML patients treated with imatinib had BCR-ABL testing recorded in each of 4 consecutive quarters. Inadequate compliance with recommended BCR-ABL testing can delay treatment decisions, and may be associated with poor clinical outcome.']",
        "Doc_id":"ASCO_30507-65",
        "Doc_title":" Inadequate BCR-ABL monitoring in imatinib-treated patients with chronic myelogenous leukemia.",
        "_version_":1606189029373509632},
      {
        "Meeting_name":" Direct assessment of sequence heterogeneity in human cancers by Duplex Sequencing",
        "Background":"['The extent of heterogeneity in DNA sequence within human cancers has been difficult to fully assess, due to the absence of methods with sufficient sensitivity to detect minority variants. For example, next-generation sequencing could in principle detect sub-clonal mutations at any genomic position; however due to amplification errors and inaccuracies in the sequencing platform itself, such approaches are limited to detection of mutations present in >1% of cells. We have overcome this limitation by developing an approach, Duplex Sequencing, which improves the accuracy of next-generation sequencing by >100,000 fold. Duplex Sequencing is based upon separately tagging and sequencing the two strands of single molecules of duplex DNA. True mutations are present at the same position in both DNA strands and are complementary, whereas artifacts arising from amplification or sequencing errors are seen in only one strand. The calculated error rate of our approach is less than one artifactual mutation per billion nucleotides sequenced (ref. 1). We have also developed an enrichment approach based on sequential rounds of hybridization to biotinylated probes which enables efficient sequencing of targeted regions of the genome (ref. 2). Duplex Sequencing thereby enables exceptionally sensitive detection of sequence heterogeneity within any set of genes. We have now applied Duplex Sequencing to study of sequence heterogeneity in both normal and malignant samples. In acute myeloid leukemia (AML), we find multiple sub-clonal mutations which fall below the detection limit of conventional approaches, some of which encode mutations that can drive chemotherapy resistance and cancer progression. Our results indicate that prior studies have under-estimated the burden of sub-clonal mutations in AML by more than 1,000-fold. We have additionally studied chronic myeloid leukemia (CML); treatment of CML with inhibitors directed against the Abl kinase represents the prototypical targeted cancer therapy. With Duplex Sequencing, we find that Abl mutations are extremely uncommon at the time of CML diagnosis. In contrast, refractory patients who fail therapy frequently possess multiple sub-clonal mutations within the Abl kinase, most of which are below the resolution of conventional approaches but are readily detected with our method. In ongoing work, we have found multiple sub-clonal mutations within human prostate cancer and colon cancer, suggestive of widespread intratumor heterogeneity that may limit the efficacy of single-agent therapy in these diseases.References', '1. Schmitt MW, Kennedy SR, Salk JJ, Fox EJ, Hiatt JB, Loeb LA (2012). Detection of ultra-rare mutations by next-generation sequencing. Proceedings of the National Academy of Sciences USA. 109(36)', '14508-13.2. Schmitt MW, Fox EJ, Prindle MJ, Reid-Bayliss KS, True LD, Radich JP, Loeb LA (2015). Sequencing small genomic targets with high efficiency and extreme accuracy. Nature Methods. 12(5)', '423-5.']",
        "Doc_id":"AACR_2016-2395",
        "Doc_title":" Direct assessment of sequence heterogeneity in human cancers by Duplex Sequencing",
        "_version_":1606188977207902208},
      {
        "Meeting_name":" Novel mutations and expression of SMAD4 gene in chronic myeloid leukemia patients.",
        "Background":"['Background', ' SMAD4 gene is an important element of tumor suppressor Transforming growth factor (TGF)-- Smad pathway. It is found differentially expressed and mutated in variety of solid cancers. In this study, we examined the role of SMAD4 gene in Chronic Myeloid Leukemia (CML) patients. Methods', ' CML patients (n = 20) were considered strictly according to inclusion criteria (Age', ' 18+, Confirmation of BCR-Abl by PCR and FISH test). Patient pool included IM responsive cohort (n = 10), IM resistant cohort (n = 8) and 2 treatment nave patients. Healthy controls (n = 17) were also included (Age', ' 18+). Next Generation Sequencing (Illumina TS) was used for sequencing of exons with exon-intron margins. mRNA levels were studied by Real-Time PCR. Beta Actin was used as housekeeping gene. The study was approved by Institutional Ethics Committee. Results', ' SMAD4 mRNA levels were down-regulated in 59% CML patient and only 17% patients revealed increased expression. In responders, 50% patients exhibited down-regulation with 25% patients presented and over-expression, whereas in IM resistant group, more than 60% patients had low transcript levels and only12% patients showed higher expression. Expression data was correlated with sequencing findings. The gene had 7 mutations. Variation in Intron 7 was shared by all three patient groups. Two genetic variations in Exon 12 (g.48604844T > A & g.48604849G > C) were reported in IM responders. Both the mutations were present in 3 UTR region 6560 bases upststream of transcription end site. Resistant group had 4 genetic changes, with 3 intronic and 1 mutation in Exon 5 (g.48581300G > T).This change occured in codon 202, replaces Alanine by Serine, which in turn changes amino acid property from Hydrophobic non-polar to hydrophilic polar. All 3 mutations reported above were never reported to best of our knowledge.. Treatment nave patients had no specific mutation. Conclusions', ' Data suggest decreased SMAD4 RNA levels IM resistant patients compared to responders. Genetic changes in Exon 5 and Exon 12 could be related to mRNA level changes. Mutations reported in this study seem acquired after occurrence of disease as no exclusive genetic change was found in new patients. This study indicates the role of SMAD4 gene in CML.']",
        "Doc_id":"ASCO_169958-176",
        "Doc_title":" Novel mutations and expression of SMAD4 gene in chronic myeloid leukemia patients.",
        "_version_":1606188988021866496},
      {
        "Meeting_name":" Comparison of digital PCR with real-time PCR calibrated to the International Scale for BCR-ABL monitoring.",
        "Background":"['Background', ' Monitoring BCR-ABL1 fusion transcripts is the cornerstone of management in chronic myeloid leukemia (CML). Real Time PCR(RTPCR) has been the tool of choice for its sensitivity and dynamic range. The International Scale was recently introduced to allow for standardization across laboratories. Chip based Digital PCR(dPCR) which allows for absolute quantitation may obliviate the need for such standardization by giving absolute results.It has the potential to increase sensitivity for detection of minimal residual disease. This assumes great significance as we move into the era of treatment free remission. Methods', ' A total of 31 EDTA-blood samples of CML patients with known values ranging from 0.003-0.5 IS were processed via an accredited RTPCR protocol calibrated to the IS scale and a parallel dPCR workflow without any specific calibration . The analysis of digital PCR samples was performed on the Thermofisher Cloud Platform. Results', ' Both RTPCR and dPCR yielded extremely concordant results. The Pearson correlation between the two methods was r = 0.6043 (95%CI', ' 0.318 to 0.789; p = 0.0003). The calculated BCR-ABL/ABL ratios were comparable with a median of 0.098 for RT-PCR calibrated to the IS (range 0.003-0.55; n = 26) and 0.11 for dPCR (range 0.003-0.37; n = 29). The mean difference for the ratios between the two methods used for the detection was around 0.08. Conclusions', ' We demonstrate here the capability of dPCR to provide a parallel result to an IS scale calibrated protocol without any standardization. This approach required no specific calibrators or standards and resulted in extremely cost effective testing. This freedom from routine calibration provides for a significantly more robust workflow and greatly increased reliability. Limitations do persist in dPCR on account of limited chip densities which are the main parameter for the Poisson statistics. This has limited the dynamic range on dPCR to a maximum of Log 4 for accurate quantification. However as chip densities and emulsion concentrations increase in these technologies, they are poised to introduce a new era in the quest of accurate quantification.']",
        "Doc_id":"ASCO_195034-199",
        "Doc_title":" Comparison of digital PCR with real-time PCR calibrated to the International Scale for BCR-ABL monitoring.",
        "_version_":1606189003945541632},
      {
        "Meeting_name":" The antileukemic drug nilotinib inhibits the invasive activity and the metastatic potential of colorectal cancer cells by targeting the receptor tyrosine kinase DDR1.",
        "Background":"['Tyrosine kinases (TK) are frequently deregulated in human cancer and they play important roles in tumor progression. Since then, they have become valuable therapeutic targets and several inhibitors are currently used in the clinic. For example, the BCR-ABL inhibitor nilotinib is currently used for the treatment of patients with chronic myeloid leukemia (CML). Here we show that this antileukemic drug also inhibits invasive properties of colorectal cancer (CRC) cells. Inhibition was observed at the same dose-range for growth inhibition of CML cells. Nilotinib also strongly reduced liver metastasis induced by injection of CRC cells in the spleen of nude mice. Since we could not detect Abl deregulation in CRC cells, we speculated the involvement of an alternative target to be identified. Interestingly, a previous chemical-proteomic approach identified DDR1 as a novel target of nilotinib (Rix et al, Blood, 2007). DDR1 is a poorly-characterized TK and a receptor for collagen, a major component of the extracellular matrix. Accordingly, we found that DDR1 catalytic activity regulates cell invasion and metastasis of CRC cells. In addition, we demonstrate that nilotinib pharmacological activity is mediated by the inhibition of DDR1 in CRC cells', ' expression of the nilotinib resistant DDR1/T701I mutant renders CRC cells resistant to nilotinib treatment. Finally, we found that DDR1 catalytic activity is significantly increased in metastatic nodules compared to the primary tumor and the healthy tissue of the same patient. Altogether, these data suggest that the targeting of DDR1 by nilotinib may be of therapeutic value in metastatic CRC.Citation Format', ' Priscillia Tosti, Cdric Leroy, Valrie Simon, Bruno Robert, Josiane Pierre, Audrey Sirvent, Serge Roche. The antileukemic drug nilotinib inhibits the invasive activity and the metastatic potential of colorectal cancer cells by targeting the receptor tyrosine kinase DDR1. [abstract]. In', ' Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA)', ' AACR; Cancer Res 2013;73(8 Suppl)', 'Abstract nr 2085. doi', '10.1158/1538-7445.AM2013-2085']",
        "Doc_id":"AACR_2013-2085",
        "Doc_title":" The antileukemic drug nilotinib inhibits the invasive activity and the metastatic potential of colorectal cancer cells by targeting the receptor tyrosine kinase DDR1.",
        "_version_":1606189038922891264},
      {
        "Meeting_name":" Zhx2 promotes survival of B-cell acute lymphoblastic leukemia cell lines",
        "Background":"['Zhx2, a zinc finger containing transcription factor is frequently overexpressed in B cell malignancies including B cell acute lymphoblastic leukemia (B-ALL), however its role in development of B cell malignancies remains unknown. Previously, dysregulated activity of transcription factors due to mutation e.g. Myc or overexpression e.g. Sox11 has been shown to perturb B cell differentiation leading to malignant phenotypes, resistance to chemotherapeutics and genetic heterogeneity. Zhx2 is required for normal neuronal and erythropoietic differentiation and has been identified as a tumor suppressor in hepatocellular carcinoma. Furthermore, analysis of public databases shows that Zhx2 is highly overexpressed in several cell lines representing B cell malignancies including B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma. Consistently, Zhx2 is also overexpressed in patient samples derived from different subtypes of B cell malignancies. Quantification of Zhx2 mRNA expression obtained from human donors showed a marked upregulation during transition from common lymphoid progenitor to Pro B-cell stage suggesting potential role in B cell differentiation. Here we report that Zhx2 is overexpressed in Philadelphia chromosome positive (Ph+) B-ALL and T-ALL cell lines as well as Ph- B-ALL cell line. Zhx2 silencing in BV-173 (Ph+ B-ALL) and CMLT1 (Ph+ T-ALL) showed enhanced apoptosis with low doses of Dasatinib, a dual Src/Abl kinase inhibitor. Furthermore, global gene promoter and gene expression analysis on Zhx2 silenced cells identified putative Zhx2 regulated genes including CREB and YY1. Both of these transcription factors have roles in B cell differentiation, survival, proliferation and are commonly deregulated in B cell malignancies. We propose that Zhx2 regulates a B cell differentiation program and that overexpression of Zhx2 could lead to blocked differentiation of B cell progenitors promoting the malignant phenotype. Therefore, Zhx2 could be exploited as a chemo-therapeutic target in B cell malignancies.']",
        "Doc_id":"AACR_2016-1145",
        "Doc_title":" Zhx2 promotes survival of B-cell acute lymphoblastic leukemia cell lines",
        "_version_":1606189035761434624},
      {
        "Meeting_name":" Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia.",
        "Background":"['Background', ' Angina, arrhythmias and QT prolongation have been cardiac adverse effects reported in clinical trials with nilotinib, which inhibits the tyrosine kinase activity of BCR-ABL and KIT. The objective of this study was to assess cardiac events in acute myeloid leukemia (AML) patients treated with standard therapy (an anthracycline plus cytarabine or 7+3) versus KIT positive AML patients treated with 7+3 plus nilotinib as part of a clinical trial. Methods', ' After IRB approval, 100 consecutive patients treated for newly diagnosed AML at Mayo Clinic who consented to the use of their medical records for research were identified and a retrospective chart review performed. The primary endpoint was heart failure defined by the modified Framingham criteria. Secondary endpoints included cancer therapeutics-related cardiac dysfunction (CTRCD) defined as a drop in ejection fraction of > 10% to < 53%, arrhythmias defined as a new rhythm abnormality other than sinus bradycardia or tachycardia resulting in a change to therapy or transfer to a higher level of care, and acute coronary syndromes (ACS) diagnosed by a cardiologist. Between group differences were assessed using t-tests, Wilcoxon tests, or Fishers exact tests. Results', ' Thirteen patients (13%) received nilotinib plus 7+3 and 87 patients (87%) received 7+3. No patients had a prior exposure to nilotinib. Median follow-up was 73 weeks (55-87) in the nilotinib plus 7+3 group and 83 weeks (30-139) in the 7+3 group. Groups were similar with respect to age, sex, comorbidities and baseline medical therapy. No significant difference was observed between those who did versus did not receive nilotinib respectively in the incidence of heart failure (8% vs. 14%), CTRCD (15% vs. 16%), ACS (0 vs. 3%) and arrhythmias (0 vs. 16%)(all p > 0.1). Conclusions', ' The addition of nilotinib to standard therapy for AML was not associated with an increase in cardiac events for at least 1 year of follow up. This finding is important as the use of tyrosine kinase inhibitors in combination with other chemotherapeutic agents may increase in the future with personalized medicine. However, the follow-up was insufficient to detect late onset cardiac toxicity and studies with longer follow-up are needed.']",
        "Doc_id":"ASCO_163174-176",
        "Doc_title":" Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia.",
        "_version_":1606189018426376192},
      {
        "Meeting_name":" PLK1 inhibitors interact synergistically with HDAC inhibitors in IM-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.",
        "Background":"['Purpose', ' Previous studies have shown that inhibitors of the serine/threonine kinase PLK1 potently induce cell death in human BCR/ABL+ leukemia cells both sensitive and resistant to imatinib mesylate (IM; Cancer Research 70', '1513, 2010). Furthermore, HDACIs are known to potentiate tyrosine kinase lethality in such cells. The goal of the present studies was to determine whether PLK1 inhibitors (e.g. BI2536) and HDACIs interacted synergistically in BCR/ABL+ cells sensitive or resistant to imatinib mesylate in vitro and in vivo and if so, to identify the mechanism(s) underlying this interaction. ExperimentalDesign', ' K562 and LAMA84 cells, IM-resistant Adult-T315I and BV173/E255K cells, and primary CML cells were exposed to BI2536 with or without vorinostat (Merck) for various intervals. Effects on apoptosis and signaling pathways were determined by flow cytometry, western blotting, and gene transfection. K562 and BV173/E255K cells were used to test the in vivo efficacy of this drug regimen in animal models.Results', ' Co-treatment with BI2536 and vorinostat synergistically induced cell death in parental or IM-resistant BCR/ABL+ cells and primary CD34+ bone marrow cells but was minimally toxic to normal cells. BI2536/vorinostat co-treatment triggered pronounced mitochondrial dysfunction, caspase activation, PARP cleavage, ROS generation, and DNA damage (manifested by increased expression of H2A.X, p-ATM, p-ATR), all of which were significantly attenuated by the anti-oxidant TBAP. Combined treatment had little effect on T210 phosphorylation of PLK1, but clearly reduced S137 phospho-PLK1 without changing PLK1 expression. While the agents alone had little effect on BCR/ABL phosphorylation, combined treatment induced modest reductions in phospho-BCR/ABL but not total expression. Exposure of cells to BI2536 alone induced marked G2M arrest, whereas vorinostat co-administration abrogated this effect. PLK1 shRNA knockdown significantly increased HDACI lethality, whereas HDAC 1-3 shRNA knockdown reciprocally increased BI2536-induced apoptosis. Genetic interruption of the DNA damage linker H1.2 partially but significantly reduced PLK1/HDAC inhibitor-mediated cell death, arguing for a functional role for DNA damage in lethality. Finally, BI2536/vorinostat co-treatment dramatically reduced tumor growth in both subcutaneous and systemic BCR/ABL+ leukemia xenograft models (including those resistant to IM), and significantly enhanced animal survival. Notably, the regimen was highly effective in a late stage tumor model which is classically resistant to most therapeutic interventions.Conclusions', ' These findings suggest that concomitant PLK1 and HDAC inhibition is active against IM-sensitive or refractory CML cells both in vitro and in vivo, and that this strategy warrants further evaluation in the setting of BCR/ABL+ leukemias.']",
        "Doc_id":"AACR_2013-588",
        "Doc_title":" PLK1 inhibitors interact synergistically with HDAC inhibitors in IM-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.",
        "_version_":1606189022678351872},
      {
        "Meeting_name":" Calorie and fat restriction during chemotherapy improves survival in obese mice with syngeneic acute lymphoblastic leukemia",
        "Background":"['Obesity promotes the pathogenesis of many cancers, including acute lymphoblastic leukemia (ALL), the most common childhood malignancy. Clinical studies have shown that children who are obese at the time of ALL diagnosis have a greater risk of relapse than normal weight children; however, this risk may be attenuated if their weight normalizes over the majority of treatment. One possible explanation is that nutrient-deficiency may induce host, but not ALL, cell senescence, thereby augmenting chemotherapy specificity and efficacy. Here, we hypothesize that a calorie- and fat-restricted diet during chemotherapy differentially alters host and ALL cell metabolism, improving chemotherapy efficacy and overall survival of high-fat diet-induced obese mice with ALL.To test the effect of dietary restriction on survival, C57BL/6J mice were placed on a high-fat diet (60% calories from fat) upon weaning. At 20 weeks of age, obese and control mice were implanted with syngeneic BCR/ABL+ ALL cells. After a 7-day latency, half of the obese mice were switched onto a low-fat (10% calories from fat) diet. Concurrently, vincristine chemotherapy (0.5mg/kg/wk x 4wks) was initiated and mice were tracked for survival. Separate groups of implanted mice were sacrificed 1 day before, 1 day and 1 week after dietary restriction for bone marrow and spleen collection. BrdU incorporation and p-AKT(Ser 473), p-eIF2A(Ser51) and p-S6K(Thr412) levels in marrow and spleen ALL and host cells were analyzed via flow cytometry for changes in cell cycle and metabolism. Finally, we also evaluated the effect of dietary restriction on human ALL outcome, using an obese xenograft ALL model treated with vincristine, dexamethasone and L-asparaginase.Dieted obese C57BL/6J leukemic mice exhibited a greater percentage of weight loss over the first two weeks of chemotherapy compared to non-dieted obese mice (Dieted vs. non-dieted obese', ' -25.210.6% vs. -0.34.5%, p<0.001). Dieted obese leukemic mice had significantly higher survival than non-dieted obese and lean mice after 4 months (Dieted', ' 91.6%, Obese', ' 16.7%, Lean', ' 41.7%; n = 12/group; p<0.001). Flow cytometry of the murine bone marrow and spleen showed no diet-induced alterations in BrdU incorporation or AKT pathway activation in either host or ALL cells. Surprisingly, however, we did not observe a similar effect of dietary restriction on survival in the obese xenograft ALL model.Based on these findings, a calorie and fat restricted diet initiated at the onset chemotherapy improves overall survival in obese mice with syngeneic ALL, though this phenomenon was not observed in a human xenograft model. Further work is needed to explore the possibility of a dietary intervention as an effective potential adjuvant during chemotherapy in obese cancer patients.']",
        "Doc_id":"AACR_2015-1633",
        "Doc_title":" Calorie and fat restriction during chemotherapy improves survival in obese mice with syngeneic acute lymphoblastic leukemia",
        "_version_":1606188983298031616},
      {
        "Meeting_name":" Sample specific outlier kinase expression identified by RNA-Seq provide targets for precision therapy.",
        "Background":"['Protein kinases represent a most effective class of therapeutic targets in cancer cells, and potent inhibitors of oncogenic kinases including ABL, AKT, ALK, AURKs, BRAF, CDKs, EGFR, ERBB2, FGFRs, KIT, MAPKs, MET, PIK3CA, PLKs, RET, SRC, S6Ks, and VEGFR are in clinical use, trials, or development. Presence of activating mutations, gene fusions or copy number amplification of many of these kinases predict responsiveness to specific inhibitors, for example, imatinib for BCR-ABL-positive chronic myeloid leukemia, trastuzumab and lapatinib for ERBB2-amplified breast cancers, gefitinib for lung cancers with kinase domain mutations in EGFR, and crizotinib for lung cancers with ALK gene fusions. However, tumors with defined kinase aberrations represent a very small proportion of all cancers, and we hypothesize that potentially most, if not all, cancers are dependent on specific kinases, and that Outlier Expression of specific kinases in individual samples may be indicative of selection during clonal evolution, and thus may represent a therapeutic avenue. To explore this hypothesis, we analyzed RNA-sequencing data from a compendium of 482 cancer and benign samples belonging to 25 different tissue types to define sample-specific kinome expression profiles. Comparing the expression of kinases within a sample and across sample sets, we identified distinct outlier kinases in individual samples, defined as genes showing the highest statistically significant levels of absolute and differential expression. Frequently observed outlier kinases included known therapeutic targets like ERBB2 and FGFR4 in breast cancer, distinct from MET, AKT2, and PLK2 in pancreatic cancer. Outlier kinases imparted sample-specific dependencies in various cell lines as assessed by siRNA knockdown or pharmacologic inhibition in vitro and in vivo. Outlier expression of polo-like kinases (PLKs) observed in a subset of KRAS-dependent pancreatic cancer cell lines conferred increased sensitivity to the PLK inhibitor BI 6727. Together, our results suggest that outlier kinases represent effective personalized therapeutic targets that are readily identifiable through RNA-sequencing of tumors. Next, to help translate these observations into treatment options, we are attempting to establish 3D tumoroid cultures from tumor samples that can be used to optimize combinations of therapeutics including outlier kinase inhibitors.']",
        "Doc_id":"AACR_2013-3136",
        "Doc_title":" Sample specific outlier kinase expression identified by RNA-Seq provide targets for precision therapy.",
        "_version_":1606188996075978752},
      {
        "Meeting_name":" A long noncoding RNA plays a critical role in Bcr-Abl-mediated cellular transformation",
        "Background":"['It is well documented that malignant transformation of myeloid and lymphoid cells by Bcr-Abl involves the dysregulation or mutation of a variety of protein-coding genes that are normally involved in regulating the proliferation and survival of hematopoietic cells. However, the functional relevance of long noncoding RNAs (lncRNAs) and their in vivo regulation during Bcr-Abl-mediated tumorigenesis remain unknown, although recent studies have shown that aberrant expression of lncRNAs is associated with various human cancers. In this study, we performed a comprehensive analysis of lncRNAs in human CML cells using an lncRNA cDNA microarray, and identified an lncRNA termed lncRNA-BGL3 that acted as a key regulator of Bcr-Abl-mediated cellular transformation. Notably, we observed that lncRNA-BGL3 was highly induced in response to disruption of Bcr-Abl expression or by inhibiting Bcr-Abl kinase activity in K562 cells and leukemic cells derived from CML patients. Ectopic expression of lncRNA-BGL3 sensitized leukemic cells to undergo apoptosis and inhibited Bcr-Abl-induced tumorigenesis. Furthermore, transgenic mice expressing lncRNA-BGL3 were generated. We found that transgenic expression of lncRNA-BGL3 alone in mice was sufficient to impair primary bone marrow transformation by Bcr-Abl. Interestingly, we identified that lncRNA-BGL3 was a target of miR-17, miR-93, miR-20a, miR-20b, miR-106a and miR-106b, microRNAs that repress mRNA of PTEN. Further experiments demonstrated that lncRNA-BGL3 functioned as a competitive endogenous RNA (ceRNA) for binding these microRNAs to cross-regulate PTEN expression. Additionally, our experiments have begun to address the mechanism of how lncRNA-BGL3 is regulated in the leukemic cells and showed that Bcr-Abl repressed lncRNA-BGL3 expression through c-Myc-dependent DNA methylation. Taken together, these results reveal that Bcr-Abl-mediated cellular transformation critically requires silence of tumor suppressor lncRNA-BGL3 and suggest a potential strategy for the treatment of Bcr-Abl-positive leukemia.']",
        "Doc_id":"AACR_2014-3543",
        "Doc_title":" A long noncoding RNA plays a critical role in Bcr-Abl-mediated cellular transformation",
        "_version_":1606189012579516416},
      {
        "Meeting_name":" Unraveling the mechanism of action",
        "Background":"['The tumor suppressor 2A (PP2A) is a multi-enzyme complex that targets a variety of oncogenic signaling cascades such as Raf, MEK and AKT. Numerous reports have now emerged indicating that the inhibition of PP2A leads to the development of tumors including breast, gastric and lung and a range of hematological malignancies such as chronic and acute myeloid leukemia (CML and AML, respectively). We and others have shown that inhibition of PP2A is crucial for the oncogenic effects of leukemia associated receptor tyrosine kinases such as BCR/Abl, c-KIT and FLT3. Importantly when PP2A is reactivated using pharmacological agents (FTY720 and AAL(S)), growth and survival of these cells is inhibited. This approach targets molecules downstream of these oncogenic kinases and thus PP2A reactivation is designed to avoid resistance associated with kinase inhibitor therapy. As the mechanism of action of these PP2A activators is unknown, it is essential that we now determine the molecular targets of these compounds to generate more effective drugs. Using a chemical proteomics approach incorporating click chemistry linking the drugs to beads, unbiased pull down assays were performed in myeloid leukaemia cells and protein isolates were identified by mass spectrometry. Using this approach we have identified a novel cellular target, which is known to be overexpressed in a range of cancers, including leukemias. We have also shown that this protein associates with PP2A complexes in these cells, and thus may act as an endogenous inhibitor of PP2A activity. We have also performed phospho-proteomics and co-immunoprecipitation studies to identify protein changes in myeloid leukemia cells in response to PP2A activators. In addition to identifying known PP2A targets, such as Akt and ERK, we have also identified a number of novel protein changes, including altered expression of the SET oncoprotein. SET is a known inhibitor of PP2A, suggesting that FTY720 may act via inhibition of SET. Other PP2A regulatory proteins such as CIP2A, PME-1 and PP2A-B56alpha are also affected by FTY720/AAL(S) treatment. Our research findings are thus providing the vital clues necessary for determining the mechanism of action of clinically relevant PP2A activators, thereby moving us towards the provision of novel anti-cancer treatment regimes.']",
        "Doc_id":"AACR_2013-2038",
        "Doc_title":" Unraveling the mechanism of action",
        "_version_":1606189022134140928},
      {
        "Meeting_name":" Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa)",
        "Background":"['Background', '  Dasatinib, a potent oral BCR-ABL and SRC family kinase (SFK) inhibitor, is approved for first- and second-line therapy of Philadelphia chromosome-positive chronic phase chronic myeloid leukemia (CML) in pts with newly diagnosed CML or CML resistant/intolerant to prior therapy. SRC expression and activity is upregulated in PaCa and correlates with reduced survival in resected high-grade PaCa (Morton, Gastroenterology 2010) and resistance to Gem, a PaCa standard of care (Duxbury, J Am Coll Surg 2004). In preclinical PaCa studies, inhibition of SFKs with dasatinib reduces tumor cell proliferation, migration, and invasion; increases apoptosis; sensitizes cells to Gem; and inhibits development of metastases in vivo either alone or in combination with Gem (Duxbury, Clin Cancer Res 2004; Duxbury, J Am Coll Surg 2004; Nagaraj, Mol Cancer Ther 2010; Morton, op cit). Phase I clinical studies of dasatinib and Gem therapy in PaCa have demonstrated feasibility and suggested efficacy of the combination (Uronis, ASCO 2009, abstract e15506).  Methods', '  This double-blind phase II study tests whether addition of dasatinib to Gem is tolerable and improves efficacy in pts with histologically/cytologically confirmed unresectable locally advanced nonmetastatic PaCa. Eligible pts, aged 18 years with Eastern Cooperative Oncology Group performance status 1 and adequate organ function, are randomized 1', '1 to Gem 1000 mg/m2 IV once weekly (Weeks 13 of a 4-week cycle) plus either dasatinib 100 mg once daily or matched placebo. Pts are treated until progression, unacceptable toxicity, withdrawal of consent, or study termination. The primary endpoint is OS, and secondary endpoints are progression-free survival and safety. Exploratory endpoints include freedom from distant metastases, measures of pain and fatigue, overall response rate, and carbohydrate antigen 19-9. Final study analysis will be conducted after 135 deaths; all pts will be followed for survival. To date, 23/200 pts have enrolled; estimated primary completion date is March 2013. ClinicalTrials.gov identifier', ' NCT01395017.']",
        "Doc_id":"ASCO_92821-114",
        "Doc_title":" Dasatinib combined with gemcitabine (Gem) in patients (pts) with locally advanced pancreatic adenocarcinoma (PaCa)",
        "_version_":1606188984106483712},
      {
        "Meeting_name":" Imatinib treatment for gefitinib-resistant lung cancer harboring epidermal growth factor receptor mutation",
        "Background":"['Background', ' Epidermal growth factor receptor (EGFR) mutant-lung cancer showed significant response to EGFR-tyrosine kinase inhibitor (TKI) treatment, however, treatment failure due to acquired resistance to EGFR-TKI become important clinical problem for long-term survivors. Our purpose is to develop the new treatment for EGFR-TKI resistance. Methods', ' We used PC9 human lung cancer cell line harboring EGFR exon 19 deletion (E746-A750). When PC9 cells were cultured with 2 M gefitinib solved in dimethylsulfoxide (DMSO), most of cells died and surviving cells proliferated slowly. By 90 days-culture with 2 M gefitinib, PC9 gefitinib resistant cells (PC9GR90) were established and confirmed that EGFR-T790M resistance-related mutation was negative. In PC9GR90, an immunoblot assay revealed MET (hepatocyte growth factor receptor) amplification and alternative EGFR3 tyrosine phosphorylation, which is known as one of the major resistant mechanisms. Results', ' When PC9GR90 were cultured with 2 M gefitinib and one inhibitor (histone deacetylase inhibitor, insulin-like growth factor receptor inhibitor, gamma secretase inhibitor, or imatinib known as bcr-abl, c-kit and platelet derived growth factor receptor inhibitor), 10 M imatinib treatment with gefitinib showed significant suppression of cell growth. The ratio of cell count of 2 M gefitinib/DMSO and 10 M imatinib with 2 M gefitinib/DMSO were 91.7% and 6.0%, respectively. When imatinib concentration was decreased to 1 M known as appropriate concentration for chronic myeloid leukemia treatment, there was no effect. The imatinib effect was not shown for NCI-H1975 lung cancer cells harboring both EGFR-L858R and -T790M. By immunoblot, we found EGFR3 phosphorylation was inhibited by imatinib treatment. Conclusion', ' It is the first report that imatinib inhibits EGFR3 phophorylation and induce cell death in the EGFR-TKI resistant lung cancer with MET amplification and EGFR3 phophorylation. Although further studies are required to apply this strategy to a clinical setting, we demonstrate a hopeful data to conquer one important resistant mechanism.']",
        "Doc_id":"AACR_2012-1793",
        "Doc_title":" Imatinib treatment for gefitinib-resistant lung cancer harboring epidermal growth factor receptor mutation",
        "_version_":1606188984108580864},
      {
        "Meeting_name":" Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.",
        "Background":"['Background', ' Management of chronic myeloid leukemia (CML) has evolved from nonspecific conventional chemotherapy with hydroxyurea or busulfan, with poor efficacy, to therapy with interferon- alone or with cytarabine in patients ineligible for transplantation. BCR- ABL-targeted tyrosine kinase inhibitors like imatinib have changed the landscape of CML treatment and produced improved rates of long-term response and survival. However, resistance to imatinib has emerged as a significant clinical issue. Treatment with second-line dasatinib can overcome multiple mechanisms of resistance to imatinib in patients with chronic-phase CML. This study compares the response and outcome in patients primarily refractory to imatinib with those who responded to imatinib but relapsed, as well as the effect of other prior treatments. Methods', ' Two-year follow-up data from all dose and schedule arms of the CA180-034 study were analyzed. Results', ' Based on univariate analyses, patients receiving dasatinib 100mg once daily who were pretreated with interferon- had a lower likelihood of achieving complete cytogenetic response (CCyR; 39% vs. 61%). Similarly, the CCyR rate was lower among patients who had undergone prior transplantation (38% vs. 50%) in the 100 mg once daily arm. The 24-month rates of progression-free survival (73% vs. 71%) and overall survival (89% vs. 89%) were similar between patients with primary or secondary resistance to imatinib in those receiving any dose of dasatinib. Patients with prior CCyR or those < 18 months from diagnosis of CML exhibited more durable major cytogenetic response. Conclusions', ' These data suggest that patients who are minimally pretreated have a greater likelihood of achieving CCyR on dasatinib. The type of resistance to imatinib may impact the likelihood of response to second-line dasatinib; patients who had once benefited from imatinib appear to have improved response rates with dasatinib compared with patients with primary resistance. With relatively limited follow- up, both groups experienced similar survival outcomes. Further analysis evaluating the type and degree of imatinib resistance is ongoing to assess the impact on outcomes with second-line dasatinib.']",
        "Doc_id":"ASCO_50427-74",
        "Doc_title":" Types of resistance to imatinib and other potential predictors of response to second-line dasatinib therapy.",
        "_version_":1606189032204664833},
      {
        "Meeting_name":" Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib.",
        "Background":"['Background', ' Response dynamics in pts treated with nilotinib for imatinib failure may be different than imatinib in front line. Many pts treated with nilotinib in the second line achieved cytogenetic responses early (median time to MCyR and CCyR of 2.8 mo and 3.3 mo). A previous landmark analysis demonstrated BCR-ABL% (IS) at 3 months (mo) on nilotinib predicted achievement of subsequent cytogenetic response. Here, we investigated whether early molecular response before 3 mo was associated with subsequent cytogenetic response. Methods', ' CML-CP pts (N = 321) with imatinib resistance or intolerance were grouped by 1 mo BCR-ABL% (IS) and landmark analyses were performed to evaluate probability of cytogenetic response with a minimum follow-up of 24 mo. Results', ' Early molecular response of BCR-ABL% (IS)  10 occurred in 19% of pts who received nilotinib. Pts with BCR-ABL% (IS) >1 - 10 (n = 37) had higher probability of MCyR by 12 mo (84%) compared with pts with BCR-ABL% (IS) >10 (55%) (n = 202). Pts with BCR-ABL% (IS) >1 - 10 also had higher probability of achieving CCyR by 12 mo (72%) compared with pts with BCR-ABL% (IS) >10 (38%). Similar trends in the probability of achieving MCyR and CCyR on nilotinib by 12 mo were observed for pts when analyzed by the presence or absence of baseline (BL) mutations (Table). Similar results were seen when analyzing the probability of cytogenetic response by 24 mo. Estimated MCyR and CCyR by 12 mo by BCR-ABL% (IS) at 1 mo on nilotinib therap. Conclusions', ' Molecular response to nilotinib at 1 mo was associated with cytogenetic responses by 12 and 24 mo, even in the presence of BL mutations. While treatment decisions based on 1 mo BCR-ABL% (IS) are not recommended, these data indicate that reductions in BCR-ABL transcripts may occur before 3 mo on nilotinib and are associated with subsequent cytogenetic responses in these pts. BCR-ABL% (IS) at 1 Mo> 1 -  10> 10p value (log-rank test)MCyR by 12 MoAll pts, n = 23984%55%<0.0001Pts with BL mutations, n = 9576%42%<0.0001Pts without BL mutations, n = 12189%64%<0.0001CCyR by 12 MoAll pts, n = 24172%38%<0.0001Pts with BL mutations, n = 9658%25%0.0022Pts without BL mutations, n = 12289%45%<0.0001']",
        "Doc_id":"ASCO_54156-74",
        "Doc_title":" Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinib.",
        "_version_":1606188987029913600},
      {
        "Meeting_name":" A novel diagnostic assay for detection of primate-specific RNA editing events in leukemia stem cells",
        "Background":"['IntroductionThe adenosine deaminase acting on RNA (ADAR) family of RNA editases has been linked to the pathogenesis of diverse malignancies, including leukemia, breast cancer and hepatocellular carcinoma. We previously showed that human leukemia stem cells (LSC) from blast crisis (BC) chronic myeloid leukemia (CML) patients harbor increased ADAR1 expression compared with normal and chronic phase (CP) progenitors. Whole transcriptome RNA sequencing (RNA-Seq) revealed increased adenosine to inosine (A-to-I) RNA editing during CML progression concentrated within primate specific Alu-containing transcripts. However, detection of RNA editing by RNA-Seq in rare cell populations can be technically challenging, costly and requires PCR validation. Thus, the objectives of this study were to validate RNA editing of a subset of these LSC-associated transcripts in the context of lentivirally enforced ADAR1 expression, and to develop an RNA editing reporter reporter assay in human leukemia cells and a qPCR-based diagnostic test to rapidly detect CSC-associated aberrant RNA editing.MethodsThe BCR-ABL+ human leukemia cell line K562 was stably transduced with lentiviral human ADAR1 or vector. FACS-purified K562-ADAR1 cells were transfected with a luciferase-based reporter vector to confirm RNA editing activity. Two genes, MDM2 and APOBEC3D, were selected from our previous RNA-Seq studies of BC progenitors (Jiang et al, 2013). Targeted sequencing was performed on high fidelity PCR products using primers flanking each of 2 editing sites in each gene. RNA editing-specific qPCR primers were designed for each editing site using an allele-specific strategy that detects cDNA containing either an A or G(I) representing an RNA editing event. Both targeted sequencing and qPCR were used to detect RNA editing in K562-ADAR1 and primary cord blood-derived hematopoietic stem cells (HSC) lentivirally transduced with ADAR1.ResultsLentivirally enforced ADAR1 expression promoted RNA editing activity as measured by luciferase reporter activity. Increased A-to-I changes in MDM2 and APOBEC3D were confirmed by targeted sequencing. In independent experiments, RNA editing site-specific qRT-PCR accurately detected RNA editing in K562-ADAR1 cells (n=3) and in primary HSC overexpressing ADAR1 (n=4). Site-specific primers distinguished G(I) bases at RNA editing sites in cDNA and as predicted gave no signal in gDNA. Relative A-to-I RNA editing ratios were increased by 2 to 3 fold in ADAR1-expressing cells at all four sites.ConclusionsThese results set the stage for development of primate-specific RNA editing as a novel diagnostic strategy for clinical LSC detection and identify ADAR1 as a potential therapeutic target in LSC. These data shed new light on the mechanisms of ADAR1-mediated generation of malignant progenitors that drive therapeutic resistance, disease progression and relapse in CML and may be applicable to other CSC-driven malignancies.']",
        "Doc_id":"AACR_2014-375",
        "Doc_title":" A novel diagnostic assay for detection of primate-specific RNA editing events in leukemia stem cells",
        "_version_":1606188997787254784},
      {
        "Meeting_name":" Lymphocyte cytosolic protein 1 (LCP1) is a membrane-associated molecular target in chronic lymphocytic leukemia and is activated in microenvironment signaling.",
        "Background":"['Chronic lymphocytic leukemia (CLL) is an incurable accumulation of malignant B-cells in peripheral circulation, which home to supportive leukemic microenvironments. Critical to the pathogenesis of CLL are membrane-associated antigens since they facilitate leukemic cell signaling, microenvironment homing, proliferation, and survival. Targeting these CLL surface molecules is a current focus of CLL therapeutic development. Rituximab, alemtuzumab, and ofatumumab are commonly used antibody-based therapeutics that proved to be effective at targeting CLL membrane associated antigens. Despite enhanced patient survival, targeting of non-obligate antigens ultimately leads to antibody resistance. In addition, off target expression often produces unacceptable toxicity. Immunosurveilance antigens may provide a key to overcome these obstacles. A number of relevant tumor antigens such as p53, EGFR, WT1, BCR-Abl and ROR1 elicit robust autoimmune responses in cancer patients due to high levels of ectopic expression, high relative immunogenicity and obligate oncogenic signaling that forces expression despite autoimmune recognition. In many cases, autoantibody signatures were realized long after identification of the oncologic target antigens; however, the convergence of these two datasets implies that such signatures could be utilized to identify novel targets. To further explore this possibility, we interrogated anti-tumor humoral reactivity specifically directed against autologous CLL membrane antigens. Immunoreactive leads were identified by mass spectrometry. Potential membrane antigens were further confirmed using immunoblot and ELISA. Our analysis revealed Lymphocyte Cytosolic Protein 1 (LCP1), a membrane associated lymphocyte-specific target that is constitutively expressed on CLL and ectopically expressed in various cancers. Confirmatory assays unveiled robust LCP1-specific IgG autoimmune responses in CLL patients despite a profound absence of reactivity to common viral and vaccine antigens. LCP1 plays a critical role in B-cell biology by cross linking f-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for CLL-critical signaling pathways such as PKC. Transwell assays confirmed that LCP1 activity contributed to the migration of CLL cells towards CXCL12. We further utilize a novel xenograft model to demonstrate LCP1 involvement in CLL pathogenesis. We have also characterized LCP1 expression within cancer derived exosomes revealing a previously unknown function of this gene. Our data reveals that LCP1 is a novel membrane associated target antigen in CLL with evidence of differential immune response as compared to common vaccine antigens. We also demonstrate that LCP1 plays a role in CLL microenvironment signaling and progression.']",
        "Doc_id":"AACR_2013-4925",
        "Doc_title":" Lymphocyte cytosolic protein 1 (LCP1) is a membrane-associated molecular target in chronic lymphocytic leukemia and is activated in microenvironment signaling.",
        "_version_":1606188990439882752},
      {
        "Meeting_name":" Discovery of dual MNK 1 and 2 and BCR-ABL kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia",
        "Background":"['Chronic Phase Chronic Myelogenous Leukemia (CP-CML) is well treated with tyrosine kinase inhibitors (TKI) through BCR-ABL kinase modulation. However, TKI are ineffective for late-stage or blast crisis (BC) CML in which phase, granulocyte macrophage progenitors (GMPs) have acquired the ability to function as leukemic stem cells (LSCs), and are thought to act as a reservoir for TKI resistance with poor prognosis. An effective BC-CML therapy will likely have to target the BC-LSC population to ensure long-term disease control.Recent studies have shown the importance of the MAP kinase interacting serine/threonine kinase (MNK1/2)-eukaryotic translation initiation factor 4E (eIF4E) axis in sustaining BC-LSC self-renewal. Thus, a single agent which inhibits both BCR-ABL and MNK1/2 kinase simultaneously represents a rational approach to target BC-LSCs. Such an agent should be able to distinguish between normal hematopoietic stem cells (HSC) and LSCs.Here, we report the discovery of a potential BC-CML therapy that relies on the inhibition of MNK1/2 and BCR-ABL kinases using a dual specific MNK/ABL inhibitor. We will also report the in vitro and in vivo biological data, pharmacokinetic properties, and biochemical characteristics of such compounds. These compounds are able to prevent eIF4E phosphorylation, thus selectively inhibiting the MNK-eIF4E-dependent self-renewal function of BC-LSCs as a single agent while leaving normal HSCs unscathed.']",
        "Doc_id":"AACR_2016-2137",
        "Doc_title":" Discovery of dual MNK 1 and 2 and BCR-ABL kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia",
        "_version_":1606188994747432960},
      {
        "Meeting_name":" Differential roles of BCL-XL and BCL-2 in protecting mitochondria against oxidative stress in CML cells",
        "Background":"['Previous studies have identified that BCR-ABL elevates cellular reactive oxygen species (ROS) through mitochondria and NAD(P)H oxidase (NOX). However, it is still unknown how BCR-ABL over-expressed cells can maintain such altered redox status, while escaping from the persistent oxidative stress-induced cell damage or apoptosis. Therefore elucidation of the mechanisms by which CML cells cope with oxidative stress will provide important insights into the molecular events leading to leukemia development and drug resistance. The major goals of this study are to investigate the role of BCR-ABL-regulated downstream cell survival factors in providing an adaptive mechanism which allows CML cells to survive in the presence of cellular oxidative stress, and to evaluate the potential therapeutic implications. Several experimental models were used to test the cellular redox status and relative sensitivity of oxidative stress-induced cell death in our study, including BCR-ABL inducible cell lines, BCR-ABL stably transformed cell lines and BCR-ABL-expressing CML blast crisis cells with different BCL-XL/BCL-2 patterns. Additionally, we established an artificial CML cell model with heterogenic BCL-XL/BCL-2 expression to assess the correlation between cell survival factor genetic background and cell sensitivity to Imatinib and oxidative stress. In this study, BCL-XL has been identified as the major survival factors responsive to BCR-ABL-promoted cellular oxidative stress and plays a dominant role in regulating the threshold of oxidative stress-induced apoptosis. The cell survival factors BCL-XL and BCL-2 differentially protect mitochondrial integrity under oxidative stress. BCL-XL is an essential survival factor in maintaining viability of the cells with the excessive ROS while BCL-2 seems to play a relatively minor role. In addition, combination of redox-modulating reagent -phenethyl isothiocyanate (PEITC) with BCL-XL/BCL2 inhibitor ABT737 or suppression of BCL-XL expression by BCR-ABL inhibitor Gleevec dramatically sensitizes CML cell to ROS stress-induced apoptosis. These data together suggest that elevation of BCL-XL is important for the development of CML, and that redox-directed therapy may merit further clinical investigations in CML treatment.']",
        "Doc_id":"AACR_2012-2007",
        "Doc_title":" Differential roles of BCL-XL and BCL-2 in protecting mitochondria against oxidative stress in CML cells",
        "_version_":1606189001479290880},
      {
        "Meeting_name":" BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.",
        "Background":"['Background', ' CML patients with different types of BCR-ABL transcript may vary in disease prognosis and responses to therapy. An analysis was conducted to investigate the correlation between BCR-ABL transcript type and responses to nilotinib in the second-line setting. Methods', ' CML-CP pts (n = 321) with imatinib resistance or intolerance were included. In order to determine if transcript type influenced response dynamics, BCR-ABL transcript types were analyzed in 301/321 (94%) of pts. In addition, the BCR-ABL transcript dynamics were modeled as previously described (Stein et al. Blood. 2009;114(22)', '209). Results', ' Median nilotinib exposure was 561 days. The majority of pts (95%) were observed to have typical b3a2 (63%) and b2a2 (32%) BCR-ABL transcript types; 3% of pts had both typical transcripts and 2% had atypical transcripts (e1a2, e19a2, b3a3). The incidence of BL mutations was higher in patients with b3a2 transcripts compared with b2a2 (46% vs. 32%, p = 0.03). Response to nilotinib was similar regardless of transcript type (Table). A two-sample 2 test of the four endpoints (CHR, CyR, MMR, and PFS) did not show a significant difference (p > 0.05) between the b2a2 and b3a2 populations. Modeling results demonstrated no statistically significant difference in the response dynamics between the major BCR-ABL transcript types. Conclusions', ' These data suggest that nilotinib is effective in patients with all BCR-ABL transcript types including those with atypical transcripts. Patients with typical b3a2 and b2a2 transcripts have similar patterns of response to nilotinib. Best response to nilotinib by transcript typeNumberHematologic response, %Cytogenetic response, %Molecular response, %Event-freesurvival, %Transcript typenCHRCCyRPCyRMMREFSb2a29587.444.213.716.858.3b3a219080.534.210.015.351.4b2a2 + b3a21090.050.020.010.071.4e1a22100.0050.0100.0e19a2250.0000b3a32100.0100.00100.0p value', ' comparing b2a2  vs. b3a2 using 2  2-sample test0.150.090.730.34']",
        "Doc_id":"ASCO_53901-74",
        "Doc_title":" BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.",
        "_version_":1606189013296742401},
      {
        "Meeting_name":" High frequency of BCR-ABL oncogene in pediatric acute lymphoblastic leukemia (ALL) patients as revealed by RT-PCR and interphase FISH",
        "Background":"['Background', ' ALL is a complex genetic disease involving many fusion oncogenes (FGs)1 frequency of which can vary in different ethnic groups2,3 thus having implication in differential diagnosis, prognosis and treatment. Methods', ' We studied FGs in 101 pediatric ALL patients using RT-PCR1 at Day 0, Day 15 and Day 29 and Interphase FISH, and their association with clinical features and treatment outcome. Results', ' Five most common FGs i.e. BCRABL (t 22; 9), TCF3-PBX1 (t 1; 19), ETV6-RUNX1 (t 12; 21), MLL-AF4 (t 4; 11) and SIL-TAL1 (del 1p32) were found in 88.1% (89/101) patients. Frequency of BCR-ABL was 44.5% (45/101). Patients with BCR-ABL had significantly lower survival (43.733 weeks 4.241) as compared to others except MLL-AF4 and significantly higher TLC count. Overall survival was lower (52.23.75) than the patients with ETV6-RUN X 1 (65.2 9.9) which may be due to overall high frequency of poor prognostic FGs (71%) as compared to ETV6-RUNX 1 (17.1%) (p=0.01). Conclusions', ' This is the first study from Pakistan correlating molecular markers, disease biology and treatment response. It is the highest reported frequency of BCR-ABL in pediatric ALL  and was associated with disease biology and survival. Some authors have reported BCR-ABL frequency higher than in West2,4,5 while others reported 45% frequency of ETV6-RUNX16.  These and our data reflect strong interplay of genetic and environmental factors in biology of pediatric ALL and its correlation with disease biology and treatment2,3. Our data indicates immediate need for large clinical trials of imatinib, dasatinib and nilotinib in paediatric ALL treatment in our ethnic group. This study will lead to unravel the mechanisms of BCR-ABL Leukemogenesis and to find population-specific biomarkers and drug targets.  References', '  1) van Dongen JJ, et al., Leukemia. 1999 Dec; 13(12)', '1901-28.  2) Iqbal Z, et al. J Pediatr Hematol Oncol. 2007 Aug; 29(8)', '585.  3) Ariffin H, et al. J Pediatr Hematol Oncol. 2007 Jan; 29(1)', '27-31.  4) Ramos C, et al.  2011 Sep; 139(9)', '1135-42.  5) Artigas A CG, et al. Rev Med Chil. 2006 Nov; 134(11)', '1367-76.  6) Karrman K, et al. Br J Haematol. 2006 Nov; 135(3)', '352-4.']",
        "Doc_id":"ASCO_101360-114",
        "Doc_title":" High frequency of BCR-ABL oncogene in pediatric acute lymphoblastic leukemia (ALL) patients as revealed by RT-PCR and interphase FISH",
        "_version_":1606189027087613952},
      {
        "Meeting_name":" Inhibition of eIF4B suppresses the growth and induces the apoptosis of Bcr-Abl positive cells",
        "Background":"['Alterations in translation are associated with various human malignancies, but the precise pathogenic processes and mechanistic underpinnings remain to be better understood. The oncogenic tyrosin kinase Bcr-Abl, which is believed to induce chronic myelogenous leukemia (CML), could cause the dysregulation of mRNA translation initiation by activating a series of signal pathways. Eukaryotic initiation factor 4B (eIF4B), a critical element in the assembly of translation initiation complex, has been shown to anticipate in Bcr-Abl-mediated tumorigenesis. eIF4B is activated through Ser422 phosphorylation by several pathways including JAK/STAT/Pim and PI3K/AKT/mTOR. Such redundant activation provides mechanistic bases for the less potent antitumor consequences under single-pathway targeted therapy. Interestingly, profound synergy was observed against cell survival and tumor growth and greater decrease of eIF4B Ser422 phosphorylation was detected upon the combination of Pim and mTOR inhibitors. Knockdown of eIF4B would increase the dependence of Bcr-Abl positive cells on Pim and mTOR signaling and then sensitize cells to the synergistical effect mediated by the combined inhibition. In addition, inhibiting mTOR pathway by shRNA targeting AKT or mTOR renders cells dependent on Pim pathway and knockdown Pim1 would sensitize cells to mTOR inhibitor. Thus, eIF4B acts as a prominent role in Bcr-Abl-driven pathogenesis by playing as the convergent point of these pathways which are active in Bcr-Abl positive tumors. Our results reveal a novel mechanism by which Bcr-Abl-induced cellular transformation can be blokced and provides a rationale for combination therapy targeting the dysregulation of translation for CML.Note', ' This abstract was not presented at the meeting.']",
        "Doc_id":"AACR_2015-4976",
        "Doc_title":" Inhibition of eIF4B suppresses the growth and induces the apoptosis of Bcr-Abl positive cells",
        "_version_":1606189007974170624},
      {
        "Meeting_name":" Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis",
        "Background":"['The fusion protein Bcr-Abl responsible for the oncogenic activity in chronic myelogenous leukemia (CML) depends heavily on oligomerization for function. Formation of Bcr-Abl oligomers occurs through a coiled-coil domain existing at the N-terminal portion of the Bcr segment. Previously, we have shown that disruption of this oligomerization utilizing a modified coiled-coil domain (CCmut2) both decreases the proliferation of CML cells and results in the induction of apoptosis. An important contributing factor to these results stems from the increased destabilization of CCmut2 homo-dimers. This phenomenon occurs due to the rationally mutated residues in the modified coiled-coil which allow for favorable interactions with the wild-type Bcr-Abl, but destabilizing interactions with other CCmut2 molecules, thus discouraging the formation of CCmut2 homo-dimers. In turn, this increases the availability and affinity for the modified coiled-coil to interact with and inhibit endogenous Bcr-Abl in CML cells. An additional mutation (K39E) was included that could potentially further destabilize the mutant homo-dimer. Added to the other mutations found in CCmut2 (C38A, S41R, L45N, E48R, Q60E), the new construct was termed CCmut3. To show that CCmut3 results in enhanced binding to a wild-type coiled-coil domain (representative of endogenous Bcr-Abl), 2 separate assays were performed. Colocalization studies were used to show the degree to which CCmut3 localizes intracellularly with Bcr-Abl. Additionally, a mammalian two-hybrid assay was conducted to show the relative selective dimerization between CCmut3 and the Bcr-Abl coiled-coil. Next, caspase 3/7 assays were performed and showed the ability of CCmut3 to induce apoptosis. The CCmut 3 also showed nuclear segmentation (a measurement of late-stage apoptosis) and decrease in oncogenic proliferation (via the colony forming assay). Taken together, these results provide strong evidence for using CCmut3 as a therapeutic for CML. Lastly, attempts to truncate the CCmut3 to find the smallest possible sequence needed (e.g., helix 2) to bind and kill cells effectively is currently underway.']",
        "Doc_id":"AACR_2012-3852",
        "Doc_title":" Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis",
        "_version_":1606189007497068544},
      {
        "Meeting_name":" New therapeutic options for CLL treatment",
        "Background":"['B-cell chronic lymphocytic leukemia (CLL) is characterized by actively dividing B-lymphocytes in the lymph nodes and bone marrow, associated with the accumulation of quiescent lymphocytes in the peripheral blood of affected patients. Current treatments for this disease include chemotherapeutic (chlorambucil (CLB), cyclophosphamide, fludarabine) and immunotherapeutic agents (Rituximab, Alemtuzumab) or the combination of immunotherapy with chemotherapeutics drugs. In 2008, the FDA approved bendamustine, a bifunctional agent with a nitrogen mustard moiety and a purine analog, for the treatment of patients with CLL. Signals from the bone marrow and lymph node microenvironments protect CLL lymphocytes from drug-induced apoptosis. During treatment the enzyme-mediated repair of DNA damage can induce resistance to chemotherapeutic drugs. We have previously shown that small molecule inhibitors of c-abl (a key protein of the homologous recombinational repair pathway) such as imatinib, nilotinib or dasatinib, sensitize primary CLL lymphocytes to CLB. We also demonstrated that ZRF4, a combi-molecule designed to target c-abl (through an imatinib moiety) and to induce DNA damage (through a nitrogen mustard moiety), has a more potent cytotoxic effect than the combination of CLB plus imatinib in CLL lymphocytes. Here we report the anticancer effect of three different combi-molecules composed of a chlorambucil moiety and a dasatinib (a dual Src/c-abl inhibitor) moiety compare to the individual components in primary CLL lymphocytes in-vitro. Using MTT assays on CLL lymphocytes from 40 CLL patients, we found that the IC50 (concentration which kills 50% of the cells) of AL748, AL758 and AL816 are significantly lower than the IC50 of CLB when used alone and the combination of CLB with 0.1 M dasatinib (median value = 1.7 M, 0.6 M, 0.9 M, 11 M and 3.1 M respectively). Moreover, our biochemical results suggest that the mechanism of action of AL758, AL816, CLB and CLB plus dasatinib share common downstream targets including inhibition of Src kinase, chemotaxis, and cross-talk with the microenvironment along with induction of DNA damage (p53, p21, comet assay) and apoptosis (AnnexinV, cleaved caspase-3). We also determined, by the MTT assay, the cytotoxic effect of the combi-molecule AL887 composed of a bendamustine moiety and a dasatinib moiety, compare to the individual components in vitro in primary B-lymphocytes from 20 CLL patients. Our results demonstrated that this combi-molecule has a better anticancer activity than bendamustine in combination with 0.1 M dasatinib (p<0.0005).Dose-limiting toxicity and drug pharmacokinetics are important and limiting factors to take into account for the development of chemotherapy and will be tested in a CLL mouse model. Our results suggest that the combi-molecules AL758, AL816, and AL887 may be useful alternatives for treatment of CLL patients.']",
        "Doc_id":"AACR_2014-1881",
        "Doc_title":" New therapeutic options for CLL treatment",
        "_version_":1606189001256992768},
      {
        "Meeting_name":" The dual SRC-ABL inhibitors in Ph+ acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors.",
        "Background":"['Background', '  Outcomes in adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) remain poor with a 5 year overall survival of less than 40%. Addition of the targeted BCR-ABL inhibitors (TKI) to standard cytotoxic therapy has greatly improved upfront treatment, yet relapse remains common with a median survival of just 4.5 months. Therefore identification of targeted agents that could enhance the activity of TKIs is urgently needed. ABT 199 is a BCL-2 inhibitor which has shown pre-clinical activity against a variety of B cell malignancies. Here we evaluate the combination of ABT199 across a panel of TKIs to explore potential mechanisms of synergy in hopes to better define the optimal combination for future clinical studies.  Methods', '  Drug efficacy in vitro was determined using the Ph+ALL cell line SupB15. Cells were incubated with varying concentrations of dasatinib, imatinib, nilotinib or ponatinib in combination with ABT199 for 72 hours. Cell viability was assessed using a colorimetric MTS assay, and cell apoptosis was assessed with annexin V staining. Combination effects were calculated using Calculsyn software. Standard immunoblots were used to assess inhibition of downstream pathways.  Results', '  The combination index (CI) values for each of the TKIs with ABT199 ranged between 0.13  1.4 for Imatinib, 0.4  1.05 for Nilotinib, 0.06  0.33 for Ponatinib, and 0.07  0.64 for Dasatinib, where CI < 1 predicted synergy. As a single agent, ABT199 induced the highest degree of apoptosis, enhanced preferentially by dasatinib and ponatinib. Evaluation of key phosphorylated kinases showed that all four TKIs effectively inhibited the downstream ABL1 target pCRKL. In addition, both dasatinib and ponatinib inhibited pLYN while dasatinib also inhibited pBTK.  Conclusions', '  Combination of BCL-2 and BCR-ABL targeting in Ph+ALL is synergistic in vitro. The enhanced synergy seen with dasatinib and ponatinib may be due to the ability of these agents to target additional pathways active in leukemic cells. The addition of ABT-199 as part of TKI therapy for adult Ph+ALL warrants further clinical investigation, particularly in patients with relapsed or refractory disease.']",
        "Doc_id":"ASCO_152414-156",
        "Doc_title":" The dual SRC-ABL inhibitors in Ph+ acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors.",
        "_version_":1606189022784258048},
      {
        "Meeting_name":" BCR-ABL tyrosine kinase inhibition combined with a novel pan BCL2 family inhibitor abrogates leukemia stem cell survival in a niche-dependent manner.",
        "Background":"['Leukemia stem cells (LSC) play a crucial role in initiation, maintenance, and progression of chronic myeloid leukemia (CML). Targeted therapy with a BCR-ABL targeted tyrosine kinase inhibitor (e.g. dasatinib) has improved survival of patients with chronic phase CML. However, like blast crisis (BC) CML, survival remains only 30% over 5 years, and treatment frequently fails to eliminate dormant LSC that are hypothesized to drive CML relapse. Overexpression of BCL2 family genes has been observed in human BC CML and may fuel LSC survival. Our previous data demonstrated that pro-survival long isoforms of BCL2 and MCL1 were preferentially expressed in BC CML LSC compared to normal stem cells. These data showed that the bone marrow (BM) is enriched for BCL2 and MCL1-expressing LSC and serves as a reservoir for therapeutic resistance, thereby underscoring the importance of pan-BCL2 inhibition in the BM. A potent pan-BCL2 inhibitor, sabutoclax, has been identified that inhibits the binding of BH3 peptides to Bcl-XL, Bcl-2, Mcl-1 and Bfl1-1 at nanomolar concentrations.To demonstrate whether sabutoclax or the combination of sabutoclax and dasatinib could synergize to eradicate LSC in the BM, humanized BC CML LSC mouse models were established by using 50,000 CD34+ cells selected from primary BC CML patient samples and transplanted into neonatal RAG2-/-c-/- mice. Mice were screened for peripheral blood (PB) engraftment of human cells at 6 weeks, randomized, and dosed with (1) vehicle, (2) sabutoclax (10mg/kg, i.v., twice a week for 2 weeks), (3) dasatinib (50mg/kg, p.o., daily for 2 weeks), or (4) combination. Mice were sacrificed one day after last dose; PB, spleen (SP) and BM were collected for FACS analysis to measure engraftment and cell cycle status of LSC in different hematopoietic niches. BCL2 and MCL1 expression was measured in BM and SP by isoform specific qRT-PCR and immunohistochemistry. Treatment of CML LSC-transplanted mice with sabutoclax alone led to a significant reduction in LSC burden in the SP, but only slightly in the BM. Meanwhile, Single agent sabutoclax reduced the engraftment of quiescent LSC. The effect of sabutoclax synergized with dasatinib to further reduce LSC burden in the BM to eradicate LSC that drive therapeutic resistance. Importantly, these treatments spare normal human stem cells in both BM and SP thereby providing in vivo evidence of a reasonable therapeutic index. Sabutoclax not only reduced the expression of BCL2 and MCL1 mRNA long isoform in the BM, but also significantly reduced the number of human CD34+, BCL2+ and MCL1+ cells in both BM and SP. These results demonstrate that BM and SP niche BC CML LSC survival is driven by overexpression of multiple pro-survival BCL2 family isoforms rendering them susceptible to a novel pan-BCL2 inhibitor, sabutoclax, at doses that spare normal hematopoietic progenitors.']",
        "Doc_id":"AACR_2013-217",
        "Doc_title":" BCR-ABL tyrosine kinase inhibition combined with a novel pan BCL2 family inhibitor abrogates leukemia stem cell survival in a niche-dependent manner.",
        "_version_":1606189028019798016},
      {
        "Meeting_name":" Discovery of dual MNK 1 and 2 and BCR-ABL kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia",
        "Background":"['Although targeting the BCR-ABL kinase with tyrosine kinase inhibitors (TKI) is effective in chronic phase (CP) CML, targeting BCR-ABL alone is not sufficient to treat late-stage or blast crisis (BC) CML. In BC CML, granulocyte macrophage progenitors (GMPs) acquire the ability to function as leukemic stem cells (LSCs), and are thought to act as a reservoir for TKI resistance. While long-term remission in BC CML is possible with allogeneic stem cell transplantation, only a minority of patients are eligible for transplantation, and may experience high morbidity and mortality. Safe and effective BC CML therapy will likely have to target the BC LSC population to ensure long-term disease control.Recent studies have shown the importance of the MAP kinase interacting serine/threonine kinase (MNK1/2)-eukaryotic translation initiation factor 4E (eIF4E) axis in sustaining BC LSC self renewal. Thus, a single agent which inhibits both BCR-ABL and MNK1/2 kinase simultaneously represents a rational approach to target BC LSCs. Such an agent should be able to distinguish between normal hematopoietic stem cells (HSC) and LSCs.Here, we report the discovery, structure activity relationships, pharmacokinetic properties, and biochemical characteristics of dual MNK1/2 and BCR-ABL inhibitors, ETC-027 and ETC-219. These compounds are able to prevent eIF4E phosphorylation, BCR-ABL-driven growth and proliferation of BC CML cells, as well as inhibit the MNK-eIF4E-dependent self-renewal function of BC LSCs, while leaving normal HSCs untouched.']",
        "Doc_id":"AACR_2014-948",
        "Doc_title":" Discovery of dual MNK 1 and 2 and BCR-ABL kinase inhibitors for the treatment of blast crisis chronic myeloid leukemia",
        "_version_":1606188979621724161},
      {
        "Meeting_name":" Effect of epigenetic modulation on interleukin-6 (IL-6) gene expression with adjuvant selenomethionine (Se-Met) with imatinib mesylate (IM) in remission of chronic myelogenous leukemia (CML-cp) patients.",
        "Background":"['Background', '   Histone deacetylase (HDAC) are enzymes involved remodeling chromatin and epigenetic regulation of gene expression. Histone deacetylase inhibitors (HDACI) can reverse aberrant epigenetic changes in CML stem cells. BCR-abl tyrosine kinase inhibitors IM is effective in inducing remission in CML-cp patients but residual leukemia stem cells (LSC) may give rise to resistance and relapse. Pan-HDACI may arrest this  with downregulation of IL-6,  and NFkb activation when adjuvant Se-Met is combined with IM.  Methods', '    CML-cp , CML-bc cases were presented with evidence of overexpression of BCR-abl fusion protein reported previously in elderly patients. A 91 YOF with CML-cp , subclinical hypothyroidism with elevated IL-6,  CRP, sIL-2R, VEGF, NFkb, and IGF-1 was treated for seven years with adjuvant Se-Met, IM and levothyroxine ith normalization, minmal toxicity and extended trending down of IL-6, CRP,sIL-2R.  Results', '    After seven years of adjuvant therapy with Se-Met, IM, and Levothyroxine a significant reduction of IL-6, CRP  of 9.8075 down from 30.783 mg/L. Subsequuent normalization of the other pro-inflammatory cytokines were normalized.  Conclusions', '    HDACI activity expressed in synergism of Se-Met with IM and Levothyroxine may lower the apoptotic threshold in CML-cp  stem cells decreasing BCR-abl expression and rescuing quiescent progenitor cells that may prolong remission and decrease disease relapse.']",
        "Doc_id":"ASCO_101619-114",
        "Doc_title":" Effect of epigenetic modulation on interleukin-6 (IL-6) gene expression with adjuvant selenomethionine (Se-Met) with imatinib mesylate (IM) in remission of chronic myelogenous leukemia (CML-cp) patients.",
        "_version_":1606189038456274944}]
  }}
